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General introduction
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1.1 Human papillomavirus
Human papillomavirus (HPV) is one of the most common sexually transmitted pathogens 
worldwide [1]. From the general population 80% will be infected at some time during their 
life [1]. Most persons become infected soon after their sexual debut [3]. Harald zur Hausen 
proposed the concept of viral oncogenesis in the development of cervical cancer in the nineteen 
seventies [4, 5]. Thereafter, it was confirmed that HPV was associated with the development 
of cervical intraepithelial neoplasia (CIN) [6-9] and that in 99.7% of the cervical cancer cases 
HPV-DNA could be identified [10, 11]. Cervical cancer is the second most common cancer 
among women worldwide with approximately 490.000 new cases and 274.000 deaths each 
year. Of all cervical cancer cases 83% occurs in developing countries [12]. It has now been 
recognized that HPV-associated cancers extend beyond cervical cancer, with HPV being the 
major etiological agent in squamous cell carcinoma of the anus and to a major proportion of 
squamous cell carcinoma of the vulva, vagina, penis, mouth and oro-pharynx [13-17].
1.2 Classification and structure of HPV
HPV, belonging to the family of the Papillomaviridae, is a non-enveloped 8000 nucleotides 
double-stranded circular DNA virus (Fig. 1). Its genome is encapsidated in an icosahedral 
structure composed of two molecules (Late proteins L1 and L2) [18]. The HPV genome has 
the coding capacity for these two capsid proteins and for at least six early proteins (E1, E2, 
E4-E7) (Fig. 2). The early proteins are necessary for the replication of the viral DNA and for the 
assembly of newly produced virus particles within the infected cells [19]. There are more than 
120 genetically different, yet closely related human HPVs, that are referred to as genotypes 
[18, 20]. Clusters of HPV types are subdivided into genera [18]. The alpha genera contain 40 
HPV types that commonly infect the ano-genital epithelium. These ano-genital HPV types are 
subdivided into high-risk (hr) and low-risk (lr) HPV types according to their oncogenic potential. 
Some 13-18 hr-HPV types, belonging to the α7 and α9 species, have been identified as 
Fig. 1. Schematic picture of a HPV virion. HPV virions consist of a non-enveloped capsid containing the 
major protein L1, along with the minor capsid protein L2 (adapted from Galloway [2]).
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probable or definite highly oncogenic and are commonly detected in HPV-associated cancers 
[21]. From this group, HPV16 and 18 are predominant and responsible for 70% of all cervical 
cancer cases [22]. Infections with lr-HPV types, such as HPV6 and 11, can cause benign 
lesions of the ano-genital areas known as condylomata acuminate (genital warts), as well as 
low-grade squamous intraepithelial lesions of the cervix [23].
1.3 Infection and immunology
Most individuals are infected with HPV soon after their first sexual intercourse with highest 
HPV-DNA prevalence found in sexually active individuals under 25 years of age [24]. The 
median period from first sexual intercourse to first detection of HPV-DNA is only less than 
3 months and within three years after sexual debut up to 46% of the women are infected 
with hr-HPV [3]. Although HPV is a sexually transmitted pathogen, penetrative vaginal or anal 
sexual intercourse appears not to be the only prerequisite for infection as the virus may also 
be transmitted by skin to skin contact, via intimate contacts of the genitalia or other mucosal 
surfaces [25]. Papillomaviruses are perfectly adapted to their natural host tissue by infecting 
and replicating only in a fully differentiating squamous epithelium [26].
HPV infection leads to a productive infection in which viral episomes can be found. When HPV 
persist (10-20% of the HPV infections) a transforming infection may develop in which the virus 
is often integrated in the epithelial cells (Fig. 2).
In a productive infection, HPV infects the basal cells of the cervical epithelial lining of preferably 
the transformation zone through micro-lesions occurring e.g. during sexual intercourse [27] 
(Fig. 2).  Following infection, the early genes E6 and E7 are expressed in the suprabasal layers 
of the cervical epithelium [26]. The virus activates, by expression of the other early genes, the 
DNA machinery of the differentiating keratinocytes thereby promoting the replication of these 
cells. Expression of the L1 and L2 genes occurs only in the upper layers of the epithelium. The 
L1 and L2 proteins encapsidate the viral genome and new virus particles are shed from the 
squamous epithelium. These new virus particles can then initiate a new infection of the cervical 
epithelium [28]. 
In case the HPV infection persists, this can result in a transforming infection which might lead 
to cervical (pre)cancer [29] (Fig. 2). In contrast to a productive infection, in a transforming 
infection the oncogenes E6 and E7 are then highly expressed in the basal cells, which have 
dividing capacity. The early oncoproteins E6 and E7 contribute to carcinogenesis by interacting 
with multiple tumor suppressor proteins of the host (reviewed by Korzeniewski et al. [30]). 
These viral oncoproteins inactivate the host cell’s tumor-suppressor gene products, p53 by E6 
and retinoblastoma protein by E7. These interactions result in an immortalised phenotype and 
genetic instability of the infected cell. The resulting additional changes in host cell oncogene 
expression and loss of tumor suppressor gene function further drive the cell to the invasive 
neoplastic phenotype.
12
Fig. 2. Life cycle organization during productive HPV infection. Persistent HPV infection can mediate 
progression to squamous cell carcinoma (adapted from Doorbar et al. [26, 29]). 
The intraepithelial life cycle of HPV has evolved to evade immune recognition, in part, through 
its modulating effect on Langerhans cells and dendritic cells [1, 31]. One prominent evasion 
mechanism is the ability to replicate without inducing cell death and the subsequent pro-
inflammatory signals. This mechanism can possibly result in inactivated or incomplete activated 
dendritic cells with a restricted ability to migrate to a local lymph node [1, 27]. Immunological 
tolerance occurs if there is incomplete activation of antigen presenting cells (APCs) and 
therefore only a reduced antigen-specific immune response towards the pathogen is initiated 
by lymphocytes. 
Most HPV infections are transient and will be cleared, meaning that HPV-DNA can no longer 
be detected, within 2 years in more than 80% of individuals [32]. For the hr-HPV types the 
time for clearance takes approximately 8-16 months, considerably longer than the 4-8 months 
reported for the lr-HPVs [33, 34]. An estimated 10-20% of individuals infected with HPV do not 
effectively clear the virus and they remain DNA-positive with a persistent active viral infection. 
These individuals are at risk for progression to high-grade pre-cancers in the cervix (CIN2/3) 
[35-38]. The pre-cancerous lesions can progress to cervical cancer over a period of several 
years if left untreated [39].
1.4 Humoral immune responses
The mucosal surface of the genital tract provides the first line of defence against genital HPV 
infection. After HPV infection, HPV-specific IgA antibodies are detectable at the cervix and 
might reflect current HPV infection [40]. Naturally derived HPV-specific antibodies may have 
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neutralizing capacity and inhibit the binding to receptors for entering the host cells, or enable 
viral uptake and destruction by APCs. Although in most mucosal tissues IgA is the predominant 
immunoglobulin, the endo-cervical mucosa contains a higher proportion of plasma-derived 
or locally produced IgG antibodies, which are detectable in cervico-vaginal secretions [41-
44]. The level of IgG proportions in cervico-vaginal secretions might depend on the sampling 
location and different sampling techniques [41].
A detectable antibody response to the L1 capsid protein develops in 50-70% of infected 
individuals [45, 46]. In HPV infections there is no viremia and free virus particles are shed from 
the squamous epithelia surfaces with poor access to vascular and lymphatic channels and 
thus to the lymph nodes, were immune responses would be initiated [1, 47]. This is reflected by 
the time needed for IgG seroconversion, which is approximately 6-12 months for HPV16 after 
the detection of HPV16 DNA [46]. Although persistent HPV16 infection is a factor significantly 
associated with seroconversion to IgG [46, 48-51], some studies identified a high viral load 
to be associated with IgG seroconversion, often observed in transient infections [52-54]. 
HPV persistence and viral load might be markers indicative of sufficient antigenic exposure, 
required for the development of a detectable level of IgG antibodies. A persistent HPV infection 
maintains a slow gradual antibody boosting effect, whereas a high viral load may provide an 
antigenic dose that is acute and rapid [54].
Different antibodies can be distinguished in humans with their own effector functions. Antibodies 
of the IgG isotype are most common in serum and consist of four subclasses. Most abundant 
is IgG1 followed by IgG2, IgG3 and IgG4 [55, 56].
1.5 Naturally induced HPV-specific antibodies
HPV IgG antibodies are a measure of past HPV exposure as HPV antibody levels can persist 
for many years in infected individuals [57, 58]. However, antibodies are not always induced 
after HPV infection and the levels of naturally induced antibodies are much lower than those 
observed following prophylactic HPV vaccination [59]. HPV-specific antibodies that are elicited 
by HPV infection might protect the host against HPV reinfections with the same or related HPV 
types although results are inconsistent [60, 61]. Naturally derived HPV-specific antibodies that 
actually protect against reinfections were more often observed in young women than in older 
(>35 years) women [62]. This suggests that HPV-specific antibodies can provide substantial 
protection in young women against reinfections, which was also observed in studies among 
female university students [60, 63, 64]. Moreover, the highest naturally induced HPV16 and 
18 antibody levels could be associated with a reduced risk of subsequent new HPV16 and 18 
infections as compared to seronegative women [64]. Ho et al. observed that persistent HPV16 
antibodies in serum were associated with a reduced risk for subsequent HPV16 infection and 
with HPV16 phylogenetically related types [63]. It has been described that naturally derived 
HPV16 antibodies cross-protect against HPV33 infection [65, 66]. In contrast, Palmroth et 
al did not observe cross-protection, after HPV16 or 18 infection, against other types of the 
HPV α7 and α9 species, indicating that HPV seropositive women continue to be susceptible 
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for infection by other HPV types over time [61]. High levels of persistent HPV-specific IgG 
or IgG together with IgA could be markers for the hosts ability to produce strong protective 
HPV type-specific immune responses against HPV types that infected the host previously 
[63]. It is unknown whether IgA antibody levels in the systemic circulation play a role in virus 
neutralization, but systemic IgA responses were more associated with HPV clearance than 
locally produced IgA at the cervical mucosa which might be an indication of a successful 
immune response induced at the local lymph nodes [67]. 
For cervical infections such as with HPV, the mucosal immune response may be more important 
than the systemic response in determining the outcome of infection. Mucosal IgG antibodies 
negatively correlated with cervical disease and HPV16 infection, which implicates that higher 
antibody concentrations at the cervix were associated with no disease to HPV infection [68]. 
However, limited data are available about antibody responses at the cervical mucosa and it is 
still unclear whether naturally derived HPV antibodies provide protection against re-infection or 
subsequent infection due to related HPV types [69]. 
1.6 HPV-specific antibody seroprevalence
Seroprevalence studies of naturally derived antibodies showed that HPV acquisition takes place 
soon after sexual debut [70, 71]. The highest HPV antibody seroprevalence is found among 
women 20-40 years of age and thereafter levels decline [69, 71, 72]. In contrast to the increase 
in HPV antibody seroprevalence among middle aged individuals (35-55 years), HPV-DNA 
prevalence declines in this age group and the reduced exposure to reinfections might reflect 
fewer sexual partners at older ages or the cumulative effect of naturally acquired immunity 
[64, 73]. In older women (>55 years), a decrease in antibody seroprevalence and reversely 
an increase in HPV-DNA prevalence is observed [71, 74], which could indicate reactivation of 
latent HPV infections acquired many years earlier following immune senescence. 
Risk factors that are strongly associated with HPV antibody seropositivity are age of first sexual 
intercourse and life time number of sexual partners [71, 72].
Men were found to be less antibody seropositive than women, in both general [71, 72] and 
high-risk populations [75, 76]. The infection site in men may reduce either the likelihood of 
HPV infection or the induction of a detectable systemic antibody response [75, 77, 78]. Other 
explanations for the lower seroprevalence are that the duration of infection in men may be 
shorter and that antibodies might be less likely to develop after a transient HPV infection due 
to the site of infection [71]. 
1.7 Vaccine-derived HPV-specific vaccine antibodies
In 2006 the quadrivalent HPV vaccine (HPV6/11/16/18, Gardasil, Merck & Co, Inc), was 
licensed for use in women aged 9-26 years in Europe and in the USA [79, 80]. The bivalent 
HPV vaccine (HPV16/18, Cervarix, GlaxoSmithKline Biologicals) was licensed in 2007 for use 
in women aged 10-25 years in Europe and in 2009 in the USA [80, 81]. The Cervarix vaccine 
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was implemented in the Dutch national immunization program (NIP) in 2010 for girls 12 years 
of age in a 2+1 schedule.  The vaccine coverage was somewhat disappointing and amounted 
to 56% probably due to negative media attention [82]. In addition, a catch-up vaccination 
campaign was initiated among girls aged 13-16 years in 2009 resulting in a vaccine coverage 
of 52%. 
Both HPV vaccines are prophylactic and consist of HPV-specific L1 protein based virus-
like-particles (VLP). VLP-vaccines are delivered via intra-muscular injections and are highly 
immunogenic [83]. Randomized controlled clinical trials showed that these prophylactic 
administered vaccines are highly efficacious against HPV16/18 associated CIN2/3 in naïve 
women [84, 85]. The bivalent vaccine continues to provides sustained protection against 
HPV16/18 infections over at least eight years after the first vaccination [59]. In addition, cross-
protection against persistent infection and/or high grade lesions (CIN2+) from HPV31, 33, 
and 45 was observed up to 4 years after vaccination [86, 87].  HPV vaccination has shown to 
induce L1-specific T-cell responses detectable by proliferation of both CD4 and CD8 T-cells, in 
vitro production of Th1 and Th2 type cytokines and humoral and memory B-cell responses [88, 
89]. These vaccine induced cell-mediated immune responses are involved in the clearing of 
new HPV infections, but does not accelerate clearance of HPV in already infected individuals 
[90]. 
Vaccine efficacy is associated with high and persistent levels of specific IgG and neutralising 
antibodies against the vaccine HPV types. Vaccine-derived HPV16/18-specific antibody levels 
were found to be approximately 10-100 times higher as compared to naturally derived HPV-
specific antibodies [59, 91]. The amount of neutralizing antibodies is important, as these 
antibodies are most likely an important part of the immune response that actually protects 
against HPV infection. Vaccine induced antibodies probably transudate or exudate across the 
cervical epithelium to the cervical mucus in sufficiently high amounts to bind and neutralize 
HPV virus particles [91, 92]. Vaccine-derived antibodies found in the mucosal secretions may 
prevent new HPV infections, re-infection at another site in the cervical, vaginal or vulvar region, 
or reduce the viral load of HPV particles shed from an active infection [92]. However, HPV-
specific antibodies are not always detectable in the cervical mucosa or cervical secretions after 
HPV vaccination [87, 91, 93]. 
In HPV vaccine clinical trials, CIN3+, the most advanced precursor lesion of invasive cervical 
cancer, is used as marker for HPV vaccine efficacy [94]. At present, HPV vaccine clinical trials 
did not yet establish a minimal HPV-specific antibody level or other HPV-specific antibody 
characteristics that correlate with protection against subsequent HPV infections, as too few 
disease cases occurred and breakthrough infections could not be clearly distinguished from 
reactivation of prevalent HPV infections. 
1.8 Serological assays
To offer protection, antibodies should be functional in terms of virus neutralization. Therefore, 
assays that detect or correlate well with levels of HPV-neutralizing antibodies are preferred to 
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measure the antibody response after HPV infection and vaccination. Several assays have been 
developed to measure HPV type-specific IgG antibodies and these assays have been used for 
seroprevalence studies and vaccine clinical trials in several countries [71, 95, 96]. The most 
common assays used in serology are the pseudovirion-based neutralization assay (PBNA), 
competitive luminex immunoassay (cLIA), VLP-ELISA and the in situ-purified glutathione-S-
transferase L1-based multiplex immunoassay (GST-L1-MIA) [52, 97-99].  
Although the PBNA is recognized as the gold standard and is expected to provide the most 
meaningful evaluation of the functional immune response against HPV after infection or 
vaccination, its use in large sero-epidemiological studies or clinical trials is challenging since 
this assay is laborious and difficult to perform [97]. In an attempt to overcome the laboriousness 
of the PBNA, an automated pseudovirion-based HPV neutralization assay is in development 
by Sehr et al., which is well suited for high-throughput screening and validation experiments 
are in progress [100]. 
Most serological analyses of antibody responses after HPV infection have relied on assays, 
e.g. cLIA, VLP-ELISA, and GST-L1-MIA that are alternatives of the PBNA. The cLIA and VLP-
ELISA are based on VLPs consisting of the L1 major capsid protein of the virus produced 
via a recombinant baculovirus system or formed by expression of the L1 gene in yeast 
Saccharomyces cerevisiae [101, 102]. 
In the cLIA, HPV-specific antibodies are determined in a competitive format. Type-
specific neutralizing monoclonal antibodies compete with serum antibodies for binding to 
conformationally neutralizing epitopes on the VLPs. In this competitive assay, mainly high-
affinity antibodies directed towards one epitope are measured [101]. In contrast, the VLP-ELISA 
measures both neutralizing and non-neutralizing HPV-specific antibodies. A good correlation 
was observed between the PBNA and the VLP-ELISA for HPV16 and 18 [102]. The GST-L1-
MIA detects also both neutralizing and non-neutralizing antibodies and in addition allows the 
determination of HPV-specific antibodies to a large number of HPV types in one assay run. 
In general, comparisons between these serological assays are hindered due to the lack of a 
good international reference serum and the use of different cut-off values. Currently, only an 
international reference serum for HPV16 is available [103], which unfortunately contains a low 
HPV-specific antibody concentration and therefore is not very suitable for vaccine studies or 
seroprevalence studies. 
1.9 Design of the study
In the present study, the quality and quantity of HPV immune responses after HPV infection 
and HPV vaccination were investigated. HPV immune responses were assessed in population-
based studies, in vaccination target groups and in immune compromised girls. First, two large 
independent cross-sectional population-based serosurveillance studies, performed in the 
Netherlands in the pre-vaccination era, were available for studying naturally derived HPV 
antibody seroprevalence. The first serosurveillance study was performed between October 
1995 - December 1996 and the second one between February 2006 - June 2007. Both 
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studies are representative for the Dutch population between the ages of 0-79 years. These 
serosurveillance studies enabled us to study the population-based natural immunity against 
seven hr-HPV types and risk factors associated with HPV seropositivity. Secondly, a large 
HPV vaccination monitoring study (HAVANA, HPV Amongst Vaccinated And Non-vaccinated 
Adolescents) was designed to assess the vaccine-derived HPV-specific antibody responses 
up to five years after HPV vaccination and started in 2009. In the HAVANA study, we examined 
the vaccine-derived humoral immune responses in the systemic circulation and at the cervix up 
to two years post-vaccination. Finally, a prospective controlled observational cohort study was 
available in which general immune responses were monitored among immune compromised 
girls. This cohort was used to examine the kinetics of HPV vaccine-induced humoral immune 
responses. 
1.10 Objectives and outline thesis
The following objectives, to assess the HPV immune responses after HPV infection and HPV 
vaccination, addressed in this thesis are: 
• Which serological assay is most suitable for the detection of HPV-specific antibodies in 
sero-epidemiological studies or vaccine trials? (Chapter 2)
• What are the HPV-specific antibody characteristics? Which differences in HPV antibody 
characteristics are found after HPV infection and HPV vaccination? (Chapter 3)
• What is the HPV-immune status of the Dutch population against seven hr-HPV types 
before the introduction of the HPV vaccine in the NIP, and are there any changes in 
antibody seroprevalence over time? (Chapter 4 and 5)
• What is the baseline HPV antibody seroprevalence and HPV-DNA prevalence among 
young girls eligible for HPV vaccination? (Chapter 6)
• How does the vaccine-derived HPV-specific immune response in serum contributes to 
detectable and protective antibodies at sites were HPV infections take place? (Chapter 
7)
• Is the immunogenicity and safety of the HPV vaccine in female immune compromised 
patients comparable to healthy female adolescents? (Chapter 8 and 9)
In chapter 2, the comparison between three serological assays (cLIA, GST-L1 MIA, and 
VLP-based MIA) for the determination of HPV-specific antibodies was described. Besides the 
frequently used VLP-based ELISA, the cLIA and GST-L1-MIA are also used in HPV sero-
epidemiology but the comparisons between these assays are limited. HPV-specific antibody 
characteristics, i.e. cross-reactivity of antibodies, neutralizing capacity, antibody avidity and 
IgG subclasses, provide insight into the differences between naturally derived and vaccine-
derived HPV-specific antibodies. In chapter 3 we explored these HPV-specific antibody 
characteristics. In chapter 4, the antibody seroprevalence and risk factors associated with 
naturally derived HPV antibody seropositivity against seven hr-HPV types in a representative 
sample of the Dutch population were investigated. To determine possible changes in HPV 
18
antibody seroprevalence over the years we compared two representative serosurveillance 
studies performed in 1995-96 and 2006-07 in the Netherlands. Changes in HPV antibody 
seroprevalence over an 11-year period are described in chapter 5. To monitor the impact of 
HPV vaccination among young adolescent girls targeted for HPV vaccination, we determined 
the HPV antibody seroprevalence and HPV-DNA prevalence before the introduction of the 
HPV vaccination (chapter 6). Vaccine-derived HPV antibody levels in serum are well described 
in the literature but information about local vaccine-derived HPV antibody levels at the cervix 
is limited. To provide protection HPV vaccines need to induce sufficient antibody levels at the 
cervix. However, the mechanism by which vaccine-derived antibodies contribute to antibody 
levels at the cervix is not yet completely understood. In chapter 7, we provide insight in the 
vaccine mechanism of protection by exploring HPV-specific antibodies at the cervix and in 
the systemic circulation up to two years post-vaccination. Vaccine clinical trials have shown 
that the HPV vaccination is safe and immunogenic in healthy girls. However, information on 
vaccine-derived immune responses in immune compromised girls is scarce. We investigated 
the humoral immune responses after HPV vaccination in female adolescents with juvenile 
idiopathic arthritis (chapter 8), systemic lupus erythematosus, and juvenile dermatomyositis or 
overlap syndromes (chapter 9) and compared these immune responses with healthy female 
adolescents. Finally, in the general summarizing discussion in chapter 10, we summarized and 
discussed our main findings and we have proposed recommendations for optimizing future 
HPV vaccination strategies. 
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2.1 Abstract
We compared the measurement of human papillomavirus (HPV)-specific serum antibody lev-
els with the virus-like-particle-multiplex immunoassay (MIA), competitive Luminex immunoas-
say (cLIA), and glutathione S-transferase (GST) L1-based MIA. Using a large panel of serum 
samples, these assays showed mutually good correlations for both naturally induced and vac-
cine-derived HPV-specific antibody levels. However, an adaptation of the GST-L1-based MIA 
resulted in an improved correlation with both cLIA and VLP-MIA. 
2.2 Introduction
Serological assays that determine human papillomavirus (HPV)-specific antibodies are useful 
for the evaluation of past HPV infections, as naturally derived antibody concentrations re-
mained relatively constant after HPV infection [1]. Monitoring vaccine-derived HPV-specific 
antibodies can provide information about the immunogenicity of the HPV vaccine, protection 
in the general population, groups at risk for HPV infections and possible type replacement. To 
assess humoral immune responses after HPV vaccination and infection, several serological 
assays have been developed [2-5]. The pseudovirion-based neutralization assay (PBNA) is 
the “gold standard” and known to provide the most meaningful evaluation of the functional 
humoral immune response against HPV. However, its use in large sero-epidemiological stud-
ies or clinical trials is challenging, since these assays are laborious and difficult to perform. In 
an attempt to overcome the laboriousness of the PBNA, Sehr et al. developed an automated 
pseudovirion-based HPV neutralization assay. This assay is well suited for high-throughput 
screening and validation experiments are in progress [6]. Most serological assays available for 
the determination of HPV-specific antibody responses are alternatives for the PBNA. The most 
commonly used assay for the determination of vaccine-derived or naturally derived HPV-spe-
cific antibodies is the virus-like-particle enzyme-linked immunosorbent assay (VLP-ELISA) [3]. 
The fluorescent multiplex bead-based assays are a good alternative for the ELISA, as they 
can rapidly detect multiple analytes in a single well with high reproducibility and sensitivity 
using reduced amounts of serum compared to ELISA. The competitive Luminex immunoassay 
(cLIA) [7], the virus-like-particle (VLP)-based multiplex immunoassay (VLP-MIA) [8] and the 
in-situ purified glutathione S-transferase L1-based MIA (GST-L1-MIA) [5] have been used for 
seroprevalence studies in several countries [8-11]. In general, comparisons between these 
serological assays are hampered by the use of different cut-off values and the lack of a good 
international reference serum. 
Here we describe comparison of the cLIA, VLP-MIA and GST-L1-MIA for the detection of HPV 
type 16 (HPV16)- and 18-specific IgG antibodies in serum samples of nonvaccinees and indi-
viduals vaccinated with 3 doses of the bivalent HPV16/18 Cervarix vaccine (GlaxoSmithKline 
Biologicals S.A., Rixensart, Belgium). 
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2.3 Materials and methods 
Serum samples of nonvaccinees were derived from a cross-sectional population-based sero-
surveillance study in the Netherlands (subset of n = 622) [12] and a cohort study of individuals 
at risk for HPV infection (subset of n = 80) [13]. Serum samples of vaccinees 6 months after 
they received the third vaccine dose of the bivalent Cervarix vaccine in a 2+1 schedule (vac-
cination at month 0, 1 and 6) were available from an HPV monitoring cohort study (subset of 
n = 160) [14].  
The cLIA, VLP-MIA and GST-L1-MIA were performed as previously described [5, 7, 8] with an 
addition to the GST-L1-MIA that median fluorescent intensity (MFI) was converted to Luminex 
Units/ml (LU/ml) using the reference standard as described for the VLP-MIA [8]. Serum sam-
ples of the serosurveillance study were previously tested in the cLIA [15]. 
The serum panel used in the VLP-MIA and GST-L1-MIA contained serum samples of the se-
rosurveillance study and both cohort studies of which duplicate results were obtained. Agree-
ment between the assays was estimated using cut-offs previously determined for the cLIA [4] 
(HPV16, 20 milliMerckUnits (mMU) and HPV18, 24 mMU) and VLP-MIA (HPV16, 9 LU/ml and 
HPV18, 13 LU/ml) [8]. Antibody seropositivity in the GST-L1-MIA was assessed using arbitrary 
cut-offs similar to the VLP-MIA for both HPV16 and 18. The degree of agreement between the 
serological assays was quantified by Cohen’s kappa coefficient (к). 
 
2.4 Results and Discussion
The cLIA can detect HPV-specific neutralizing antibodies whereas the VLP-MIA detects the 
total amount of HPV-specific antibodies. In addition, these assays can distinguish between 
different HPV types as well. In the VLP-MIA, 97% and 98% of the results were in agreement 
with the cLIA for HPV16 (к=0.66) and 18 (к=0.55), respectively. The discordant results were 
seropositive in the VLP-MIA and seronegative in the cLIA (Table 1). The VLP-MIA measures 
HPV-specific antibodies directed against neutralizing and nonneutralizing epitopes, which re-
sults in a higher percentage of seropositivity than for the cLIA. We showed earlier that the 
VLP-MIA is reproducible and that the reactivity with monoclonal antibodies (MAbs) recognizing 
conformational epitopes on HPV16 and 18, was type-specific [8]. In contrast to the VLP-MIA, 
the cLIA detects high-affinity, neutralizing HPV-specific antibodies by using HPV-specific MAbs 
directed to a known single conformational epitope that compete with the HPV-specific serum 
antibodies. Although the detected antibodies in the cLIA have neutralizing capacity, this assay 
might underestimate the total neutralizing activity of both naturally derived and vaccine-derived 
HPV-specific antibodies [7].
The cLIA and VLP-MIA are based on VLPs consisting of the L1 major capsid protein of HPV 
that are expressed in yeast Saccharomyces cerevisiae and in a baculovirus expression vector 
system, respectively [3, 16]. However, the development of VLPs for research purposes is time 
consuming and complicated, and therefore only a limited number of VLP types is currently 
available. This hampers the use of VLP-based assays for the measurement of HPV-specific 
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antibodies because VLPs are not commercially available. For the measurement of HPV anti-
bodies, there is value in a low-cost assay that is easy to perform and reproducible, does not 
require VLPs, and compares favourably in performance with VLP-based assays. The GST-
L1-MIA allows the determination of HPV-specific antibodies to a large number of HPV types, 
as the viral L1-proteins expressed as glutathione S-transferase fusion proteins are easily pro-
duced [11, 17]. However, the L1 fusion proteins might contain fewer conformational epitopes 
and more linear epitopes, due to some denaturation of the L1 proteins. The comparison be-
tween the GST-L1-MIA and cLIA resulted in an overall agreement of 64% for both HPV16 and 
18 (Table 1), however к-values were poor (к=0.09 for HPV16, к=0.03 for HPV18). Discordant 
results were GST-L1-MIA seropositive and cLIA seronegative.  A similar overall percentage 
of agreement was found in the comparison of the GST-L1-MIA and VLP-MIA for both HPV16 
(70%, к=0.41) and HPV18 (65%, к=0.33) (Fig. 1A and B). When evaluated separately, the 
vaccine sera showed a higher percentage of agreement for HPV16 (85%, к=0.37) and HPV18 
(82%, к=0.18) than did the sera of naturally infected individuals between the VLP-MIA and the 
GST-L1-MIA (Table 1). The GST-L1-MIA and adapted GST-L1-MIA showed similar percentag-
es of agreement with the VLP-MIA using only the vaccine sera.  
Fig. 1. Comparison between the original GST-L1-MIA and the VLP-MIA for HPV16 (A) and HPV18 (B). 
Panels C and D display the comparison between the adapted GST-L1-MIA (light grey dots) and original 
GST-L1-MIA (dark grey dots) with the VLP-MIA for HPV16 and 18, respectively. The dotted lines lines 
indicate the VLP-MIA cut-off values (HPV16: 9 LU/ml, HPV18: 13 LU/ml); similar arbitrary cut-off values 
were used in the GST-L1-MIA.
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Table 1.  Comparison between the VLP-MIA, cLIA, GST-L1-MIA and adapted GST-L1-MIA. The total 
number of serum samples tested in each assay is shown. For each comparison,  the number of samples 
tested and agreeing or discordant percentages are displayed. Serum samples tested in the VLP-MIA 
are also separated in sera of HPV-negative and naturally infected individuals (NI) and in sera of HPV- 
vaccinated individuals (VAC). 
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We showed that the GST-L1-MIA is appropriate for measuring vaccine responses. Howev-
er, the nonspecific background in this assay results in a loss of specificity and subsequently 
less good correlations with antibody levels close or below the cut-off values. Waterboer et al. 
described that human sera might contain antibodies that directly bind to the Luminex micro-
spheres, resulting in nonspecific background [18]. They found that preincubation with polyvinyl 
alcohol, polyvinylpyrrolidone and a proprietary reagent (Super ChemiBlock, CBS-K) reduced 
this non-specific background. In an attempt to reduce this background even further, we ad-
justed the GST-L1-MIA by purifying the GST-L1 proteins from the bacterial lysates using a 
commercially available kit based on glutathione-coupled magnetic beads (MagneGST Protein 
purification system; Promega, WI). After elution of the GST-L1 proteins from the magnetic 
beads, the GST-L1 proteins were subsequently dialysed twice against storage buffer (1xPBS, 
0.01% Tween20, 0.25M NaCL) using a 20-kDa dialysing frame (20,000-molecular-weight cut-
off (MWCO) Slide-A-Lyzer dialysis cassette; Thermo-Scientific). 
This purified fraction contained a much higher percentage of GST-L1 proteins compared to the 
bacterial lysates (Fig. 2). The coupling of this purified fraction to the glutathione-casein-con-
jugated microspheres instead of the bacterial lysates decreased the nonspecific background 
and increased the overall agreement with the VLP-MIA for HPV16 (88%, к=0.71) and HPV18 
(83%, к=0.59). Although the overall agreement with the cLIA also increased for HPV16 (89%) 
and 18 (86%), the kappa values were below moderate (к=0.30 and к=0.10 for HPV16 and 18, 
respectively) (Fig. 1C and D and Table 1). 
Fig. 2. SDS-PAGE of the GST-L1 proteins before and after the coupling to the glutathione-casein-
conjugated microspheres. Lane 1 shows the protein markers (kilodaltons) and lane 2 contains the buffer 
with 1 mg/ml casein in which the bacterial lysates are diluted. GST-L1 proteins were separated from the 
gluthation-casein-conjugated microspheres by addition of a SDS buffer. Subsequently, samples were 
heated at 56oC for 5 min. The GST-L1 protein fraction which is used in the original GST-L1-MIA is shown 
before (lane 3) and after (lane 4) coupling to the gluthatione-casein-microspheres. Lane 5 and lane 
6 display the fraction of purified GST-L1 proteins, used in the adapted GST-L1-MIA, before and after 
coupling to the gluthatione-casein-microspheres, respectively.
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2.5 Conclusion
In conclusion, a high agreement of seropositivity was observed between the VLP-MIA and 
cLIA. Using purified GST-L1 proteins in the GST-L1-MIA, we could increase the overall agree-
ment between the VLP-MIA and GST-L1-MIA possibly due to a decrease in nonspecific back-
ground in the GST-L1-MIA. Although these serological assays have different assay character-
istics, they can all be used for the determination of vaccine-derived HPV-specific antibodies. 
For the detection of naturally derived HPV-specific antibodies the cLIA, and VLP-MIA are good 
surrogates for the PBNA. The use of an international reference serum, containing high levels 
of IgG and IgA antibody against several HPV types, and quality control serum panels could 
facilitate the comparisons between these serological assays.  
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 3.1 Abstract
In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects of the hu-
moral antibody response that will provide insight in the HPV humoral immune response in-
duced by HPV infection and vaccination. Cross-reactivity of HPV-specific antibodies induced 
by infection or vaccination was assessed with VLP16 or 18 inhibition using a VLP-based mul-
tiplex immunoassay (MIA) for HPV16, 18, 31, 33, 45, 52 and 58. HPV16/18 specific IgG1-4 
subclasses and avidity were determined with the VLP-MIA in sera after HPV infection and 
after vaccination. Neutralizing antibodies were determined in a small subset of single-sero-
positive and multi-seropositive naturally derived antibodies. Naturally derived antibodies from 
single-positive sera were highly genotype-specific as homologue VLP-inhibition percentag-
es varied between 78-94%. In multi-positive sera, cross-reactive antibodies were observed 
both within and between α7 and α9 species. After vaccination, cross-reactive antibodies were 
mainly species-specific. Avidity of vaccine-derived HPV-specific antibodies was 3 times higher 
than that of antibodies induced by HPV infection (p<0.0001). IgG1 and IgG3 were found to 
be the predominant subclasses observed after HPV infection and vaccination. In the small 
subset tested, the number of single-positive sera with neutralizing capacity was higher than 
of multi-positive sera. Naturally derived HPV-specific antibodies from single-positive samples 
showed different characteristics in terms of cross-reactivity and neutralizing capacity com-
pared with antibodies from multi-positive sera.  Post-vaccination, HPV antibody avidity was 
approximately 3 times higher than antibody avidity induced by HPV infection. Therefore, anti-
body avidity might be a potential surrogate of protection. 
3.2 Introduction
Persistent infection with high-risk (hr) human papillomavirus (HPV) is a necessary event of 
cervical cancer. Almost all cervical cancers are HPV DNA-positive to at least one of the 15 hr-
HPV types that can cause genital infections. Most hr-HPV types cluster together in the α7 and 
α9 species [1, 2].
After an incidental HPV infection, only 50-70% of the infected individuals develop detectable 
HPV-specific antibodies in serum mainly directed against the L1 capsid protein of the virus 
[3]. In contrast to the weak immune response induced by naturally HPV infections, the HPV 
vaccines induce strong immunogenic responses against HPV16 and 18 in serum [4]. The 
HPV-specific antibody levels after vaccination in serum are 10-100 times higher as compared 
to naturally derived antibody levels. Vaccine-derived antibody levels are thought to be largely 
responsible for the protection against subsequent infection and cervical intraepithelial neopla-
sia (CIN), the precursors of cervical cancer [4, 5]. 
HPV vaccines provide a degree of cross-protection against persistent infection and/or high-
grade lesions (CIN2+) attributed to some of these non-vaccine HPV genotypes, particularly 
HPV31, 33 and 45, but probably not HPV52 and 58 [6, 7]. It is not clear whether naturally 
derived HPV-specific antibodies can also protect against subsequent homologous infection or 
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against infection with phylogenetically related HPV genotypes [8, 9].
At present, no immune parameter or antibody concentration has been defined that correlates 
with protection. While the HPV-specific antibody levels in response to HPV infection or HPV 
vaccination have been previously described [10-13], information about HPV-specific antibody 
avidity or IgG subclasses is scarce [14-16]. In this study, we evaluate multiple aspects of the 
humoral antibody response induced by HPV infection and after prophylactic HPV vaccina-
tion. Therefore, we determined, next to the antibody concentration, the antibody avidity, IgG 
subclasses, cross-reactive antibodies and neutralizing activity of antibodies induced by HPV 
infection for HPV genotypes of the α7 (HPV18 and 45) and α9 species (HPV16, 31, 33,  52 and 
58). These antibody characteristics will provide insight in the HPV humoral immune response, 
which is important for the interpretation of sero-epidemiological data and might contribute to a 
definition of an HPV-specific correlate of protection.
 
3.3 Materials and methods
3.3.1 Study populations
Naturally infected individuals: Serum samples were available from a large cross-sectional pop-
ulation-based surveillance study (PIENTER-2), performed in 2006-07 in the Netherlands. This 
serumbank contained samples from individuals 0-79 years of age and at low risk for HPV 
infection [17]. The surveillance study design and the study proposal were approved by the 
Medical Ethics Testing Committee of the foundation of therapeutic evaluation of medicines 
(METC-STEG) in Almere, the Netherlands (clinical trial number: ISRCTN 20164309). A signed 
informed consent was obtained from all participants and for those below 18 years of age also 
from the parents, care takers or guardians. 
From this serosurveillance study, a panel of naturally HPV infected individuals was selected 
that included HPV single-positive (n = 121) and multi-positive sera (at least seropositive for 
HPV16 (n = 136) or seropositive for HPV18 (n = 91)) of a broad range of antibody concen-
trations [12]. The vast majority of the individuals included in this selection were older than 15 
years of age. 
Some infants and children (up to 10 years of age) in the large serosurveillance study were HPV 
antibody seropositive. To investigate the quality of the antibodies we tested in the PBNA some 
sera of infants and children, who were part of the previous mentioned selection (n = 11). 
From a prospective cohort study in Rwanda, Africa [18], a panel of sera from women, who were 
at high risk for HPV infection, was selected for IgG subclass determination because of the high 
HPV antibody concentrations in these sera. 
Vaccinated individuals: From an HPV vaccine monitoring study (HAVANA study, HPV amongst 
vaccinated and non-vaccinated adolescents [19]) in the Netherlands, serum samples of girls 
aged 14-16 years, 12 months after the first vaccine dose were available (n = 100). The girls 
from the HAVANA study received three doses of the bivalent Cervarix® vaccine (GlaxoSmith-
Kline, Rixensart, Belgium) at months 0, 1 and 6. The study protocol was approved by a medical 
36
ethics review committee of the Faculty of Medicine, VU University Amsterdam (2009/22). 
3.3.2 Serological measurements
VLP-based multiplex immunoassay: HPV-specific IgG antibodies against L1 VLP16, 18, 31, 33, 
45, 52 and 58 were measured using a VLP-MIA [12]. Sera were incubated with the VLP-cou-
pled microspheres. HPV-specific IgG antibodies were detected using R-phycoerythrin (R-PE) 
conjugated goat anti-human IgG (Jackson ImmunoResearch laboratories Inc, Westgrove, PA). 
For the determination of HPV16/18-specific IgG subclasses (IgG1, IgG2, IgG3 and IgG4) after 
HPV infection (HPV16 n = 67, HPV18 n = 29) and vaccination (HPV16 n = 64, HPV18 n = 63), 
isotype-specific mouse anti-human R-PE-conjugated antibodies were used. The mouse an-
ti-human IgG1 monoclonal was used in a 1/500 dilution and the IgG2-4 monoclonals in a 1/100 
dilution (all 4 from SouthernBiotech, Birmingham, AL). Four ‘in-house’ control sera and an 
‘in-house’ standard were used on each plate. The ‘in-house’ standard (IVIG, lot LE12H227AF, 
Baxter) was calibrated against reference serum of GSK for all the seven HPV types.  HPV-spe-
cific antibodies were analyzed using the Bioplex system 200 with Bioplex software (Bio-Rad 
Laboratories, Hercules, CA). Sera were assumed to be IgG seropositive at the following cut-
offs determined previously with this assay [12]: 9, 13, 27, 11, 19, 14 and 31 LU/ml for HPV16, 
18, 31, 33, 45, 52 and 58, respectively. Distributions of IgG subclasses in percentages were 
calculated using median fluorescent intensity (MFI) of the IgG subclasses separately in rela-
tion to the MFI of HPV-specific total IgG, which was set at 100%. 
VLP16 and 18-based inhibition assay: Homologous inhibition of HPV-specific antibodies in-
duced by infection was assessed for single-positive sera with virus-like particle (VLP) 16, 18, 
31, 33, 45, 52, and 58, separately. Inhibition of HPV antibodies in multi-positive sera from the 
Dutch serosurveillance study and sera from vaccinated girls was determined with VLP16 and 
18 separately. VLPs were kindly donated by GlaxoSmithKline Vaccines. Sera were pre-diluted 
1/100 and 1/200, respectively, and subsequently added to the same volume of PBS containing 
10 µg/ml VLPs. Sera, containing vaccine-derived HPV-specific antibodies, were pre-diluted 
1/10,000. After an incubation period at RT for 1 hour, all samples were analyzed using the VLP-
based multiplex immunoassay (VLP-MIA). The inhibition index was determined as a percent-
age of the antibody levels post-inhibition in comparison with the antibody levels pre-inhibition, 
which were set at 100%. 
Antibody avidity measurement: Avidity of HPV16 and 18-specific IgG antibodies was assessed 
by using a modification of the VLP-MIA for determining HPV-specific IgG antibodies. HPV16 
and 18-specific antibody concentrations in sera induced by HPV infection (HPV16 n = 65, 
HPV18 n = 55) or after HPV vaccination (HPV16/18 n = 60) were diluted for HPV16 and 18 
separately and adapted to a starting concentration of 0.25 LU/ml (approximately 6000 MFI, 
which is the middle of the linear part of the reference dilution curve).
Ammonium thiocyanate (NH4SCN; Sigma-Aldrich St. Louis, Missouri, USA) was used to disso-
ciate low-avidity antigen-antibody binding [20]. After a 60 minute incubation period of VLP-cou-
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pled microspheres with serum, 25 µl of NH4SCN in PBS (pH7.2) was added in a final concen-
tration of 2.5M or only PBS for 10 minutes at RT. Subsequently, sera were washed 3 times with 
PBS. Residual bound IgG antibodies were detected as described above. The avidity index was 
determined as a percentage of the remaining IgG levels in the presence of NH4SCN in com-
parison with the IgG levels after addition of PBS in which the antibody avidity was set at 100%. 
Pseudovirion-based neutralization assay: Subsets of single-positive (n = 11) and multi-positive 
(n = 10) sera, containing naturally induced HPV16, 18, 31 and 45-specific antibodies, were 
tested in a pseudovirion-based neutralization assay (PBNA) for the detection of neutralizing 
antibodies against VLP16, 18, 31 and 45. The PBNA was performed at GSK as previously 
described [21]. Serum neutralization titers were calculated by linear interpolation of the serum 
dilutions of every sample and defined as the reciprocal of the serum dilution, which caused 
50% reduction in secreted alkaline phosphatase activity (ED50, when compared to control wells 
containing only neutralization buffer and HPV pseudovirions). The cut-off of the PBNA was 40 
ED50 for HPV16, 18, 31 and 45.
3.3.3 Statistical analysis 
Data analyses were conducted using Graphpad Prism version 5. Percentage inhibition was 
calculated using the antibody concentrations pre- and post-inhibition of each tested sam-
ple. Subsequently, an average inhibition percentage was calculated. Significant differences 
(p<0.05) of geometric mean concentrations (GMCs) of antibodies pre- and post-inhibition or 
between antibody avidity indices were calculated using a Mann-Whitney test.
3.4 Results
3.4.1 Cross-reactivity of HPV-specific antibodies derived after HPV vaccination
Homologous inhibition of vaccine-derived HPV16 and 18-specific antibodies was nearly com-
plete and amounted to 99.7% and 99.6%, respectively (Fig. 1A and 1B). Therefore, vac-
cine-derived HPV-specific antibodies were genotype specific. 
After vaccination, cross-reactive antibody levels were mainly species-specific. A significant 
reduction in antibody levels of phylogenetically related HPV types was observed after VLP16 
inhibition with inhibition percentages varying between 76% and 88% for HPV31, 33, 52 and 
58 (Fig. 1A). However, we also found a small decline in HPV45 antibody levels (28%). The 
reduction in antibody levels after VLP18 inhibition was also mainly species-specific and the 
inhibition percentage for the α9 species (HPV45) was 73% (Fig. 1B). Small reductions in an-
tibody levels varying between 18% and 27% were observed after VLP18 inhibition for the α7 
species (HPV31, 33, 52 and 58). 
3.4.2 Cross-reactivity of HPV-specific antibodies induced by HPV infection
Homologous inhibition of naturally acquired HPV-specific antibodies against a single HPV type 
amounted to 94.5% for HPV16 and 83.1% for HPV18 (p<0.0001 for both HPV16 and HPV18,). 
38
Homologous inhibition percentages for the other 5 single-seropositive HPV types tested varied 
between 78% and 92%, indicating that these antibodies were type-specific as expected (data 
not shown). 
In contrast to vaccine-derived and naturally induced antibodies of single-positive sera, anti-
bodies of multi-positive sera were less specific. In sera positive for HPV16 or HPV18 and up 
to 5 other HPV types, inhibition with VLP16 or 18 amounted to an average percentage of 75% 
and 80%, respectively (Table 1). Heterologous inhibition with VLP16 or VLP18 of these sera 
multi-positive for 2-6 HPV types reduced the antibody levels of phylogenetically related HPV 
types both within and between species α7 and α9 varying between 45 and 62%.
Fig. 1. Vaccine-derived antibody concentrations (LU/ml) pre- (dark grey dots) and post-inhibition (light 
grey dots) with VLP16 (A) or VLP18 (B). Dark grey lines indicate geometric mean concentrations. * 
p=0.05, *** p<0.0001.
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Inhibition with VLP16 Inhibition with VLP18
Homologous 
inhi (%) Heterologous inhi (%)
Homologous 
inhi (%) Heterologous inhi (%)
Types positive HPV16 α9 – HPV16 α7 HPV18 α9 α7 – HPV18
2 types 78 42 39 83 76 38
3 types 80 23 44 72 62 55
4 types 75 54 56 85 61 65
5 types 69 47 44 78 48 43
6 types 71 56 57 81 65 56
2-6 types 75 45 48 80 62 51
Note: inhi = inhibition; α9: HPV16, 31, 33, 52, 58; α7: HPV18, 45.
3.4.3 HPV-specific neutralizing antibodies induced by HPV infection in single-positive and 
multi-positive sera
A subset of sera with high homologous inhibition percentages (98% for HPV16 and 97% for 
HPV18), indicating that the antibodies were genotype-specific, was selected from the sin-
gle-and multi-positive samples. In the single-positive sera from this subset, neutralizing an-
tibodies were found in 5 out of 6 for HPV16 and in 4 out of 5 for HPV18 (Table 2A). In the 
multi-positive sera from this subset, the naturally derived HPV-specific antibodies showed less 
neutralizing activity than HPV-specific antibodies of single-positive sera (Table 2B). Although 
these samples were selected for high HPV16 and 18 inhibition percentages, only 1 out of 6 for 
HPV16 and 1 out of 4 for HPV18 showed neutralizing capacity. Antibodies that cross-reacted 
with HPV31 and HPV45 showed no neutralizing capacities.
Naturally derived HPV16-specific antibodies in serum samples of children 1-10 years of age (n 
= 8) showed no neutralizing capacity while from the samples of 3 infants tested (0-6 months of 
age) in 1 case HPV-specific neutralizing antibodies were found. 
3.4.4 HPV16 and 18-specific antibody avidity derived after HPV infection and vaccination
HPV16 and 18-specific antibodies induced by HPV infections are mainly of low-avidity (Fig. 2A 
and 2B). On average, 35% (95%CI 23-47%) and 28% (95%CI 13-42%) of HPV16 and 18-spe-
cific antibodies of single-positive sera, respectively, remained detectable after NH4SCN treat-
ment. No significant differences in naturally induced antibody avidity were observed between 
single-positive and multi-positive sera. In contrast, vaccine-derived HPV16 and 18 antibodies 
showed a significant 3 times higher avidity than naturally induced antibodies, with an avidity 
index of 86% (95%CI 84-88%) and 84% (95%CI 82-86%), respectively. The avidity indices of 
the antibodies induced by HPV infection of the vast majority of the single-positive (19/20 for 
HPV16, 17/20 for HPV18) and multi-positive sera (43/45 for HPV16, 33/35 for HPV18) were 
lower than the avidity of vaccine-derived antibodies. We observed no correlation between the 
Table 1.  VLP16 and 18 homologous inhibition and heterologous inhibition percentages of multi-positive 
sera induced by HPV infection. The percentage of VLP16 an 18 inhibition within and between the α7 and 
α9 species are shown for sera antibody seropositive for 2 up to 6 HPV types.
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level of antibody avidity and the number of HPV types for which participants are positive. Also 
no correlation was observed between antibody avidity indices and the level of HPV16 and 
18-specific antibody concentrations after HPV infection and vaccination (data not shown). 
Table 2A. HPV16 and 18 antibody characteristics of single-positive sera induced by HPV infection. 
Antibody concentrations (LU/ml) assessed with the VLP-MIA, homologous inhibition percentages, 
neutralizing antibody levels (ED50) and antibody avidity indices are presented for HPV16 and HPV18
VLP-MIA PBNA Avidity
# Conc (LU/ml) Inhi (%) ED50 %
HPV16 1 138 99 591 54
2 105 98 297 54
3 105 99 110 52
4 99 100 <40 10
5 92 97 263 25
6 41 97 100 65
HPV18 7 130 99 94 81
8 96 97 108 3
9 57 99 187 81
10 49 94 <40 1
11 28 94 62 16
Note: Conc, concentration; inhi, inhibition; PBNA antibody levels <40 were not neutralizing.
Table 2B. HPV-specific antibody characteristics of multi-positive sera induced by HPV infection. 
Antibody concentrations (LU/ml) assessed with the VLP-MIA, homologous and heterologous inhibition 
percentages and neutralizing antibody levels (ED50) are shown for HPV16, 18, 31 and 45. Antibody 
avidity indices are presented for HPV16 and 18.
VLP-MIA PBNA Avidity
# Conc (LU/ml) Inhi (%) ED50 %
HPV16 HPV31 HPV16 HPV31 HPV16 HPV31 HPV16
HPV16+31
1 224 131 99 74 <40 <40 63
2 142 42 98 98 <40 <40 4
3 27 51 85 77 <40 <40 1
HPV16 HPV45 HPV16 HPV45 HPV16 HPV45 HPV16
HPV16+45
4 27 28 97 68 <40 <40 37
5 19 26 94 74 127 <40 12
6 9 29 79 69 <40 <40 24
HPV18 HPV45 HPV18 HPV45 HPV18 HPV45 HPV18
HPV18+45
7 121 52 99 96 209 <40 1
8 40 162 97 94 <40 <40 53
9 37 35 97 76 <40 <40 30
10 25 20 96 61 <40 <40 15
Note: Conc, concentration; inhi, inhibition; PBNA antibody levels <40 were not neutralizing.
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3.4.5 HPV16 and 18-specific IgG subclass antibody distributions after HPV infection and vac-
cination.
The most abundant antibody subclass of IgG induced after HPV16 and 18 infection was IgG1 
(78% and 92%, respectively), followed by IgG3 (20% and 6%, respectively) (Table 3). Small 
amounts of IgG2 and IgG4 subclass were found, 2% and 1% for HPV16 and 1% and 2% for 
HPV18, respectively. Similar IgG isotype distributions were observed after HPV vaccination, 
although IgG2 and IgG4 tended to be even lower. 
Table 3. HPV16 and HPV18 IgG subclasses (IgG1, IgG2, IgG3 and IgG4 induced by HPV infection 
(HPV16 n = 67, HPV18 n = 29) and vaccination (HPV16 n = 64, HPV18 n = 63). Proportions of IgG 
isotypes are expressed as percentages towards total HPV-specific IgG. 
Natural Infection Vaccination
HPV16 HPV18 HPV16 HPV18
% 95%CI % 95%CI % 95%CI % 95%CI
IgG1 78 71-84 92 86-98 80 73-87 70 61-78
IgG2 2 1-4 1 0-1 0 0-1 1 0-3
IgG3 20 13-26 6 0-11 19 13-26 26 19-34
IgG4 1 0-1 2 0-6 0 0-1 3 1-4
 Note: CI, Confidence interval.
Fig. 2. Antibody avidity (%) for HPV16 (A) and HPV18 (B) of HPV-specific single-seropositive and 
multi-seropositive naturally derived antibodies and HPV vaccine-derived antibodies. The dark grey line 
indicates the mean antibody avidity. *** p<0.0001.
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3.5 Discussion
Here we describe HPV-specific antibody characteristics after HPV infection and vaccination. 
Cross-reactivity of HPV antibodies derived after HPV vaccination was mainly species-specific. 
Naturally induced HPV-specific antibodies from single-positive sera were genotype-specific as 
expected and tended to be neutralizing. In contrast, antibodies of multi-positive sera were less 
genotype-specific, cross-reactive, and tended to be non-neutralizing. IgG1 was found the pre-
dominant subclass induced after HPV infection and vaccination, followed by IgG3. Moreover, 
post-vaccination antibody avidity was approximately 3 times higher than after HPV infection. 
3.5.1 Vaccine-derived HPV16 and 18-specific and cross-reactive antibodies
Vaccine efficacy against HPV16 and 18 infection sustains over 8 years post-vaccination [4] 
in which HPV-specific IgG antibody levels together with its neutralizing activity remained 
well above antibody levels induced by HPV infection [4, 16]. In addition, HPV vaccines offer 
cross-protection against a few non-vaccine HPV types in individuals without a previous HPV 
infection [22]. Antibodies that were capable of neutralizing also non-vaccine HPV types were 
most frequently found to be directed against HPV31 and 45 [23]. Cross-neutralizing antibody 
levels against HPV31, 33, 35 and 45 were found to be significantly associated with their phylo-
genetically related vaccine type antibody levels [23]. We showed that 12 months after the first 
vaccine dose, vaccine-derived HPV16 and 18 antibody levels were indeed cross-reactive as 
inhibition with VLP16 or 18 resulted in species-specific inhibition of antibodies directed against 
HPV31, 33, 45, 52 and 58. The HPV types 31, 33, and 45 are often detected in cervical cancer 
worldwide and vaccines that are efficacious against these HPV types might further reduce 
cancer incidence. As, similar to the vaccine-induced HPV-specific antibodies, cross-reactive 
HPV-specific vaccine antibodies wane in time, the duration of protection against non-vaccine 
HPV types will also decrease thereby reducing the beneficial effect of the vaccine [22]. Al-
though we found vaccine-derived HPV52 and 58 cross-reactive antibody levels to be associ-
ated with HPV16, these cross-reactive antibodies are probably of limited biological relevance. 
Vaccine efficacy studies did not observe cross-protection against HPV52 and 58 as these HPV 
types are more distantly related to HPV16 [7]. 
3.5.2 Naturally derived cross-reactive antibodies
It is unclear whether naturally derived HPV-specific antibodies can protect against subsequent 
homologous HPV infection or infection with phylogenetically related HPV types. In women, the 
protective role of HPV16 serum antibodies induced by HPV infection has been inconsistent 
in the literature, with moderate protection observed in a limited number of studies [8, 24-26]. 
Palmroth et al. did not find cross-protection with naturally induced HPV16 or HPV18 anti-
bodies against infection with phylogenetically related genotypes of α7 or α9 species among 
single-seropositive women [9]. We also found that naturally induced HPV16 and 18 antibodies 
in single-positive sera were non-cross-reactive. In addition, we found that single-positive sera 
showed neutralizing capacity while antibodies in multi-positive sera were cross-reactive and 
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non-neutralizing, albeit tested in a small subset. We hypothesize that in single-positive sera the 
HPV-specific antibodies might be induced by transient HPV infections, whereas for multi-posi-
tive sera the HPV-specific antibodies might be induced after persistent HPV infections. A high 
viral load could induce an acute and strong immune response [27, 28]. This might result in an 
effective HPV type-specific humoral immune response, in which it is more likely that natural-
ly induced antibodies are directed against HPV-specific neutralizing epitopes. Cross-reactive 
HPV antibodies in multi-HPV type positive sera might be induced by, i.e. persistent HPV in-
fections that generate and maintain a less developed humoral immune response with a slow 
gradual boosting effect of the HPV antibodies. Moreover, continued exposure to more than one 
HPV genotype may favour the induction of HPV-specific antibodies that are directed against 
the common non-neutralizing epitopes shared by different HPV genotypes. This might denote 
that naturally induced HPV-specific antibodies in multi-HPV positive individuals could not or 
only partially protect against subsequent HPV infection and that HPV seropositive individuals 
are still at risk for subsequent infection with related HPV types. Of course we realise that these 
explanations are speculative and need further immunological corroboration. The low inhibition 
percentages of naturally induced antibodies in multi-positive sera might be due to the pres-
ence of antibodies directed against epitopes that are specific for the non-HPV16 and 18 HPV 
types. Although these HPV types are phylogenetically related to HPV16 and 18, VLP16 and 18 
could not inhibit these HPV type specific antibodies. In addition, cross-reactive HPV antibod-
ies (recognizing common epitopes) not measured in the VLP-MIA, of the α7 and α9 species, 
could also contribute to the low inhibition percentages. Cross-reactive antibodies induced by 
HPV infection, might play an important role in the interpretation of HPV sero-epidemiological 
data from cross-sectional studies. Although cross-reactivity after HPV infection is relatively 
rare [12], it can lead to an overestimation of seropositivity and indirectly to an overestimation 
of HPV infection rates. 
Cross-sectional serosurveillance studies [12, 29] showed that naturally induced HPV-specific 
antibodies could be detected in sera of infants and children (0-10 years of age). However, 
whether these HPV-specific antibodies have any biological relevance in terms of neutralizing 
capacity in children and infants has not been investigated. We showed, in a small subset, that 
naturally derived HPV-specific antibodies in children were non-neutralizing. HPV seropositivity 
in children might be associated with non-sexual transmission of HPV, as HPV-DNA can be 
detected in the oral mucosa, tonsils and fingers [29-31]. However, HPV-specific antibodies 
in children might also be cross-reactive antibodies against other HPV types e.g. cutaneous 
HPV types which are highly prevalent in children. The neutralizing HPV-specific antibodies in 
1 infant (age 3 months) can be explained by transfer of maternal antibodies that subsequently 
wane within a few months after birth [29, 32].  
3.5.3 Potential surrogates of protection
With the HPV vaccine clinical trials performed so far, a level of HPV-specific antibodies that 
can be used as a correlate of protection is still not established as too few disease cases oc-
curred within these trials and breakthrough infections could not be clearly distinguished from 
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the reactivation of prevalent HPV infections [33]. Longet et al. showed in mice, by in vivo gen-
ital HPV pseudovirion challenge, that already very low vaccine-derived HPV-specific antibody 
levels could protect against HPV infections and that these protective antibody levels are far 
below detection limits of the pseudovirion-based neutralization assay [33]. We could not find 
an association between the level and the neutralizing capacity of naturally induced antibodies. 
This is in line with a study of Lu et al., showing that the level of HPV16 antibodies was not asso-
ciated with a lower risk of HPV infection [34]. Apparently, the HPV antibody level after infection 
will provide limited information about a correlate of protection.
Other immune parameters than antibody levels, that might correlate with protection, have not 
been defined and data on antibody characteristics such as avidity are scarce [16]. Antibody 
avidity generally increases over time following encounter with an antigen. Memory respons-
es are characterized by the production of high-avidity antibodies. Thus, the level of antibody 
avidity could be considered a surrogate of successful induction of immunological memory [35]. 
Vaccine-derived neutralizing antibody levels correlate with antibody avidity 6 months and one 
year after HPV vaccination [15, 16]. 
We found that antibody avidity after vaccination was 3 times higher than after HPV infection. 
After HPV infection, we observed a wide range of antibody avidity levels in sera of naturally 
infected individuals reflecting a great biological diversity in individual responses to HPV infec-
tion. Naturally induced HPV16 antibodies of low avidity have been associated with possible 
susceptibility to infection with other HPV types [14]. Higher avidity indices tended to be associ-
ated with naturally derived neutralizing HPV-specific antibodies, albeit tested in small sample 
sizes. This indicates that levels of antibody avidity might be useful to distinguish between pro-
tective and non-protective HPV-specific antibodies. Therefore, antibody avidity might be a po-
tential immune surrogate of HPV protection, but further research is necessary to confirm this. 
Our findings on IgG subclasses are in line with Harro et al. reporting that IgG1 was the pre-
dominant subclass induced after VLP vaccination [36].  In contrast, Matsumoto et al. found 
the IgG2 subclass to be dominant in HPV16 seropositive women and that IgG2 dominance 
was associated with the regression of CIN, albeit in a small sample size [37]. IgG1 and IgG3 
are generally induced in response to protein antigens, whereas IgG2 is associated with the 
immune response against polysaccharide antigens and IgG4 with allergy [38, 39]. 
3.6 Conclusion
In conclusion, we showed that vaccine-derived antibodies were mainly genotype-specific 
and cross-reacted only for a smaller part with other HPV types within the species. After HPV 
infection, single-seropositive antibodies were highly type-specific and neutralizing whereas 
multi-positive sera were less specific and tended to be non-neutralizing. This might mean that 
naturally induced HPV-specific antibodies in multi-HPV positive individuals could not or only 
partially protect against subsequent HPV infection and these individuals are still at risk. 
Although sample sizes were small, neutralizing antibodies in single-positive sera inclined to be 
associated with higher antibody avidity indices than non-neutralizing antibodies. Further, we 
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found the avidity of vaccine-derived antibodies to be approximately 3 times higher than after 
HPV infection. These results imply that the avidity of HPV antibodies might be used as a po-
tential surrogate of protection. However, more studies are needed to establish the role of HPV 
antibody avidity as a potential surrogate of protection and the use of this immunological tool in 
sero-epidemiological and vaccine monitoring studies.  
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4.1 Abstract 
We obtained insight into the age-specific seroprevalence for seven high-risk human 
papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general 
population in the pre-vaccination era in the Netherlands. From a cross-sectional population-
based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and 
children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based 
multiplex immunoassay with virus-like particles of the seven HPV serotypes. An increase in 
seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 
(up to 11.3%). The increase was most pronounced in women, but was less clear for the other 
six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts 
and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among 
women (25.2%) was higher compared with men (20.3%) (p=0.0002). We found that 10.1% of 
the population was seropositive for multiple HPV serotypes.  The HPV vaccination program 
is targeted at preadolescents as is justified by the results in this study in which a step-up in 
HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of 
seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data 
are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination 
program. 
4.2 Introduction
Human papilloma virus (HPV) is one of the most common sexually transmitted pathogens 
worldwide. From the general population it is established that 80% will be infected at some time 
during their life [1]. More than 100 different HPV genotypes have been identified, of which 40 
infect the genital tract [2]. High-risk (hr) HPV, such as types 16 and 18, can cause cervical 
cancer and other genital cancers, and also oro-pharyngeal cancer. HPV16 and HPV18 are 
the most common HPV types detected in women worldwide and are responsible for 70% of 
all cervical cancer cases [1-3]. When infected with HPV, most genital transient HPV infections 
regress within two years [4]. Only a small proportion of infected individuals suffer from persistent 
infections and they are at risk for cervical cancer [5, 6]. 
Assays developed for the detection of HPV-specific IgG antibodies to virus-like-particles 
(VLPs), have been used for seroprevalence studies in several countries [7-9]. Not all HPV 
infected individuals seroconvert and 20-50% of the women who are carriers of HPV-DNA do 
not have detectable HPV antibodies in their serum [1, 3]. When HPV antibody responses 
develop after a natural HPV infection, they are relatively stable over time [10]. Therefore, the 
measurement of HPV-specific antibodies will be useful to provide information about the HPV 
seroprevalence in population studies and can be used to estimate lifetime cumulative HPV 
exposure and past HPV infections. 
In this study, we describe the age-specific seroprevalence of seven hr-HPV types (16, 18, 31, 
33, 45, 52 and 58) and the risk-factors associated with seroprevalence in a representative 
51
4
S
er
op
re
va
le
nc
e 
of
 s
ev
en
 h
ig
h-
ris
k 
H
P
V
 ty
pe
s
sample of the Dutch population before the implementation of the HPV vaccine in the national 
immunization program (NIP). In the Netherlands, HPV vaccination (Cervarix) was included in 
the NIP in 2010 for girls 12 years of age with vaccination coverage of 50% [11]. In addition, 
a catch-up vaccination campaign was performed for girls 13-16 years of age. Age-specific 
seroprevalence data from the pre-vaccination era in the Netherlands are scarce. Previous 
studies in the Netherlands were limited to the number of HPV types (only 6, 11, 16 and 18), age 
groups or focused only on a specific city (Amsterdam) in the Netherlands [12, 13]. Our study 
provides insight in risk factors associated with seropositivity, in the distribution of hr HPV types 
and is valuable in the evaluation of long-term population effects of the HPV16/18 vaccination 
program.
4.3. Materials and methods 
4.3.1 Study population
Serum samples from a cross-sectional population-based serosurveillance study performed 
from February 2006 to June 2007 were available (n = 6384) for analysis. Participants, women 
and men, were 0-79 years of age. The study design has been described previously [14]. Briefly, 
a total of 19,781 individuals were invited into the study of which 6386 (32%) participated. Two 
sera were not available for analysis (0.03%) because serum quality was not sufficient.  The age 
strata 0 and 1-4 years and non-Western migrants were over-sampled. Each invited individual 
was requested to fill in a questionnaire and to provide a blood sample. The questionnaire 
included for instance demographic characteristics, vaccination history and information related 
to sexually transmittable infections (STIs). Information regarding sexual activity and STI was 
only available from participants older than 14 years of age. A signed informed consent was 
obtained from all participants and for those below 18 years of age also from the parents. The 
study proposal was approved by a medical ethics review committee (ISRCTN 20164309).
4.3.2. Serological measurements
The serum samples collected were stored at -80oC until analysis. HPV-specific serum 
antibodies against L1 VLPs for serotypes 16, 18, 31, 33, 45, 52, and 58 were measured using 
a VLP-based multiplex immunoassay (MIA). GSK (GlaxoSmithKline Biologicals, Rixensart, 
Belgium) kindly supplied the HPV VLPs and transferred the developmental VLP-based MIA. 
VLPs were coupled to a set of seven distinct fluorescent microspheres (Luminex corporation, 
Austin, TX) through a carbodiimide coupling procedure that has been described elsewhere 
[15] with minor modifications. Sulpho-NHS (Pierce, Rockford, IL) and EDC (Pierce, Rockford, 
IL) were dissolved in 0.5M NaH2PO4 (Sigma-Aldrich, St. Louis MO), pH 6.2. 25 µg VLPs/
ml were diluted in PBS and coupled to 1 x 107 fluorescent microspheres. VLP-coupled 
microspheres were stored in a buffer containing 100mM MES (Sigma-Aldrich, St. Louis MO), 
pH 6.0, 1% BSA (Sigma-Aldrich, St. Louis MO), and 0.2% Proclin300 (Sigma-Aldrich, St. Louis 
MO). The MIA was performed as described elsewhere [16] with modifications. Serumbuffer 
(PBS, 1% BSA, 0.2% Tween20 (Merck, Darmstadt, Germany) and 0.2% ProClin300) was 
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used for prewetting the MultiscreenHTS assay plates (Millipore Corporation, Billerica, MA), 
for washing procedures and sample dilutions. Sera were 1/50 diluted and incubated with 4000 
microspheres/HPV serotype/well. R-phycoerythrin (R-PE)-conjugated goat anti-human IgG 
(Jackson ImmunoResearch laboratories Inc., Westgrove, PA) diluted 1:200 was used as a 
conjugate. HPV-specific IgG antibodies were analyzed by using a Bioplex system 200 with 
Bioplex software (Bio-Rad Laboratories, Hercules, CA). For each analyte, median fluorescent 
intensity (MFI) was converted to Luminex Units/ml (LU/ml) by interpolation from a 5-parameter 
logistic standard curve (log-log) using the linear part of that curve.
4.3.3 Reference and control sera
Four quality ‘in house’ control sera were used on each plate. These four sera were composed 
of a pool of HPV negative individuals, a pool of low-positive individuals, a pool of highly-positive 
vaccinated individuals, and a commercially available positive preparation: human intravenous 
immunoglobulin (IVIG, lot LE12G071AE, Baxter, Deerfield, IL). The ‘in house’ standard (IVIG, 
lot LE12H227AF, Baxter) was calibrated against reference serum of GSK for all the seven HPV 
types.
4.3.4 HPV-MIA characteristics and cut-off values
The intra- and inter- assay variation for HPV16 and the reproducibility of the assay for all seven 
HPV types were determined using a serum panel (n = 55) consisting of pre-vaccination samples 
and serum samples from women diagnosed with cervical cancer.  Several monoclonal antibodies 
(MAbs) were used that recognize epitopes on HPV16 (Ritti (donated by M. Muller, Heidelberg), 
HPV16 L1 (GenWay Biotech, San Diego, CA), H16.V5 (donated by N.D. Christensen), Mab885 
(Millipore, Billerica, MA)) and HPV18 (HPV18 L1 (GenWay Biotech, San Diego, CA)). MAbs 
were tested in a 1/100 dilution for HPV16 L1, 1/1000 dilution for Ritti, mAb885 and HPV18 L1, 
and in a 1/10,000 dilution for H16.V5. All mAbs recognized conformational epitopes except 
Mab885, which recognized a linear epitope. The cut-off values for the MIA were determined 
using the one-sided 99% prediction interval (PI) method as described by Frey et al [17].
Table 1. Reactivity of HPV monoclonal antibodies in the VLP based multiplex immunoassay for HPV16 
and 18.
MFI-background
HPV 
type
Monoclonal Dilution HPV16 HPV18 HPV31 HPV33 HPV45 HPV52 HPV58
HPV16 Ritti, C 1000 24114 28 2 -2 9 16
HPV16 L1, C 100 18978 1 -4 -3 0 3 1
H16.V5, C 10000 24553 19 7 0 6 7 1
MAb885, L 1000 9394 1670 7124 1067 1127 1235 3449
HPV18 HPV18 L1, C 1000 7 25290 9 -2 52 24 2
Note: Results are given as MFI units; C, conformational epitope; L, linear epitope.
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4.3.5 Statistical analysis
Data analyses were conducted using SAS version 9.2 and GraphPad Prism version 4.0.3. 
Seroprevalences were calculated for different age-cohorts and weighted. Weights were 
determined proportional to the reference population (Dutch population, 1st January 2007) 
taking into account sex, age, ethnic origin and urbanization degree. Associations between HPV 
seropositivity in individuals older than 14 years of age and sample characteristics including 
sex, ethnic origin, marital status, kind of partner, education level, socio-economic status, age of 
sexual debut, condom use and number of partners in the last six months and reported a history 
of STI were tested in a multivariate logistic regression analysis. Through a backward selection 
variables that were not statistically significant (p<0.05, using the Wald statistic) were removed 
from the model. The model was also applied to analyze interactions with gender. Significance 
(p<0.05) for combinations of HPV seropositivity was calculated using the Chi-square test and 
for comparisons between log-transformed antibody concentrations an unpaired t-test was 
used. 
4.4 Results
4.4.1 Characteristics of the total study sample
Samples from the pre-HPV vaccination period were collected between February 2006 and 
June 2007, a median of 2.8 years before the introduction of HPV vaccination in the Netherlands 
in March 2010. Participants were 0-79 years of age. In this study 54% of the participants were 
female (n = 3473) and 46% were male (n = 2911). 
4.4.2 HPV-MIA characteristics and cut-off values
The mean coefficient of variation (CV) for the intra-assay plate-to-plate variation and variation 
within a plate was 8% and 7%, respectively, while the inter-assay variation, performed on 
different days, had a mean CV of 12%. The reproducibility of the assay was tested on four 
different days by two technicians for all seven HPV types and the correlation (R2) for HPV 
serotypes 16, 18, 31, 33, 45 and 58 was 0.99 and for HPV type 52 0.97 (data not shown). 
All four mAbs that recognize conformational epitopes reacted in a monospecific manner, while 
mAb885 that recognize a linear epitope reacted with all tested HPV-VLPs (Table 1). 
The cut-off value was determined using data from the most likely negative cohorts from the 
serosurveillance study: children between 1 and 10 years of age (n = 859). No significant 
differences in antibody concentrations and in number of seropositives were found among boys 
and girls. The cut-off was assessed as having anti-HPV concentrations of 9, 13, 27, 11, 19, 14, 
and 31 LU/ml for HPV types 16, 18, 31, 33, 45, 52, and 58, respectively. We could compare the 
cut-off levels from the MIA with the values of the competitive luminex immunoassay (cLIA) [15] 
for HPV16 and 18 using data (n = 637) of women aged 11-26 years who were tested in both 
assays [13]. Of this subset 96.4% and 97.0% of the MIA results were in concordance with the 
cLIA for HPV16 and 18, respectively.  For 3.6% and 3.0% of the sera the MIA was seropositive 
and the cLIA seronegative for HPV16 and 18, respectively (Fig. 1).
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Fig. 1. Comparison of seroprevalence of the MIA and cLIA for HPV16 (light gray dots) and HPV18 (black 
dots). Horizontal lines indicate the cut-off values of the MIA (9 and 13 LU/ml for HPV16 (light gray line) 
and HPV18 (black line), respectively) and vertical lines indicate the cut-off values of the cLIA (20 and 24 
mM units for HPV16 (light gray line) and 18 (black line), respectively).
4.4.3 HPV seroprevalence in the Netherlands
The overall seroprevalence for individuals 0-79 years of age for any of the seven HPV-types 
amounted to 17.7% and was 16.0% for men and 19.4% for women.  As expected reflecting 
the median age of sexual debut, a higher seroprevalence (step-up) was observed in the age 
cohort of 15-19 years and 20-24 years compared to the younger age-cohorts. This step-up 
in seroprevalence during adolescence is most pronounced for HPV16 in women (4.3% up to 
14.1%), but is less clear for the other six HPV serotypes (Fig. 2). 
Among the middle aged and elderly cohorts seroprevalences for all seven HPV serotypes 
between female and male sexes were not significantly different. However, in the overall 
seroprevalence a declining trend could be observed from 50 years onwards (p=0.0125). 
As expected, lower seroprevalences were detected in children 1-9 years of age compared 
to cohorts of older age for all seven HPV serotypes. The highest seroprevalences (up to 
4.2%) were found for HPV16 and 18 in these children, while for the other HPV types the 
seroprevalence remained below 3.5%.  For HPV16, 33, 45, 52 and 58 occasional seropositivity 
(24 of the 346) was observed in the infants (0 years of age) and 16 of the 24 seropositive 
infants were 0-6 months of age. 
Focusing on participants older than 14 years of age we found an overall seroprevalence of 
22.8%. The seroprevalence was significantly higher among women (25.2%) compared to 
men (20.3%) (p=0.0002). The prevalence of HPV16 and/or 18 was 13%. A combination of 
antibodies to both HPV16 and HPV18 was found in 4.7% of the participants older than 14 years 
of age (Table 2). This percentage was significantly lower among women (3.6%) compared to 
men (5.7%) (p<0.0001). While in contrast seropositivity for HPV16 or HPV18 was significantly 
higher in women (10.2%) compared to men (6.3%) (p<0.0001). Seropositivity for two or more 
HPV types occurred in 10.1% of the individuals older than 14 years of age. Seropositivity for all 
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Fig. 2. Total HPV seroprevalence and seroprevalence of seven high-risk HPV types in the Netherlands 
among males (dark grey bars), females (light grey bars), and overall (medium grey bars). Error bars 
indicate 95% confidence intervals.
seven HPV types was found in 0.3% of the women and 0.6% of the men older than 14 years 
of age. 
The most prevalent HPV serotype among participants older than 14 years of age was HPV16 
(Table 3), followed by HPV serotypes 45, 18, 33 and 52. Less prevalent were antibodies 
against HPV serotypes 58 and 31. 
56
Table 2. Seropositivity for HPV combinations in the Netherlands (n = 4223) of individuals older than 14 
years of age.
Seropositivity (%, 95%CI) 
Overall Males Females
HPV16 and 18 4.7 (4.1-5.3) 5.7 (4.9-6.6) 3.6 (2.9-4.4)
HPV16 or 18 8.3 (7.3-9.2) 6.3 (5.1-7.5) 10.2 (8.8-11.6)
HPV16 and/or 18 13.0 (11.8-14.1) 12.0 (10.6-13.5) 13.8 (12.1-15.5)
Positive for 1 or more HPV types 22.8 (21.3-24.2) 20.3 (18.4-22.1) 25.2 (23.1-27.3)
Positive for 2 or more HPV types 10.1 (9.2-11.0) 9.8 (8.8-10.8) 10.4 (9.1-11.7)
Positive for 7 HPV types 0.4 (0.2-0.7) 0.6 (0.2-0.9) 0.3 (0.1-0.5)
Note: CI, confidence interval. 
Table 3. Seroprevalence for HPV16, 18, 31, 33, 45, 52, and 58 in the Netherlands among males and 
females older than 14 years of age.
Males Females Overall
% (95%CI) % (95%CI) % (95%CI)
N 1937 2535 4472
Clade α9
HPV16 10.6 (9.2-12.0) 11.9 (10.3-13.6) 11.3 (10.2-12.3)
HPV31 2.5 (1.7-3.4) 3.3 (2.4-4.2) 2.9 (2.3-3.6)
HPV33 6.0 (4.7-7.2) 6.5 (5.5-7.6) 6.2 (5.5-7.0)
HPV52 5.4 (4.4-6.3) 6.9 (5.9-8.0) 6.2 (5.5-6.8)
HPV58 3.7 (2.8-4.5) 4.5 (3.6-5.3) 4.1 (3.4-4.8)
Clade α7
HPV18 7.2 (6.1-8.2) 5.6 (4.7-6.4) 6.3 (5.6-7.1)
HPV45 6.8 (5.4-8.1) 7.5 (6.2-8.9) 7.1 (6.1-8.2)
Note: CI, confidence interval.
4.4.4 Antibody concentrations
The antibody concentrations for HPV16 and HPV18 were significantly lower in children (1-9 
years of age) than in the age cohorts of 20-79 years of age. Of all seropositive children more 
than half showed antibody concentrations within 2 times the standard deviation of the cut-
off values for HPV16 and 18 (Fig. 3) and similar results were found for the other hr-HPV 
serotypes. In the middle aged and elderly cohorts antibody concentrations remained relatively 
constant and were comparable with those found in the age cohort of 20-24 years. 
4.4.5 Risk factors
HPV seropositivity for at least one of the tested seven HPV types was significantly associated 
with sex, ethnicity, marital status, having a casual partner, age of sexual debut and reported a 
history of STI (Table 4A). Female sex was associated with a higher risk of HPV seropositivity 
for at least one of the seven HPV types. HPV seropositivity was significantly higher for migrants 
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from Suriname, Aruba, and the Dutch Antilles and for first generation migrants. Also marital 
status, i.e. not married, living together, and divorced were associated with an increased risk 
for HPV seropositivity compared to married individuals. In contrast, widowed individuals were 
associated with a decreased risk for HPV seropositivity. Educational level, socio-economic 
status, condom use and number of partners in the last six months were not found to be 
significantly associated with HPV seropositivity. Marital status was the only variable showing 
a significant difference between male and female sexes (Table 4B). Women who were living 
together, not married or divorced were associated with a higher risk of HPV seropositivity. Both 
widowed men and women showed a decreased risk of HPV seropositivity. 
Fig. 3. Antibody concentrations (LU/ml) of A. HPV16 and B. HPV18 in the Netherlands for individuals 
0-79 years of age. The grey line indicates the cut-off value. Statistical significance is calculated by using 
an unpaired t-test of log-transformed data. A. 1-9 age cohorts versus 20-24 age cohort p<0.0001. B. 1-9 
age cohorts versus 20-24 age cohort p<0.0001. The age cohorts 1-9 years were significantly different 
compared to the age cohorts 20-79 years, but statistical significances are not shown.
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Table 4A. HPV seropositivity by demographic and sexual risk factors of individuals older than 14 years 
of age.
Category Total study 
population
Sero-conver-
sion
Full model  Model after back-
ward selection
Demography N n % (n/N) OR (95% CI) OR (95% CI)
Total 4472 1057 24
Age
15-19 298 41 14 Ref Ref
20-24 364 82 23 1.7 (1.1-2.7) 1.8 (1.2-2.7)
25-30 348 73 21 1.8 (1.1-2.9) 1.8 (1.2-2.9)
31-39 715 175 24 2.5 (1.6-3.9) 2.6 (1.7-4.0)
40-49 641 183 29 3.5 (2.2-5.5) 3.6 (2.3-5.6)
50-59 714 190 27 3.1 (2.0-4.9) 3.1 (2.0-4.9)
60-69 799 186 23 3.1 (2.0-4.9) 3.0 (2.0-4.8)
>69 593 127 21 3.2 (2.0-5.2) 3.1 (2.0-4.9)
Sex 
Male 1937 409 21 Ref Ref
Female 2535 648 26 1.3 (1.1-1.5) 1.3 (1.1-1.5)
Ethnicity 
Indigenous Dutch 3659 800 22 Ref Ref
First generation 378 120 32 1.6 (1.2-2.1) 1.6 (1.3-2.0)
Second generation 269 65 24 1.2 (0.9-1.5) 1.1 (0.8-1.5)
First generation SAN (a) 130 59 45 2.6 (1.8-3.8) 2.5 (1.7-3.7)
Second generation SAN 36 13 36 2.0 (1.0-4.0) 2.0 (1.0-3.9)
Education
Low 522 130 25 1.1 (0.9-1.5) NS
Middle 2713 617 23 Ref
High 1163 287 25 1.1 (0.9-1.3)
Social economic status
Low 2097 483 23 1.0 (0.8-1.3) NS
Middle 727 185 25 Ref
High 722 166 23 1.0 (0.8-1.2)
Marital status
Married 2547 560 22 Ref Ref
Living together 469 140 30 1.8 (1.4-2.3) 1.8 (1.4-2.3)
Not married 909 203 22 1.5 (1.1-2.1) 1.6 (1.2-2.0)
Divorced 240 84 35 1.5 (1.1-2.2) 1.6 (1.2-2.1)
Widow 227 41 18 0.7 (0.4-1.0) 0.7 (0.5-1.0)
Partner
No partner 831 188 23 Ref NS
Steady partner 3270 759 23 0.9 (0.7-1.3)
Casual partner 118 38 32 1.6 (0.9-2.6)
Steady and casual partner 179 46 26 1.1 (0.7-1.8)
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Sexual risk factors 
Age of sexual debut 
<17 687 180 26 Ref Ref
17-19 1251 326 26 1.0 (0.8-1.2) 1.0 (0.8-1.2)
>19 1307 265 20 0.7 (0.6-1.0) 0.7 (0.6-0.9)
Number of partners <6 
months
0 662 157 24 Ref Ref
1 2672 643 24 1.1 (0.8-1.5) 1.2 (0.9-1.5)
>1 116 33 28 1.0 (0.5-1.7) 1.3 (0.8-2.0)
Condom use last sexual 
intercourse
No 349 78 22 Ref NS
Yes 2435 595 24 1.1 (0.8-1.5)
Ever had STI
No 3647 828 23 Ref Ref
Yes 212 76 36 1.5 (1.1-2.0) 1.5 (1.1-2.0)
Note: CI, confidence interval; (a) Surinamese, Aruban and Dutch Antillean migrants; NS, not significant.
Table 4B. Gender specific HPV seropositivity by marital status of individuals older than 14 years of age.
Category Total study 
population
Sero-conversion Full model  Model after back-
ward selection
Demography N n % (n/N) OR (95% CI) OR (95% CI)
Marital status
Females
Married 1355 295 22 Ref Ref
Living together 284 91 32 2.0 (1.5-2.8) 2.0 (1.5-2.8)
Not married 511 146 29 2.3 (1.5-3.5) 2.3 (1.5-3.7)
Divorced 168 72 43 2.3 (1.5-3.7) 2.3 (1.5-3.7)
Widow 172 30 17 0.7 (0.4-1.2) 0.7 (0.4-1.2)
Males
Married 1192 265 22 Ref Ref
Living together 185 49 26 1.6 (1.1-2.3) 1.6 (1.1-2.3)
Not married 398 57 14 0.8 (0.5-1.5) 0.8 (0.4-1.5)
Divorced 72 12 17 0.6 (0.3-1.3) 0.6 (0.3-1.3)
Widow 55 11 20 0.9 (0.4-2.0) 0.9 (0.4-1.9)
Note: CI, confidence interval. 
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4.5 Discussion 
Here we describe the cross-sectional seroprevalence of antibodies to hr-HPV types 16, 18, 31, 
33, 45, 52, and 58 in a pre-vaccination era in women, men and children in the Netherlands. 
We found a step-up in the overall seroprevalence for any HPV serotype in the age cohorts of 
15-19 to 20-24 years. This step-up was most pronounced for HPV16 and less clear for the 
other HPV serotypes. A decreasing trend was observed in the seroprevalence from 50 years 
onwards. The overall seroprevalence was highest for women. HPV16 was the most prevalent 
HPV type among men and women and in 10.1% of the individuals older than 14 years of age, 
seropositivity for multiple HPV types was found.
4.5.1 Seroprevalences
Besides two other studies, information about the HPV seroprevalence in the Netherlands is 
scarce [12, 13]. This is the first study in which the HPV seroprevalence is estimated in a 
population representative for the Netherlands. By means of a cross-sectional population-based 
study, a large serum bank representative for the general population in the Netherlands was 
available. We were able to estimate the HPV seroprevalence in individuals 0-79 years of age 
in the time period before the implementation of the HPV vaccine in the national immunization 
program. This study provided insight in the distribution of hr HPV types in the Dutch population 
and the associated risk factors. 
As nearly all genital HPV infections are sexually transmitted, the step-up in seroprevalence 
is expected around puberty reflecting the start of sexual activity. This was most pronounced 
in women. This step-up in seropositivity during adolescence has been described for HPV16 
and 18 [7-9, 18], but limited serological data are available for other hr-HPV serotypes. As 
reported earlier the seroprevalence among women was higher compared to men [8, 19]. 
However, the percentages found for men were lower in comparison to other studies, while the 
seroprevalences among women were comparable. In a seroprevalence study in Amsterdam in 
specific age cohorts (17-90 years) and with the use of a different serological assay, they also 
found higher seroprevalences in women compared to men [12].
The decreasing trend starting from 50 year onwards might be related to a cohort effect. Older 
individuals might have had fewer sexual partners compared to younger individuals because of 
changing patterns of sexual behavior over time [20]. Waning antibodies might also explain the 
decline in antibody levels but the HPV humoral response is considered to be relatively stable 
over time [10].
One might not expect antibodies against HPV to be found in young children considering the 
improbability of having sexual activities at these young ages. In most studies low HPV16 
seroprevalences in children up to 9 years of age are reported (1.5-7.6%) [21, 22] in line 
with our findings.  Antibody concentrations were significantly lower in children compared to 
adults, indicating limited exposure to the hr-HPV types before adolescence. The observed 
seroprevalences in the infants (0-6 months of age) could be due to maternal IgG antibodies 
that wane within a few months after birth [22, 23]. Besides transmission of HPV by direct 
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contact during sexual activities, other routes of transmission have been suggested as HPV 
can be present in the oral mucosa, tonsils and fingers and vertical and horizontal transmission 
could result in the presence of HPV antibodies in children and infants [22, 24, 25].
Although it is possible to be infected with multiple HPV types, resulting in the observed multi-
seropositivity in 10.1% of the study population, cross-reactivity of HPV specific antibodies 
should also be taken into account. The HPV types tested are phylogenetically related and 
belong to clade α7 (HPV18 and 45) or α9 (HPV16, 31, 33, 52 and 58) making cross-reactivity 
of antibodies certainly conceivable. However, specific interactions for HPV types within a clade 
were not more often found than for HPV types of different clades probably due to a high 
homology of 60-70% of the nucleotide sequence of the L1 gene between clades of the alpha 
genus [26]. 
HPV16 is most predominant worldwide with differences in distribution of the other HPV types 
between the continents [27]. In Germany, HPV16 antibodies were also found to be the most 
dominant HPV type followed by HPV18 [9]. In our study, HPV16 antibody incidences were also 
highest, however, small differences in the distribution of the other HPV serotypes were found. 
Only for marital status female sex had a higher risk of being seropositive. Behavioral factors 
associated with HPV seropositivity were similar as those reported earlier [18, 28] and confirm 
that ethnicity, marital status, type of partner and history of STI are associated with the risk for 
HPV seroprevalence. Studies among men indicate that hr-HPV types are very common among 
men and HPV infections in men are strongly associated with anal and penile cancers [29]. 
Because women are currently vaccinated against HPV16 and 18, herd immunity can play a roll 
in the future in reducing the incidence of HPV infection in men [30]. Moreover, most women, 
older than 14 years of age, are HPV seronegative and could therefore also benefit from the 
HPV16/18 vaccination.
4.5.2 Immunoassay
Several immunoassays for the detection of HPV-specific antibodies are available [9, 15, 16, 
31]. Most assays are developed by the vaccine industry [15, 16, 31] and used in vaccine trials. 
These assays are suggested to be useful for the detection of antibodies in natural infections. 
However, the usefulness of these assays in natural infections can be discussed as serum 
antibody concentrations derived after natural infections are much lower, making the distinction 
between seronegative and seropositive complicated. We found our MIA highly reproducible 
and type specific for HPV16 and HPV18. It was based upon the VLP-ELISA [31] which showed 
a high percentage of concordance with the cLIA. But as expected, in our direct MIA we found 
more seropositive individuals compared to the cLIA. This could be due to the fact that the 
cLIA uses HPV-specific mAbs that compete with the HPV-specific serum antibodies, thereby 
measuring mainly high affinity antibodies directed towards one epitope while the MIA detects 
all antibodies directed against the VLPs. Comparisons between different HPV seroprevalence 
studies are hindered due to the use of different assays and, most importantly, the different 
cut-off definitions [9, 15, 16, 31]. Currently, only a WHO HPV standard reference serum for 
serotype 16 is available which contains a low antibody concentration. Therefore this reference 
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standard is not suitable for vaccine studies and can hardly be used in seroprevalence studies 
of non-vaccinated populations/cohorts. The development of a common standard reference 
serum positive for multiple HPV types would facilitate international comparisons. 
A possible limitation of this study is the response rate of 32% although the rate is acceptable 
for population-based studies. The number of participants in this study was high (n = 6384) but 
to minimize the bias in seroprevalences and associations with risk factors data were weighted 
taking into account age, ethnic origin and urbanization degree. A second limitation is that 
sexual behavior was self-reported and this might have led to a reporting bias due to reluctance 
to disclose information about sexual behavior in this study population. Questions not included 
in this questionnaire, such as lifetime number of sexual partners, could have been a better 
predictor of HPV seropositivity. In general, seroprevalence studies may underestimate the 
rate of HPV infections as not all HPV infected individuals develop a measurable HPV antibody 
response [32]. 
4.6 Conclusion
In summary, our study provides information about the seroepidemiology of seven hr-HPV 
types in the Netherlands. The HPV vaccination program is targeted at preadolescents as is 
justified by the results in this study in which a step-up in HPV seroprevalence is observed at 
ages of sexual debut. Direct interpretation of the frequency of infection is hampered by cross-
reactivity as well as seroconversion rate. Despite this, seroprevalences in the pre-vaccine era 
can be used as baseline to evaluate long-term population effects of HPV16/18 vaccination 
such as effect of vaccination on virus circulation in both women and men. Further studies in 
measurement of immune responses and interpretation of serological data are needed to make 
full advantage of this tool used for the monitoring HPV-vaccination programmes.
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5.1 Abstract 
This study evaluates trends in antibody seroprevalences of seven high-risk human papillomavirus 
(hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) between the 1995-96 and 2006-07 
sero-surveys among the Dutch general population in the pre-vaccination era. 
Serum samples of men and women (0-79 years of age) from two cross-sectional population-
based serosurveillance studies performed in 1995-96 (n = 3303) and 2006-07 (n = 6384) were 
tested for HPV-specific antibodies in a VLP-based multiplex immunoassay. HPV16-specific 
antibody seroprevalence increased during adolescence and shifted to younger ages in the 
2006-07 survey compared to the 1995-96 survey. This step-up in HPV16 seroprevalence was 
most pronounced in women, while a more gradual increase was observed in men. Also in 
cohorts older than 49 years, HPV16 seroprevalence was higher in 2006-07 as compared to 
1995-96 survey. A higher overall seroprevalence in individuals older than 15 years of age was 
found for HPV16, 18, 31 and 45 in 2006-07 as compared to 1995-96. For HPV33, 52 and 58 
seroprevalences were comparable over this 11-year time period. Seropositivity for one or more 
HPV types was significantly higher in 2006-07 (23.1%) than in 1995-96 (20.0%) (p=0.013). 
Multi-seropositivity increased from 7.1% in 1995-96 up to 10.2% in 2006-07 (p<0.0001). 
Differences in HPV seropositivity for at least one of the seven HPV types between both 
surveys could be explained in addition to demographic characteristics (age, sex, urbanization 
degree and ethnicity), also by changes in sexual behaviour (marital status, age of sexual 
debut and ever reported an STI). The observed increase in particular HPV16 seroprevalence 
could be due to changes in sexual behaviour over the years, and especially in age of sexual 
debut. Seroprevalence studies provide insight into the distribution of HPV types and infection 
dynamics in the general population over time, which is important to assess the impact of HPV-
vaccination.
5.2 Introduction
Human papillomavirus (HPV) consists of a large family of more than 120 HPV genotypes of 
which 40 types are oncogenic [1]. These oncogenic HPV types can cause cervical cancer, 
other genital related cancers and oro-pharyngeal cancers. HPV infections are the major cause 
of cervical cancer and in 99.7% of the cases HPV-DNA can be identified [2]. The two most 
important oncogenic HPV genotypes detected in cervical cancer are HPV16 and 18 [3]. 
HPV is a sexually transmitted virus and the highest HPV antibody seroprevalence is found 
among individuals 20-40 years of age with a decreasing seroprevalence in elderly [4, 5]. Age-
related trends in seroprevalence might be due to HPV incidence, cohort effects and waning of 
detectable antibody levels [4]. Women were found HPV seropositive more often than men [4, 
6, 7]. Infections in men often involve keratinized epithelium that may be less likely to induce a 
humoral immune response than infection of mucosal epithelium [7].
Because HPV-specific antibodies are not often observed in transient infections, seroconversion 
is more strongly associated with persistent HPV infections [8, 9]. Measurable HPV-specific 
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antibody responses in serum develop in approximately 50-70% of individuals infected with 
HPV, probably due to the fact that HPV is able to evade the host immune system [10, 11]. 
Serological HPV responses are a measure of past HPV exposure as in naturally infected 
individuals HPV antibody concentrations persist for many years [12, 13]. 
Currently, comparisons between studies on trends in serological hr-HPV prevalence over time 
are limited because most studies are focused on DNA prevalence or incidence of cervical 
intraepithelial neoplasia (CIN) in women [14-17]. We have examined changes in antibody 
seroprevalence between 1995-96 and 2006-07 surveys in men and women in the Netherlands 
for HPV serotypes 16, 18, 31, 33, 45, 52, and 58. These data will provide more information 
about the number of HPV exposures over time and possible changes in HPV serotypes within 
this time period. In addition, these data serves as a baseline before the implementation of the 
HPV vaccine in the Dutch national immunization program in 2010 and are thus valuable in 
assessing the impact of the HPV vaccination program on a population level.  
5.3 Materials and methods 
5.3.1 Ethics statement
The study proposal was approved by the Medical Ethics Testing Committee of the foundation 
of therapeutic evaluation of medicines (METC-STEG) in Almere, the Netherlands (clinical trial 
number: ISRCTN 20164309). A written informed consent was obtained from all participants 
and for those below 18 years of age also from the parents, care takers or guardians.  
5.3.2 Study populations
In the Netherlands, serum samples from two cross-sectional population-based serosurveillance 
studies performed from October 1995 to December 1996 and from February 2006 to June 2007 
were available. Participants, women, men and children, of both studies were 0-79 years of age. 
The participation rates for the 1995-96 and 2006-07 surveys were 55% and 32%, respectively. 
Study designs have been described earlier [18, 19]. Briefly, the participants were asked to fill in 
a questionnaire and to provide a blood sample. Both questionnaires included data for instance 
on demographic characteristics, ethnicity (first and second generation migrants), vaccination 
history and sexual behaviour. The questionnaire used in 1995-96 was extended in the 2006-
07 survey with more questions about sexual behaviour and migrants. Information related to 
sexual behaviour was only available from participants older than 15 years of age in the 1995-
96 study and from participants older than 14 years of age in the 2006-07 study. 
5.3.3 Serological measurements
Serum samples of both surveys were stored at -80oC until analysis. For the measurement 
of HPV-specific IgG serum antibodies against L1 virus-like-particles (VLP) of HPV16, 18, 
31, 33, 45, 52, and 58, a VLP-based multiplex immunoassay (MIA) was used as previously 
described [20]. GSK (GlaxoSmithKline Biologicals S.A., Rixensart, Belgium) kindly supplied 
the HPV-VLPs. Briefly, VLPs were conjugated to seven distinct fluorescent microspheres 
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via amine coupling. Serum samples were 1/50 diluted and incubated with the VLP-coupled 
microspheres. HPV-specific IgG serum antibodies were detected using a secondary goat anti-
human R-phycoerythrin (R-PE)-conjugated antibody. Four ‘in-house’ control sera and an ‘in-
house’ standard were used on each plate. The ‘in-house’ standard (IVIG, lot LE12H227AF, 
Baxter) was calibrated against reference serum of GSK for all the seven HPV types. HPV-
specific IgG antibodies were analyzed using the Bioplex system 200 with Bioplex software 
(Bio-Rad Laboratories, Hercules, CA). Samples were assumed to be seropositive above cut-
offs determined previously with this assay: 9, 13, 27, 11, 19, 14, and 31 Luminex Units/ml (LU/
ml) for HPV16, 18, 31, 33, 45, 52, and 58, respectively. 
5.3.4 Statistical analysis
Data analyses were conducted using SAS version 9.2 and Graphpad version 5.0. Age-
specific seroprevalences were calculated and weighted. Weights (sex, age, ethnic origin 
and urbanization degree) for the 1995-96 survey were determined proportional to the Dutch 
reference population on January 1st 1996 and for the 2006-07 survey on January 1st 2007. 
To test whether any trends could be explained by differences in risk factors between the 
two serosurveys we performed a logistic regression analysis on a pooled dataset of both 
surveys for individuals older than 15 years of age. Only persons with information about all 
risk variables were included in the analyses (74%). We included the following variables: 
age, sex, urbanization degree, ethnicity, marital status and sexual behaviour. Besides 
odds ratios, we calculated unadjusted and adjusted probabilities and converted these to 
percentages [21] to show the actual reduction in seroprevalence between both surveys. We 
compared unadjusted HPV seroprevalences (study parameter) with seroprevalences adjusted 
for demographic characteristics (age, sex, urbanization degree and ethnicity) and then 
demographic characteristics with sexual risk behaviour (marital status, age of sexual debut 
and a self-reported history of sexual transmittable infections (STI). The risk factor analysis was 
carried out for combined HPV seropositivity, in which the risk factor analysis included data on 
seropositivity for at least one of the seven HPV types. In addition, the risk factor analysis was 
assessed for seropositivity of each HPV type separately. 
Statistically significant differences (p<0.05) for HPV combinations or HPV seroprevalences 
were analyzed using a Chi-square test and differences between antibody concentrations of 
seropositive individuals were analyzed using a Mann-Whitney test. 
5.4 Results 
5.4.1 Characteristics of the serosurveillance studies
We tested 3303 serum samples from the 1995-96 survey (48% men and 52% women) and 
6384 samples from the 2006-07 survey (46% men and 54% women). In the 1995-96 survey 
the cohorts older than 15 years of age contained more individuals with the Dutch nationality, 
were married and less self-reported history of STI (Table 1). The mean age of sexual debut in 
persons younger than 26 years was higher in the 1995-96 survey (17.5 years, SD 17.1-17.9) 
69
5
C
ha
ng
es
 in
 H
P
V
 a
nt
ib
od
y 
se
ro
pr
ev
al
en
ce
Table 1. Study characteristics of the 1995-96 and 2006-07 survey of individuals older than 15 years of 
age.
1995-96 survey 2006-07 survey
Variable N (%) N (%) p-value
Age
16-19 103 (5) 160 (4) 0.0425
20-24 188 (9) 364 (8)
25-29 193 (9) 348 (8)
30-39 364 (17) 715 (17)
40-49 330 (15) 641 (15)
50-59 382 (17) 714 (16)
60-69 333 (15) 799 (18)
>70 295 (13) 593 (14)
Sex
Male 996 (46) 1864 (43) 0.0535
Female 1192 (54) 2470 (57)
Ethnicity
Dutch 1988 (91) 3544 (82) <0.0001
First generation migrants 94 (4) 498 (11)
Second gen. migrants 106 (5) 292 (7)
Marital status
Married 1372 (63) 2547 (59) <0.0001
Living together 180 (8) 469 (11)
Not married 406 (19) 851 (20)
Divorced 88 (4) 240 (6)
Widow 142 (6) 227 (5)
Ever had sexual intercourse
No 107 (5) 177 (4) 0.0531
Yes 1898 (95) 4001 (96)
Number of sex partners last 12 months last 6 months
0 370 (19) 662 (19) N/A
1-2 1506 (79) 2736 (80)
>2 26 (1) 20 (1)
Age at first sexual intercourse 
<17 236 (15) 677 (21) <0.0001
17-19 575 (36) 1251 (39)
>19 789 (49) 1307 (40)
Mean (SD), years* 17.5 (17.1-17.9) 16.9 (16.6-17.2)
Ever had STI
no 1821 (98) 3612 (94) <0.0001
yes 39 (2) 211 (6)
Note: Persons are ≥16 years of age; 1995-96 survey n = 2188; 2006-07 survey n = 4334.
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as compared to the 2006-07 survey (16.9 years, SD 16.6-17.2). In both surveys women were 
younger at first sexual intercourse (1995-96: 17.2 years, SD: 16.7-17.6, 2006-07: 16.6 years, 
SD: 16.3-16.8) than men (1995-96: 17.9 years, SD: 17.5-18.5, 2006-07: 17.3 years, SD: 16.7-
17.8). 
5.4.2 Comparison of HPV antibody seroprevalences in 1995-96 and 2006-07
The total age-specific antibody seroprevalence for any HPV type started to increase in the 
cohort of 15-19 years up to 30-39 years in 1995-96 and to 40-49 years in 2006-07 (Fig. 1). 
Fig 1. Trends in antibody seroprevalence. Total seroprevalence for any HPV serotype and overall 
seroprevalence for the seven hr-HPV serotypes tested between the 1995-96 (black bars) and 2006-07 
(grey bars) surveys. 
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In the older age groups (>49 years) a significant HPV-specific decreasing trend was observed 
in 2006-07 (p=0.013). Nevertheless, a higher total HPV seroprevalence was observed in 
2006-07 compared with 1995-96 for individuals older than 40 years of age. In addition, a 
gradual rise in total HPV seroprevalence was observed from birth up to the age cohorts of 
15-19 years. HPV16 seroprevalence was higher in 2006-07 as compared to 1995-96 in all 
age groups. Interestingly, a clear step-up in HPV16 seroprevalence was observed among the 
adolescent/young adult cohorts, which occurred at an earlier age in 2006-07 (age cohort 15-
19 years) compared with 1995-96 (age cohort 20-24 years) (Fig. 2A). This step-up in HPV16 
seroprevalence was most pronounced in women, while a more gradual increase with age 
in HPV16 seroprevalence was found in men in both surveys (Fig. 2B). For the other 6 HPV 
types also a more gradual increase in age-specific seroprevalence was observed with highest 
seroprevalences in individuals aged 30-59 years (Fig. 1). For HPV33 and 45 higher age-specific 
seroprevalences were found in 2006-07 compared with 1995-96 while HPV52 was slightly 
higher in the 1995-96 survey. Focusing on individuals older than 15 years of age, the most 
prevalent HPV-specific antibodies in 2006-07 were directed against HPV16 (11.5%) followed 
by HPV45 (7.2%), while in 1995-96 antibodies against HPV52 (6.9%) and HPV16 (6.6%) were 
1995-96 2006-07
% (95%CI) % (95%CI) p-value
Clade α9
HPV16 6.6 (5.5-7.6) 11.5 (10.4-12.5) <0.0001
HPV31 1.3 (0.7-1.8) 3.0 (2.3-3.6) <0.0001
HPV33 5.5 (4.4-6.5) 6.3 (5.5-7.1) 0.205
HPV52 6.9 (5.8-8.0) 6.3 (5.6-6.9) 0.330
HPV58 4.3 (3.2-5.4) 4.1 (3.5-4.8) 0.768
Clade α7
HPV18 4.8 (3.7-5.8) 6.4 (5.6-7.2) 0.015
HPV45 5.0 (3.8-6.2) 7.2 (6.2-8.2) 0.006
Note: 1995-96 survey n = 2188; 2006-07 survey n = 4334.
Table 2. Overall antibody seroprevalences of seven hr-HPV serotypes of individuals older than 15 years 
of age in the 1995 and 2006-07 survey. 
1995-96 2006-07
% (95%CI) % (95%CI) p-value
HPV16 and 18 2.3 (1.0-3.6) 4.7  (4.1-5.3) 0.186
HPV16 or 18 8.0 (6.7-9.2) 8.5 (7.5-9.4) 0.517
HPV16 and/or 18 9.6 (8.4-10.9) 13.2 (12.1-14.3) <0.0001
Positive ≥ 1 HPV types 20.0 (17.9-22.1) 23.1 (22.1-24.5) 0.013
Positive ≥ 2 HPV types 7.1 (6.1-8.1) 10.2  (9.3-11.1) <0.0001
Positive ≥ 3 HPV types 3.4 (2.6-4.2) 5.1 (4.3-6.0) 0.002
Note: 1995-96 survey n = 2188; 2006-07 survey n = 4334.
Table 3. Combinations of overall HPV antibody seropositivity of individuals older than 15 years of age in 
the 1995-96 and 2006-07 survey.
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most prevalent (Table 2). In 2006-07, significantly higher overall seroprevalences were found 
for HPV serotypes 16 (p<0.0001), 18 (p=0.015), 31 (p<0.0001) and 45 (p=0.006) compared 
with 1995-96, while for the other three HPV serotypes (33, 52 and 58) seroprevalences were 
comparable. A combination of HPV16 and/or HPV18 seropositivity was also higher in 2006-07 
(13.2%) than in 1995-96 (9.6%) (p<0.0001) (Table 3). Moreover, the percentage of individuals 
who were seropositive for one or more HPV types was higher in 2006-07 (23.1%) than in 
1995-96 (20%) (p=0.013). Also seropositivity for ≥2 or ≥3 HPV types significantly increased 
from 7.1% or 3.4% in 1995-96 to 10.2% or 5.1% in 2006-07 (p<0.0001, p=0.002), respectively. 
Only a small percentage of individuals (1.9% in 1995-96 and 3.0% in 2006-07 survey) was 
seropositive for ≥4 HPV serotypes in both surveys gradually decreasing to 0.2% in the 1995-96 
survey and 0.4% in the 2006-07 survey for 7 HPV types. 
Fig. 2. Comparison of trends in HPV16 antibody seroprevalence. Seroprevalence among women (A) 
and men (B) in the 1995-96 (black bars) and 2006-07 (grey bars) surveys.
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5.4.3 HPV type-specific antibody concentrations among seropositive individuals
Although a higher HPV16 seroprevalence was found in 2006-07 compared with 1995-96, 
the age-specific HPV16 geometric mean concentrations (GMCs) of seropositive individuals 
was comparable in all age cohorts between both studies (Fig. 3). For HPV18, higher GMCs 
were found in 2006-07 as compared to 1995-96 reaching significance in the age cohorts 1-4 
years (p=0.02), 50-59 years (p=0.04), and 60-69 years (p=0.02). For HPV types 33, 45 and 52 
significant higher GMCs were found in 2006-07 as compared to 1995-96 for the age cohorts 
1-4 years (HPV33, p=0.01), 40-49 years (HPV45, p=0.0004), 50-59 years (HPV33, p=0.04), 
60-69 years (HPV52, p=0.001) and 70-79 years (HPV45, p=0.04). Comparable GMCs of 
seropositive individuals were found for HPV31 and 58 between 1995-96 and 2006-07 in all 
age-cohorts.
Fig. 3. HPV antibody concentrations. HPV16 (A) and HPV18 (B) antibody concentrations (LU/ml) of 
seropositive individuals in the 1995-96 (black dots) and in 2006-07 (grey dots) surveys. The dark grey 
lines indicate the geometric mean concentration. For HPV18 significant different antibody concentrations 
were found in the age cohorts 1-4 (p=0.04), 50-59 (p=0.04) and 60-69 (p=0.02).
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5.4.4 Pooled risk factor analysis associated with HPV antibody seropositivity in the 1995-96 
and 2006-07 surveys
HPV seropositivity for at least one of the seven HPV types in individuals older than 15 years 
of age before adjustment of any variables was 20.7% in the 1995-96 study and 23.5% in the 
2006-07 study (OR:1.2, 95%CI 1.0-1.4). After pooling both surveys, adjustment of demographic 
characteristics (age, sex, urbanization degree and ethnicity) resulted in a smaller difference 
in HPV seroprevalence between the 1995-96 survey (21.0%) and 2006-07 (23.2%) survey 
(OR: 1.1, 95%CI 1.0-1.3). The difference between both surveys decreased even further with 
adjustments for demographic characteristics and sexual risk factors (marital status, age of 
sexual debut and a self-reported history of STI). The HPV seroprevalence of the 1995-96 
survey (22.2%) and the 2006-07 survey (22.8%) only differed by 0.6% (OR: 1.0, 95%CI 0.9-
1.2). 
HPV types 16, 18, 31, and 45 showed a significant difference between the 1995-96 and 2006-
07 survey before adjustment of any variables. The risk factor analysis for seropositivity of 
each HPV type separately was comparable with the risk factor analysis of combined HPV 
seropositivity (seropositive for at least one of the seven HPV types), in which a decrease in 
ORs after adjusting for demographic characteristics and sexual risk factors was observed. 
However, even after adjustment of demographic characteristics and sexual risk factors the 
difference for HPV16 (OR: 1.5, 95%CI 1.2-2.0) and HPV31 (OR: 1.7, 95%CI 1.1-2.7) between 
the two surveys remained statistically significant.
5.5 Discussion
Several observations from this study indicate that the situation on HPV incidence has changed 
in the Netherlands. First, the overall antibody seroprevalence of seven hr-HPV types has 
increased, in the age cohorts older than 15 years of age, 3.1% in 2006-07 as compared to the 
serosurveillance study 11 years earlier due to a significant higher seroprevalence for HPV16, 
18, 31 and 45.  Secondly, the clear-cut rise in HPV16 seroprevalence in particular women 
has shifted to younger aged cohorts (from 25-29 to 20-24 years). Finally, seropositivity for 
HPV16/18 combinations, for one or more types, and for multiple HPV serotypes has also 
significantly increased during the 11-year time interval. 
Comparable HPV-specific antibody levels of seropositive individuals were observed between the 
1995-96 and 2006-07 survey, suggesting that factors involved in the generation of HPV-specific 
antibodies have not changed over time. The increase in HPV seroprevalence, particularly for 
HPV16, between the two time periods could be due to an increase in HPV infection and/or 
HPV circulation [22]. However, Kibur et al. did not found major differences in the age-specific 
HPV16 seroprevalence and incidence among Finnish primiparous women between the 1980s 
and 1990s [23].  Interestingly, in the late 1990s HPV16 antibody seroprevalence increased 
in Finland especially in women up to 31 years of age [24]. In line with this, an increase in 
cervical cancer cases among women below 55 years of age was observed [25]. Also higher 
frequencies of multiple HPV infections, high-risk HPV infections and changes in the distribution 
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of HPV types was observed in women diagnosed with CIN over the period 1985-2007, with 
major changes over the last ten years [15]. A Danish study showed that HPV-associated anal 
cancers increased between 1998-2008, especially in women, while non-HPV associated 
cancers remained relatively constant [26]. In the Netherlands, an increase in CIN3 lesions in 
the cervical screening registry has been observed since 2005. This increase in CIN3 might be 
due to more HPV circulation, however, an effect of changing screening algorithms can not be 
ruled out [27, 28]. 
Over the years, higher population mobility in recent years, including immigration of populations 
who are at higher risk for HPV seropositivity and also changes in sexual behaviour, for instance 
a younger age of sexual debut and more sexual partners, increased the risk of STI [29]. These 
findings are supported by our data in which the group of immigrants was larger in the 2006-07 
survey than in the 1995-96 survey. Our pooled risk factor analysis in individuals older than 15 
years of age confirmed that the increase in HPV seroprevalence over time could partially be 
explained, in addition to demographic characteristics, by changes in sexual behaviour between 
the two time periods. After adjustments of demographic characteristics the differences in 
seroprevalence declines slightly, while a somewhat larger impact was found after adjustment 
for sexual behaviour. Then HPV seroprevalence between both studies differed only with 0.6%. 
The largest difference between both serosurveys was found for HPV16 and HPV31, indicating 
that these HPV types have increased in circulation. We can not exclude that the observed 
difference was due to variation in selective participation rates between both surveys. However, 
national data on age of sexual debut are in agreement with our data. The median age of girls 
who were sexually active decreased from 18 years in 1995 to 16 years in 2006 [30-32]. The 
observed shift in the rise in HPV16 seroprevalence to earlier age female cohorts in 2006-
07 compared with 1995-96 corresponds with these data. The HPV16 seroprevalence among 
women aged 15-24 years in the 2006-07 survey was comparable with a previous cross-
sectional seroprevalence study among Brazilian primiparous women [33].
The observed HPV seroprevalence in children might be due to vertical or horizontal transmission 
of HPV, as HPV is also transmittable without having sexual contact [20, 34]. In addition, HPV-
specific cross-reactive antibodies against HPV types not detected in our 7-valent VLP-MIA but 
with a high prevalence in children, e.g. cutaneous HPV types, might account for the observed 
HPV antibody seropositivity in children. 
In older adults (65-74 years of age) sexual activity declines with age although 53% is still sexually 
active [35]. Interestingly, the higher HPV seroprevalences in elderly in 2006-07 compared 
with 1995-96 might be due to an increase in sexual activity among older aged individuals 
because of the development of new therapeutic interventions (i.e. Viagra) that can be used 
when having sexual problems, especially in men [36].  Older women might be more vulnerable 
to STI because of post-menopausal changes. Post-menopausal changes can cause atrophy 
or thinning of mucosa with decreased lubrication that can result in small lesions of the cervix 
and facilitate the entry of pathogens when these women are sexually active [37]. An increase in 
STI of chlamydia, gonorrhoea, genital herpes, genital warts and infectious syphilis was noticed 
in the UK among older aged individuals over time [38] indicating the improved sexual activity in 
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these age cohorts, which is in line with our findings. However, infections appearing later in life 
might represent the reactivation of latent HPV infection acquired many years earlier [39, 40].
The differences in the questionnaire used in both surveys were a limitation of our study. 
Because the questionnaire used in 1995-96 survey was extended for the 2006-07 survey, not 
all questions from the 2006-07 survey matched with those from the 1995-96 survey. Questions 
that were not included in both questionnaires, such as lifetime number of sexual partners, 
could have been a better predictor of HPV seropositivity as Vaccarella et al. observed that 
this variable was associated with HPV16 and 18 seropositivity [41]. Although response rates 
between both surveys were different, adjustments to the Dutch reference population minimized 
the bias in seroprevalence and associations with risk variables. Furthermore, serum samples 
collected in the 1995-96 survey were stored for almost 15 years now at -80ºC and this storage 
time could have affected the quality of the sera. Although we observed an increase in HPV-
specific seroprevalence over time, HPV-specific antibody concentrations remained constant 
between 1995-96 and 2006-07 surveys. Moreover, if storage time had influenced the antibody 
levels one would expect this to find for all measured HPV types and not just for HPV16 and 
31 alone of which the seroprevalence had increased between the 2 surveys. Therefore, it is 
not likely that the storage time of the sera did influence the amount of HPV-specific antibodies 
measured and the observed trends in HPV seroprevalence over time are probably better 
attributed to changes in sexual behaviour and/or increased circulation of the specific HPV 
types. 
5.6 Conclusion
To conclude, our data showed that HPV antibody seroprevalences in the general population have 
increased in the Netherlands over an 11-year period. HPV16 seroprevalences among young 
women shifted to younger ages over time, probably due to changes in sexual behaviour over 
the years, in particular the age of sexual debut. Interestingly, the increase in HPV seropositivity 
in older aged individuals might be caused by a higher percentage of the older aged individuals 
who are now still sexually active and these age groups are thus more at risk for STI.  Serum 
antibody responses to HPV can persist over time, also after clearance of infection [12]. HPV 
antibody responses could therefore serve as a marker of cumulative HPV exposure that can 
be used to compare trends over time [22]. HPV seroprevalence studies, focusing on trends 
over time, can provide insight into the distribution of HPV types and infection dynamics and will 
be efficient in monitoring the impact of HPV vaccination in the general population. 
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6.1 Abstract
Monitoring the prevalence of type-specific HPV-DNA infections before and shortly after 
introduction of routine HPV vaccination offers the opportunity to evaluate early effects of the 
vaccination program. With this aim a cohort study was set up of 14- to 16 year old girls eligible 
for HPV vaccination in the Netherlands. Annually, HPV-DNA and antibody status in vaginal self- 
samples and in serum respectively, will be studied among vaccinated (58%) and unvaccinated 
girls (42%). Here we present baseline data on vaginal HPV-DNA status in relation to serum 
antibodies. The 1800 enrolled girls filled out an internet-based questionnaire and provided a 
vaginal self- sample for genotype specific HPV-DNA detection using SPF10 PCR amplification 
and reverse line probe hybridization. Furthermore, 64% of the girls provided a blood sample for 
HPV antibody analysis. IgG antibodies against virus-like particles were determined for 7 HPV 
genotypes. At baseline, type-specific HPV-DNA was detected in 4.4% (n = 79) of the 1800 girls: 
2.7% (n = 49) concerned a high risk HPV type (hrHPV-DNA). The three most common types 
were HPV type 16, 18 and 51 (40%). Out of the hrHPV-DNA positive girls, 32% was seropositive 
versus 12% in HPV-DNA negative girls (p<0.001). Risk factors independently associated with 
hrHPV-DNA infection among the sexually active girls were age >15 years vs. 14-15 years (OR: 
2.6 (1.2-5.9)), age of sexual debut <14 vs. above 14 years (OR: 3.0 (1.1-8.2)), total number of 
lifetime partners above two vs. less than two partners (OR: 3.2 (1.3-8.0)) and age of partner 
>17 vs. under 17 years (OR: 4.2 (1.5-13.0)). A low hrHPV-DNA prevalence was found in the 
adolescent girls. The observed versus expected age-related increase in HPV-DNA prevalence 
in this cohort in the coming years (with increased sexual activity) will provide understanding 
of the effect of HPV vaccination. Furthermore, this cohort study will offer the opportunity to 
improve knowledge of antibody responses following natural infection and vaccination.
6.2 Introduction
Genital infection with human papillomavirus (HPV) is the most common sexually transmitted 
infection (STI) in the world and is a necessary cause for cervical cancer [1]. Worldwide, 
approximately 529.000 women are diagnosed with cervical cancer and about 274.000 die from 
the disease each year [2]. In 2006/2007, two prophylactic vaccines were registered against 
two of the most common oncogenic HPV genotypes; HPV16 and 18. In clinical trials both 
vaccines have been shown to reduce persistent HPV infection and associated disease [3-
6]. Like in many countries, HPV vaccination was incorporated into the national immunization 
program in the Netherlands. The bivalent HPV16/18 vaccination (Cervarix) was introduced for 
12-year-old girls in 2010 with a catch-up campaign for 13- to 16 year olds in 2009. Because 
it will take a long time before the effect of HPV vaccination becomes apparent in the national 
cervical screening programme among 30- to 60-year-old women, it is necessary to monitor the 
effectiveness of HPV vaccination in a different way. 
The current paper describes the baseline prevalence of HPV-DNA and HPV antibodies 
amongst vaccinated and unvaccinated girls of 14-16 years old, prior to vaccination. Girls are 
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followed annually to assess the impact of the HPV vaccination on the occurrence of transient 
and persistent HPV-DNA infections. In addition, HPV antibodies are studied as a tool to 
investigate past exposure and persistent infection [7, 8], although this marker is imperfect and 
only 40-60% of women develop antibody responses after a natural infection [9, 10]. With type 
specific information on HPV-DNA and serology of the same girls, we will be able to study the 
relationship of these parameters longitudinally.  
6.3 Materials and methods
6.3.1 Study population and procedures
Letters of invitation were mailed to a random sample of 9500 girls aged 14-16 years who 
were eligible for the national catch-up HPV vaccination. Each girl was asked to fill in a web-
based questionnaire, to take a vaginal self-sample and optionally a tampon. Blood was taken 
at a study site in the municipalities of the girls. The questionnaire contained information on 
socio-demographic characteristics, sexual history and smoking habits. In the following years, 
information on changes in these characteristics over time will be collected. All study participants 
and their parents signed an informed consent form in accordance with the recommendations 
of the ethical review committee of the VU University medical centre, Amsterdam, which 
has approved the HAVANA cohort study (HPV Amongst Vaccinated And Non-vaccinated 
Adolescents). Vaccination status was based on data from the national vaccination registration 
system ‘Praeventis’, in which information at an individual level is available.
In March 2009, one month before the start of the vaccination campaign, 1151 girls (12%) 
participated in the study.  In March 2010, an additional group of girls was invited (n = 19662). 
These girls were eligible for HPV vaccination in April 2010 and did not previously receive 
vaccination. Of these girls 649 (3.3%) were included (Fig. 1). This extra group was included to 
be able to detect a vaccine effectiveness in 2013 in this cohort against persistent (HPV16/18) 
infection among vaccinated girls with at least 90% with probability (power) of 80% and precision 
of 5%. Of this extra group a vaginal self-sample and a questionnaire was requested but a blood 
sample and a tampon were not required.
6.3.2 HPV testing; DNA detection
The vaginal self-samples were obtained with a Viba brush, (Rovers), collected in 1 ml PBS 
and stored at -20°C. The samples were analyzed by the SPF10-LiPA25 mediated PCR enzyme 
immunoassay method [11]. Total DNA was isolated from 200 μl of the suspension using the 
MagNa Pure LC isolation platform (Roche Diagnostics, Almere, the Netherlands). DNA was 
eluted in 100 μl of elution buffer of which 10 μl was used for amplification of HPV-DNA. Broad-
spectrum HPV-DNA amplification was performed using the SPF10-LiPA25 system (SPF10 HPV 
LiPA, version 1; manufactured by Labo Bio-medical Products, Rijswijk, the Netherlands) as 
described previously [11, 12]. Positive and negative controls to monitor DNA isolation and PCR 
amplification and HPV-genotyping were included. All vaginal samples were spiked with phocine 
herpes virus before DNA-isolation to ensure equal purification efficiency and the absence of 
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inhibition during PCR amplification. Beta-actin PCR detection was performed to assure the 
presence of DNA in the samples. Over 99% of the 1122 samples that were tested for B-actin 
were PCR positive.
6.3.3 DNA typing
The presence of HPV-amplicons were assessed by an HPV-DNA enzyme immunoassay 
(DEIA) [11, 12]. Genotyping of the HPV-DEIA positive samples was performed by reverse 
hybridization in a line probe assay (LiPA). Girls were regarded high-risk HPV-DNA (hrHPV-
DNA) positive if the SPF10 was positive for at least one of the following genotypes: 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58 or 59 [2]. Girls were considered positive for a non-hrHPV-DNA 
type if they contained at least one of the following types: 6, 11, 34, 40, 42, 43, 44, 53, 54, 66, 
68, 70, 73 or 74 and no hrHPV-DNA type. Because DNA of several cutaneous HPV genotypes 
can also be amplified with the SPF10 primer set, it cannot be excluded that a considerable 
part of the only HPV-DEIA positive samples are positive due to cutaneous HPV, especially 
because self-sampling was performed without gloves. Therefore, we regarded samples that 
were positive in the HPV-DEIA analysis but did not reveal a hybridization pattern (29% of all the 
samples) in the subsequent HPV-LiPA analysis as negative for genital HPV.
6.3.4 Serology  
HPV-specific antibodies to HPV type 16, 18, 31, 33, 45, 52 and 58 were determined using 
a multiplex immunoassay (MIA). GSK (GlaxoSmithKline Biologicals, Rixensart, Belgium) 
kindly supplied the HPV VLPs. VLPs were coupled to seven distinct fluorescent microspheres 
Fig. 1. Schematic representation of study design.
83
6
P
re
va
le
nc
e 
of
 g
en
ita
l H
P
V
 in
fe
ct
io
ns
 a
nd
 H
P
V
 s
er
ol
og
y
through a carbodiimide coupling procedure that has been described elsewhere [13] with minor 
modifications in which Sulpho-NHS and EDC were dissolved in 0.5M NaH2PO4. The MIA was 
performed as described elsewhere [14] with modifications. Serumbuffer (PBS, 1% BSA, 0.2% 
Tween20 and 0.2% ProClin300) was used for prewetting MultiscreenHTS assay plates for 
washing procedures and sample dilutions. Bound HPV-specific antibodies in serum were 
detected using an R-PE labelled secondary antibody for IgG. HPV-specific IgG antibodies 
were analyzed by using a Bioplex system 200 with Bioplex software (Bio-Rad Laboratories, 
Hercules, CA). For each analyte, median fluorescent intensity (MFI) was converted to Luminex 
Units/ml (LU/ml). Girls were assumed to be seropositive at the cut-off, based on a panel of 
highly likely negative children (1-10 years, n = 859): 9, 13, 27, 11, 19, 14, and 31 LU/ml for 
HPV16, 18, 31, 33, 45, 52, and 58, respectively.
6.3.5 Statistical analysis
By univariate analysis the association between hrHPV-DNA infection and potential risk factors 
was tested amongst the sexually active girls, using crude odds ratio (OR). Sexual intercourse 
included vaginal and anal sex. A cut-off of p<0.1 was used for variables in univariate analysis 
to enter in a multivariate model. In the multivariate analysis p<0.05 was used as a cut-off for 
significance. Using backward selection adjusted OR were estimated. All statistical analyses 
were performed using the statistical package SAS 9.2.
6.4 Results
6.4.1 General characteristics
A total of 1800 girls were enrolled in the study in 2009 and 2010. During the study period 
52% of the girls were vaccinated with 3 doses of the vaccine, 5% with 1 or 2 doses and 42% 
did not get vaccinated. In table 1, the distribution of demographics and other characteristics 
by vaccination status are shown. Girls who received at least one vaccination did not differ 
systematically from the girls who received no vaccine for most characteristics that were 
studied. However, vaccinated girls were less likely to live in a city, less likely to have a partner, 
to be sexually active and were less likely to always use condoms. There was no significant 
difference in prevalence of anyHPV, hrHPV-DNA in girls who eventually received vaccination 
and girls who did not (Table 1A).
A quarter of the 1800 girls (n = 441) reported to be sexually active (Table 1B) with the median 
age of their first sexual intercourse at 14.7 years (13.2-15.4). Out of these girls, 301 (68%) 
reported to have a sexual partner of which 97% were steady partners. Oral contraceptives were 
used by 49% of the sexually active girls and 21% by the non-sexually active. Approximately 
half of the sexually active girls reported no use of condoms in the last six months. 
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Total Vaccinated Unvaccinated p-value
Demography N % N % N %
Total 1800 (100) 1037 (58) 763 (42)
Any HPV
no 1721 (96) 995 (96) 726 (95) 0.41
yes 79 (4) 42 (4) 37 (5)
Hr HPV
no 1751 (97) 1011 (97) 740 (97) 0.51
yes 49 (3) 26 (3) 23 (3)
Age 
14 133 (8) 94 (9) 39 (5) 0.01
15 1231 (69) 695 (68) 536 (71)
16 408 (23) 233 (23) 175 (23)
missing 28
Ethnicity
Indigenous Dutch 1539 (87) 875 (86) 664 (89) 0.60
first generation western 58 (3) 38 (4) 20 (3)
first generation non western 25 (1) 14 (1) 11 (1)
second generation western 23 (1) 15 (1) 8 (1)
second generation non western 116 (7) 70 (7) 46 (6)
missing 39
Education
low 317 (18) 190 (19) 127 (17) 0.44
medium 457 (26) 253 (25) 204 (27)
high 985 (56) 567 (56) 418 (56)
missing 41
Urbanization
>1500 895 (51) 600 (59) 295 (39) <0.01
<=1500 874 (49) 419 (41) 455 (61)
missing 31
Ever smoked
no 1191 (68) 690 (68) 501 (67) 0.55
yes 569 (32) 321 (32) 248 (33)
missing 40
Anti-conception
no 1056 (60) 619 (61) 437 (59) 0.39
pill 495 (28) 272 (27) 223 (30)
other 207 (12) 120 (12) 87 (12)
missing 42
Ever had sex 
no 1320 (75) 780 (77) 540 (72) 0.02
yes 441 (25) 232 (23) 209 (28)
missing 39
Table 1A. Socio-demographic characteristics of the study population (n = 1800).
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6.4.2 Prevalence and distribution of HPV-DNA type
Out of the 1800 girls of whom we received a vaginal self-sample, 79 were positive for any 
HPV-DNA type (4.4%), and 49 of those for a hrHPV-DNA type (2.7%). Approximately 1% (n = 
18) of the HPV DNA infections were found in girls who reported never to have had vaginal or 
anal sex. Concomitant HPV16 and 18 infections were present in 2 girls only. HPV genotyping 
Table 1B. Sexual risk factors of the sexually active study population (n = 441).
Sexual risk factors
Total Vaccinated Unvaccinated p-value
N       % N % N %
Sexual debut
<=13 383 (87) 199 (86) 184 (88) 0.48
>13 58 (13) 33 (14) 25 (12)
missing 0
Current Partner
no 139 (32) 85 (37) 54 (26) 0.02
yes 301 (68) 147 (63) 154 (74)
missing 1
Relationshipa
<= 6 months 73 (25) 38 (27) 35 (24) 0.28
7-12 months 85 (29) 46 (32) 39 (26)
>13 months 132 (46) 58 (41) 74 (50)
missing or N/A 151
Age partnera 
<=17 190 (65) 96 (68) 94 (62) 0.34
>17 103 (35) 46 (32) 57 (38)
missing or N/A 148
No. sex partners 
1 304 (70) 157 (69) 147 (71) 0.68
2 63 (14) 32 (14) 31 (15)
>2 70 (16) 40 (17) 30 (14)
missing 4
Condom use 
always 144 (49) 59 (41) 85 (56) 0.01
not always 150 (51) 84 (59) 66 (44)
missing 147
Ever had STI 
no 387 (88) 198 (85) 189 (90) 0.23
no but have 
been tested
50 (11) 32 (14) 18 (9)
yes 4 (1) 2 (1) 2 (1)
missing 0
Note: aOnly when current partner is yes.
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showed that hrHPV-DNA type 51, 16 and 18 were the most prevalent (Fig. 2).  Other detected 
HPV types in order of decreasing prevalence were: HPV type 6, 11, 53, 31, 52 and 66. About a 
quarter of the HPV positive girls (n = 17) had a multiple infection. All multiple infections involved 
at least one hrHPV-DNA type. 
6.4.3 Prevalence and distribution of HPV antibodies and correlation with HPV-DNA prevalence
Overall seropositivity of the 1149 available serum samples was 11% (n = 128). Type 52 was 
the most prevalent HPV type (5.2%) followed by 3% for HPV16 (Fig. 3). 
A serum sample was available for 28 girls out of the 49 hrHPV-DNA-positive girls. Nine of 
those (32%) were seropositive (Fig. 4), 7 (78%) for a concordant HPV type as detected in the 
vaginal self-sample, 4 of which were positive for HPV type 16.  All of these girls reported to be 
sexually active. Out of the 30 girls positive for a non-hrHPV-DNA type, a serum sample was 
available for 17 girls of which 2 girls were seropositive (12%) for one or more of the seven 
hrHPV types in the serological assay. From the 1721 HPV-DNA- negative girls serology was 
available for 1104 girls of which 128 were seropositive (12%). Approximately one-third of these 
girls reported to have ever had sexual intercourse.
Girls that were HPV-DNA positive and seropositive showed an increased serotiter for all types 
compared to the seronegative girls, although numbers were small (Fig. 5).
6.4.4 Risk factors
Among the sexually active girls (n = 441) a risk factor analysis was carried out. Variables 
associated with hrHPV-DNA that were significant in the univariate analysis were age, lower 
education, smoking, younger age of sexual debut, total number of partners above 2, higher 
age of partner, having one or more casual partners and not always using condoms. Multivariate 
analysis showed that age >15 years vs. 14-15 years (OR: 2.6 (1.2-5.9)), age of sexual debut 
Fig. 2. HPV genotype distribution.
87
6
P
re
va
le
nc
e 
of
 g
en
ita
l H
P
V
 in
fe
ct
io
ns
 a
nd
 H
P
V
 s
er
ol
og
y
<14 vs. above 14 years (OR: 3.0 (1.1-8.2)), total number of lifetime partners above two vs. less 
than two partners (OR: 3.2 (1.3-8.0)) and age of partner >17 vs. 17 years or younger (OR: 4.2 
(1.5-13.0)) were independently associated with hrHPV-DNA infection. No pairwise interactions 
among the variables in the final analysis were statistically significant below the p<0.05 level. 
6.5 Discussion
By determining both the genital HPV status and antibody status against the most prevalent 
HPV types, we found an overall genital HPV-DNA prevalence of 4.4% (n = 79) and hrHPV-
DNA of 2.7% (n = 49), amongst a group of 14- to 16-year-old girls (n = 1800) prior to HPV 
vaccination. HPV16 and/or 18 were present in 1% of the study sample (n = 18).
Currently, there are only a few studies that have studied a similar age group. Dunne et al. [15] 
found a DNA prevalence of any HPV type of 24.5% in girls 14-19 years of age in the United 
States. The different geographical area and the inclusion of older girls (17-19) might explain 
the higher prevalence. This last remark is supported by our risk factor analysis, which shows 
that age is an independent risk factor for a hrHPV-DNA infection. Another study that included 
15- to 17-year-old girls [16] showed a higher hrHPV-DNA prevalence (20.3%) compared to 
our study. However, this study involved girls from a geographical risk area (especially Brazil) 
who were only included if they were sexually active. When comparing the 16-year-old sexually 
active girls with all the girls in our study we also found a higher prevalence of (17% for any HPV 
instead of 4.4% overall) and hrHPV-DNA prevalence (12% instead of 2.7% overall). 
Age of sexual debut, age of partner and more then two lifetime partners were also found 
to be independent risk factors for hrHPV-DNA amongst the sexually active girls (n = 441). 
Since sexual behaviour has been implicated as the most important risk factor for infection with 
hrHPV-DNA, the large proportion of not yet sexually active girls in this study (76%) makes this
prospective cohort study particularly useful to study the relationship between the start of sexual 
activity with hrHPV-DNA infection.  
Fig. 3. HPV seroprevalence type distribution.
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In 32% (9/29) of girls of whom serum was available and who had a current hrHPV-DNA infection 
for type 16, 18, 31, 33, 45, 52 and 58 (types detected by serology test), antibody responses were 
present. This finding indicates that the presence of these antibodies is a relatively insensitive 
indicator of infection, as is known from literature, where approximately 50% seroconversion 
has been described [7, 8]. The lower percentage found in this study might be due to a delay in 
seroresponse, since both DNA and serum were taken at the same time. In the coming years, 
we may be able to observe this delay, and possibly find associations between the presence of 
HPV antibodies and clearance of current HPV infections. Furthermore, from the hrHPV-DNA 
positive girls, approximately a third was seropositive, but vice versa a lot of the seropositive girls 
(12%) show no current DNA infection. Assuming the assay specificity was high, this indicates 
that using HPV-DNA positivity only can underestimate the total exposure of HPV in the general 
population even at this young age.
Fig. 4. Flow diagram HPV-DNA and serology status. Serology was only determined for a subset of HPV 
types (16, 18, 31, 33, 45, 52, 58).
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There were some limitations to our study. HPV-DNA was detected in 1% of girls in our study 
who reported never having had anal or vaginal sex. This could be explained by the fact that 
HPV is very infectious. A few studies have shown that non-penetrative sex or contact with 
contaminated objects and surfaces can lead to infections [17, 18]. Furthermore, sexual activity 
is self-reported which could result in an underestimation of the true sexual activity. The second 
limitation of this study, as in all HPV-DNA studies, is that it could not be determined if the HPV 
detected represented an active infection of the cervix or the transient presence of HPV-DNA in 
the lower genital tract. The third limitation is the low response rate to participate in the study 
(12% in the first group and 3.3% in the additional group). In order to assess the effect of this 
low response rate we determined if the characteristics of the study population were similar to 
those of girls in the general population. We did this by comparing our data on education, 
ethnicity and age of sexual debut with that of the general population [19]. Girls in our study 
were higher educated and less likely to be a second generation migrant. Furthermore, it has 
been reported that approximately a third of the 15-year-old girls in the Netherlands are sexually 
active [20] whereas in our study we found a quarter of the girls to be sexually active. However, 
a comparison of demographic and other characteristics amongst vaccinated and unvaccinated 
girls in this study revealed a similar distribution, apart from age, urbanization, ever having had 
sex, having a partner and condom use, which are all characteristics for which we can adjust. 
Furthermore, prior to vaccination, there was no significant difference in prevalence of hrHPV-
DNA status in girls who eventually got vaccinated and girls who did not (2.5% vs. 3.0%, p<0.51). 
Fig. 5. Antibody concentrations (black dots) for HPV16 and 18 DNA positive and negative girls. The dark 
grey lines indicate the geometric mean concentration and the vertical bars show the interquartile range.
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6.6 Conclusion
In conclusion, prior to vaccination the HPV-DNA prevalence amongst a group of 1800 
girls 14-16 years old eligible for HPV vaccination, is low. Of the hrHPV-DNA positive girls, 
approximately a third were seropositive, of which almost 80% for the same type. However, a 
lot of the seropositive girls (12%) show no current DNA infection. 
Because of the expected age-related HPV-DNA increase in these girls (increased sexual 
activity), this study will be especially suitable to monitor vaccine effectiveness. In the long 
run, the impact of vaccination measured in this cohort will also include the indirect effect of 
vaccination (herd immunity) and is not limited to the direct effect of vaccination. Amongst 
the HPV-DNA negative girls (n = 1721) acquisition of new HPV infections in relation to their 
vaccination status, serostatus and risk factors will be studied longitudinally. In addition, it offers 
the opportunity to improve knowledge of antibody responses following natural infection and 
vaccination.  
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7.1 Abstract
The bivalent HPV16/18 vaccine induces high antibody concentrations in serum while data 
about antibody responses in the cervix are limited. In this study, we investigated pre- and post-
vaccination antibody responses against seven high-risk HPV types by detection of IgG and IgA 
HPV-specific antibodies in cervical secretion samples (CVS) and serum. From an HPV vaccine 
monitoring study CVS and serum samples were available (pre-vaccination (n = 297), one year 
(n = 211) and two years (n = 141) post-dose-one vaccination) from girls aged 14-16 years. The 
girls were vaccinated with the bivalent HPV vaccine at months 0, 1 and 6. CVS was self-sampled 
using a tampon. Samples were tested for HPV-specific antibodies (HPV16/18/31/33/45/52/58) 
by a VLP-based multiplex immunoassay. Post-vaccination, IgG and IgA antibody levels for 
HPV16/18 were detectable in CVS and amounted to 2% and 1% of the IgG and IgA antibody 
levels observed in serum, respectively. The antibody levels remained constant between one 
and two years after vaccination. The correlation between CVS and serum was similar for IgG 
and IgA vaccine-derived antibody levels for HPV16 (rs = 0.58, rs = 0.54) and HPV18 (rs = 0.50, 
rs = 0.55). Vaccine-derived IgG antibody levels against cross-reactive HPV types in CVS and in 
serum were highest for HPV45. No IgA cross-reactive antibody responses could be detected 
in CVS. Post-vaccination, HPV16/18 IgG and IgA antibodies are not only detectable in serum 
but also in CVS. The correlation of HPV16/18 IgG antibody levels between serum and CVS 
suggests that vaccine induced HPV antibodies transudate and/or exudate from the systemic 
circulation to the cervical mucosa to provide protection against HPV infections.   
7.2 Introduction
The HPVs that cause ano-genital cancers are sexually transmitted and can infect the basal 
cells of the cervical epithelium. Therefore, HPV vaccines need to induce protective antibody 
levels at the cervix where HPV-specific antibodies can prevent infection of keratinocytes [1, 2]. 
Prophylactic vaccination with the two available HPV vaccines, a bivalent and a quadrivalent 
protects against infections with the most common high-risk HPV types detected in HPV 
associated cancers, HPV16 and 18.  Both vaccines have proven to be very efficacious in the 
prevention of cervical intraepithelial neoplasia (CIN) in HPV naïve women [3, 4].  Also protection 
against CIN2+ of cross-reactive HPV types has been observed and for the bivalent vaccine 
this amounted to 84%, 59% and 50% for HPV31, 33 and 45 up to 4 years after vaccination, 
respectively [5, 6]. Antibody levels were found to be 10-100 times higher in vaccinated 
individuals as compared with naturally infected individuals [7], while the mechanism by which 
vaccine-induced antibodies contribute to antibody levels at the cervix is not yet completely 
understood. Vaccine-induced antibodies localized in the genital tract might be derived from the 
systemic circulation by transudation or exudation of antibodies across the cervical epithelium 
to the mucus as a result of micro-lesions of the cervical epithelium that can easily occur e.g., 
during sexual intercourse [8, 9].
In the Netherlands, the bivalent HPV vaccine was included in the national immunization 
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sprogram in 2010 for girls 12 years of age. A catch-up vaccination campaign was performed for 
girls 13-16 years of age [10].
Here, we present data of IgG and IgA HPV-specific antibody levels pre- and up to two years 
post-vaccination in self-sampled cervical secretion and serum samples for HPV types 16, 18, 
31, 33, 45, 52, and 58 of adolescent girls eligible for catch-up vaccination. 
7.3 Materials and methods
7.3.1 Study design
A random sample of 9500 girls aged 14-16 years eligible for the national catch-up HPV 
vaccinations was invited into the HAVANA (HPV Amongst Vaccinated And Non-vaccinated 
Adolescents) study of which 1151 (12%) girls participated in the study [11]. Each girl was asked 
to fill in a questionnaire, to provide a blood sample and optionally a CVS by using a tampon. 
Both CVS and blood samples were available from 737 girls pre-vaccination (M0, 2009), from 
451 girls one year after the first vaccination (M12, 2010), and from 459 girls two years after 
the first vaccination (M24, 2011). A signed informed consent was obtained from all participants 
and their parents. The study was approved by the medical ethics review committee of the Free 
University Amsterdam (approval number: 2009/22).
7.3.2 Collection of cervical secretion and serum samples
Cervical secretion was collected using a tampon (mini-pro comfort, OB, Johnson & Johnson 
Consumer). Girls were asked to use a tampon for 2 hours when they were not menstruating. 
CVS were collected from the tampons by addition of 0.5 ml of PBS containing complete 
protease inhibitor cocktail (1 tablet/50 ml, Roche Diagnostics catalog No. 11836145001) and 
subsequent centrifugation for 30 minutes, 3,200 g at 4oC. To assess for the presence of blood, 
CVS were evaluated using the Hemastix® (Siemens Healthcare Diagnostics Inc., catalog No. 
2597428) reagent strip test according to manufactures instructions. CVS were categorized into 
the following categories: no trace, 20, 25, 80, 200, and >200 erythrocytes/µl.
7.3.3 VLP-based multiplex immunoassay 
CVS and serum samples were stored at -80oC until analysis. For the measurement of HPV-
specific IgG and IgA antibodies against HPV L1 virus-like-particles (VLP) 16, 18, 31, 33, 45, 
52, and 58, a VLP-based multiplex immunoassay (MIA) was used as earlier described [12]. 
GSK (GlaxoSmithKline Biologicals S.A., Rixensart, Belgium) kindly supplied the HPV-VLPs. 
Briefly, VLPs were coupled to fluorescent microspheres. Sera and CVS were incubated with 
the microspheres in a 1/50 and 1/100 dilution (pre-vaccination) and in a 1/50 up to 10,000 
dilution (post-vaccination). HPV-specific IgG and IgA antibodies were detected using a 1/200 
dilution of R-phycoerythrin conjugated goat anti-human IgG or IgA (Jackson ImmunoResearch 
laboratories Inc., catalog No. 109-116-098) in PBS. Four ‘in-house’ control sera and an ‘in-
house’ standard were used on each plate. The ‘in-house’ standard (IVIG, lot LE12H227AF, 
Baxter catalog No. 1500912) was calibrated against reference serum of GSK for all the seven 
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HPV types. HPV-specific antibodies were analyzed using the Bioplex system 200 with Bioplex 
software (Bio-Rad Laboratories). Sera were assumed to be IgG seropositive at the following 
cut-offs determined previously with this assay: 9, 13, 27, 11, 19, 14, and 31 Luminex Units/ml 
(LU/ml) for HPV16, 18, 31, 33, 45, 52, and 58, respectively. 
As no cut-off values for CVS are known, we used the serum cut-off values as an arbitrary 
cut-off for IgG seropositivity in CVS. IgA antibody concentrations were expressed in arbitrary 
RIVM U/ml using the ‘in-house’ standard as reference serum. No international HPV-specific IgA 
reference serum is available and cut-off values for IgA seropositivity could not be determined. 
To test for possible inter-immunoglobulin isotype competition, a panel of serum samples (n = 
40) were depleted of IgG by adding GullSORB (10:1 vol/vol) (Meridian Bioscience Inc., catalog 
No. XX715). We did not observe any interference of IgG in the IgA measurement.
IgG antibodies against tetanus and diphtheria toxoid in serum and CVS were measured using 
a multiplex immunoassay as described previously [13, 14]. In order to account for the variation 
of the IgG levels in CVS during the menstrual cycle, total IgG was measured in a subset of 
CVS and serum samples (n = 35).
7.3.4 Statistical methods
All analyses were carried out in GraphPad Prism version 5. For the analyses, results were 
included from girls who had been vaccinated three times with the bivalent HPV vaccine, who 
delivered both a CVS and serum sample at M0, M12 and/or M24 and from whom the CVS 
contained a blood trace of ≤25 erythrocytes/µl. Significant (p<0.05) differences in GMCs were 
calculated using a Mann-Whitney test and differences between paired samples were calculated 
with the paired t-test of log-transformed data. Correlations between antibody concentrations in 
CVS and serum were calculated using the Spearman rank correlation coefficient (rs).  
 
7.4 Results
7.4.1 Study characteristics 
The mean age of the participating girls at the beginning of the study was 15.1 years. Girls were 
vaccinated with the bivalent HPV vaccine in a 2+1 vaccination schedule at months (M) 0, M1 
and M6. At baseline (M0) 297 out of 737 girls provided both a cervical secretion sample (CVS) 
containing a blood trace of ≤25 erythrocytes/µl and serum sample (Fig. 1). One year (M12) and 
2 years after the first vaccination (M24) 211/451 and 141/461 of these combined samples were 
available, respectively. For the non-vaccinated girls at M0 (n = 122), M12 (n = 73) and at M24 
(n = 48) the combination of a CVS containing a blood trace of ≤25 erythrocytes/µl and serum 
sample was available. The use of oral contraceptives (OC) in vaccinated girls increased from 
29% (87/297) at M0 up to 53% (111/211) at M12.
7.4.2 Evaluation of the measurement of HPV-specific antibodies in CVS collected with tampons
The tampon self-collection method was evaluated by measuring the recovery of HPV16 IgG 
and IgA antibody levels in CVS before and after tampon extractions. CVS (n = 25) were pooled 
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sand spiked with a sample of HPV16 IgG and IgA with antibody concentrations varying from 
low to high antibody levels. Importantly, the concentrations of HPV16 IgG and IgA antibodies 
before and after the tampon extractions were similar although not all the CVS volume can be 
centrifuged from the tampon. This spiking experiment indicates that there is no effect of the 
tampon on the HPV-specific antibody concentration in CVS. 
As high antibody levels are present in serum even small blood traces could account for a 
considerable contribution to the antibody levels in CVS. We found that HPV16 and 18 antibody 
concentrations in CVS with a blood trace of ≤25 erythrocytes/µl were comparable to antibody 
concentrations in CVS with no blood trace (Fig. 2). However, in CVS with blood traces ≥25 
erythrocytes/µl we observed an increasing linear trend in HPV16 (p=0.02) and HPV18 (p=0.03) 
antibody concentrations. 
The effect of OC use on vaccine-derived HPV16 and 18 antibody levels one year after the first 
HPV vaccination were not significantly different between OC users and non-OC users (data 
not shown).
Fig. 1. Flow diagram of available cervical secretion samples (CVS) and serum samples.
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7.4.3 IgG and IgA antibody concentrations for HPV16 and 18 and phylogenetically related HPV 
types in serum
Pre-vaccination, only 10/297 (3.4%, 95%CI 1.7-5.9%) and 9/297 (3.0%, 95%CI 1.5-5.5%) girls 
showed IgG antibody concentrations in their serum above the cut-off values for HPV16 and 
HPV18, respectively. HPV16 and HPV18 geometric mean concentrations (GMCs) (0.5 and 
0.6 LU/ml, respectively) were far below cut-off values. Post-vaccination (6 months after the 
last vaccine dose), all girls seroconverted. HPV16 and 18 antibody concentrations significantly 
increased as compared to pre-vaccination and GMCs amounted to 3162 LU/ml (95%CI, 2712-
3686 LU/ml) and 1611 LU/ml (95%CI, 1357-1913 LU/ml), respectively (Fig. 3A). These HPV 
antibody concentrations remained constant in the subsequent year, thus 6-18 months after the 
last vaccination. A similar result (no decrease) was found when the analysis was restricted to 
girls who provided samples at both 6 and 18 months (n = 69 pairs) after the last vaccine dose.
Post-vaccination cross-reactive IgG antibody responses were highest for HPV45 and from all 
girls tested, 89% (95%CI 84-93%) showed antibody concentrations above the cut-off values 
for HPV45. For HPV31, 33, 52 and 58 this resulted in 66% (95%CI 59-72%), 55% (95%CI 
48-61%), 62% (95%CI 55-68%) and 43% (95%CI 37-50%) seropositivity, respectively. Cross-
reactive HPV antibody concentrations remained constant in the subsequent year. 
Pre-vaccination, HPV16 and HPV18 IgA GMCs amounted to 0.8 and 0.1 RIVM U/ml, 
respectively. After vaccination, HPV16 and HPV18 IgA antibody responses in serum at M12 
rose to 112 RIVM U/ml (95%CI 93-136 RIVM U/ml) and 43 RIVM U/ml (95%CI 35-54 RIVM U/
ml), respectively, and similar antibody levels were found at M24 (Fig. 3B). The cross-reactive 
IgA antibody levels for the other 5 HPV types increased after vaccination which was most 
pronounced for HPV31 but for the other cross-reactive HPV types this increase was quite low. 
7.4.4 IgG and IgA antibody concentrations for HPV16 and HPV18 and phylogenetically related 
HPV types in cervical secretion 
Before vaccination in CVS, HPV16 and 18 GMCs were near detection limits (0.1 LU/ml) 
Fig. 2. The effect of blood contamination on HPV16 (dark grey line) and HPV18 (light grey line) geometric 
mean concentrations (GMC) in cervical secretion samples (CVS).
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sand significantly increased after vaccination. IgG antibody concentrations detected in CVS 
amounted to approximately 2% of the IgG serum antibody concentrations both for HPV16 
(GMC 51 LU/ml, 95%CI 41-64 LU/ml) and 18 (GMC 25 LU/ml, 95%CI 20-31 LU/ml) (Fig. 
4). At M12 88% (95%CI 83-92%) and 70% (95%CI 63-76%) of the girls had IgG antibody 
concentrations in CVS above cut-off values for HPV16 and HPV18, respectively. These levels 
remained constant up to M24.
Fig. 3. Antibody responses for HPV16, HPV18 and phylogenetically related HPV types 31, 33, 45, 
52 and 58 in serum for IgG (A) and IgA (B) pre-vaccination (M0, light grey dots), one year after the 
first vaccination (M12, dark grey dots) and two years after the first vaccination (M24, black dots). *** 
p<0.0001.
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The 5 cross-reactive HPV types also showed a significant increase in IgG antibody 
concentrations at M12 compared with M0, however, few girls had antibody levels above cut-
off values varying from 0-3% for HPV58 to HPV45. Similar to serum antibody levels, highest 
cross-reactive antibody levels in CVS were also found for HPV45. Cross-reactive HPV antibody 
concentrations in CVS remained constant up to M24.
The IgA antibody concentrations for HPV16 and 18 in CVS amounted to approximately 1% 
of serum IgA antibody levels. For the other 5 HPV types no IgA responses could be detected. 
7.4.5 Seropositivity in non-vaccinees
Non-vaccinated girls were tested for HPV antibody seropositivity at M0 (n = 122), M12 (n = 
73) and M24 (n = 48) (Fig. 1). In non-vaccinated girls, a higher HPV16 IgG seroprevalence 
was found at M12 (5/73 girls, 6.8%, 95%CI 2.6-14.5%) and M24 (6/48 girls, 12.5%, 95%CI 
5.2-24.2%) compared with M0 (2/122 girls, 1.6%, 95%CI 0.3-5.3%). At M12, GMCs of HPV 
seropositive girls were approximately 150 times and 40 times lower as compared to vaccine 
induced antibody concentrations for HPV16 and 18, respectively. For HPV45 and 33 similar 
seroprevalences were found as compared to HPV16. For the other 4 HPV types a small rise 
in seroprevalence was observed at M24: 2/48 girls for HPV18 and HPV31 as compared to 
M0 (0/122) and 1/48 girls for HPV52 and HPV58 as compared to M0 (1/122). In CVS, IgG 
antibodies above cut-off values were only detectable for HPV16 and 18 at M12 (HPV16/18 
both in 1/73 girls) and at M24 (HPV16 2/48 girls, HPV18 1/48 girls). IgA antibodies in CVS and 
serum samples were very low and near the detection limit. 
Fig. 4. IgG antibody responses for HPV16, HPV18 and for phylogenetically related HPV types 31, 33, 
45, 52 and 58, pre-vaccination (M0, light grey dots), one year after the first vaccination (M12, dark grey 
dots), and two years after the first vaccination (M24, black dots) in cervical secretion. *** p<0.0001. 
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s7.4.6 Correlations between serum and cervical secretion IgG and IgA antibody levels
One year after vaccination we found similar correlations between the IgG antibody 
concentrations in serum and CVS for both HPV16 (rs = 0.58) and HPV18 (rs = 0.50) (Fig. 5A 
and 5B, respectively). Although IgA antibody levels in CVS were low also similar correlations 
between serum and CVS IgA levels were found for HPV16 (rs = 0.54) and HPV18 (rs = 0.55) 
(Fig. 5C and 5D, respectively). 
Despite the lower levels in CVS, we observed after vaccination at M12 a high correlation 
between the HPV16 and HPV18 IgG antibody levels in serum (rs = 0.83) and CVS (rs = 0.88) 
(Fig. 6A and 6B, respectively). Comparable correlations were found at M24. Normalizing the 
antibody concentrations in CVS and in serum to the amount of total IgG, we did not observe 
any alterations in the correlations for both HPV16 and HPV18.  
7.4.7 IgG antibodies against tetanus and diphtheria toxoid in cervical secretion and serum 
We determined the presence of vaccine induced IgG antibody levels against tetanus (Tt) and 
diphtheria toxoid (Dt) in serum and CVS. The cervical mucosa is not a site of local production 
of antibodies for these pathogens and therefore the detection of Dt and Tt specific antibodies 
in CVS can be used as a transudation or exudation marker. Interestingly, we found a high 
correlation between IgG antibody concentrations in serum and in CVS for Tt (rs = 0.73, n = 35) 
and Dt toxoid (rs = 0.78, n = 35) in samples of girls at M12 (data not shown).
Fig. 5. Spearman rank correlations (rs) between HPV16 and 18 IgG (A and B) and IgA antibody levels (C 
and D) in serum and cervical secretion samples (CVS) one year after the first vaccination (M12). X- and 
Y-axis are in logarithmic scale.
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7.5 Discussion
In this study, we could establish the presence of HPV-specific IgG and IgA antibodies in CVS 
but the levels were much lower than in serum. Constant HPV16/18 IgG antibody levels in 
serum and CVS were found up to two years post-vaccination. 
HPV16/18 IgG and IgA levels in CVS amounted to approximately 2% and 1% of the IgG and 
IgA levels in serum, respectively. We found a correlation between the HPV16 and 18 antibody 
levels in serum and CVS up to two years after the first vaccination indicating that probably 
transudation and/or exudation of antibodies from the systemic circulation to the cervical 
mucosa takes place. 
In this study, CVS was self-sampled with a tampon while in other studies CVS is mostly 
collected with sponges, [8, 9, 15] which have to be placed in the cervix by a physician. This 
might be unpleasant, and is not suitable for large-scale studies. The girls found the tampon 
as collection method easy in use and comfortable. This collection method might contribute to 
better participation rates in large-scale studies. In addition, the determination of HPV-specific 
antibodies in CVS was also easy after extraction of the sample and the tampon collection 
method had no effect on the antibody concentrations.
The menstrual cycle has been reported to have effect on antibody levels in the genital tract 
[16]. Around ovulation Ig antibody levels might decrease because of a protective mechanism 
that reduces the level of anti-sperm antibodies in the female genital tract at the time of ovulation 
[17].  Kemp et al. found differences between IgG levels in serum and CVS during the menstrual 
cycle based on a small number of observations [8]. Therefore, information was collected on 
the last menstruation from the participants. We relied on self-reported data that might be less 
accurate than detection of sex hormones during the menstrual cycle [17]. We did not find an 
effect between non-OC and OC users even when we normalized to the total amount of IgG. 
The increase in HPV IgG seroprevalence in non-vaccinated individuals is similar to the step-up 
in HPV16 seroprevalence as observed in a large Dutch sero-epidemiological study in young 
Fig. 6. Spearman rank correlations (rs) between IgG antibody levels of HPV16 and HPV18 in serum (A) 
and cervical secretion samples (CVS) (B) one year after the first vaccination (M12). X- and Y-axis are 
in logarithmic scale.
103
7
D
et
ec
tio
n 
of
 s
ys
te
m
ic
 a
nd
 m
uc
os
al
 H
P
V-
sp
ec
ifi
c 
an
tib
od
ie
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that antibody measurements in CVS in a non-vaccinated population might not be suitable for 
the detection of naturally derived HPV-specific antibodies. 
To prevent HPV from entering the keratinocytes in the cervix, prophylactic HPV vaccination 
should induce a first line of defense by eliciting sufficient amounts of antibodies [18]. We found 
detectable antibody levels in CVS among vaccinated girls but these levels were approximately 
60 fold lower than serum levels. Antibody levels in CVS remained constant for at least two 
years post-vaccination. In 10% and 30% of the girls, we were not able to detect HPV16 and 18 
antibody levels in CVS, respectively, although HPV16 and 18 antibody levels in serum were 
high. These findings were comparable with other studies [1, 8, 9, 19] although in most studies 
less stringent exclusion criteria were handled for blood contamination in CVS as compared with 
our study. Despite a high vaccine efficacy against precancerous cervical lesions associated 
with HPV16/18 or cross-reactive HPV types [3, 6, 20], girls without detectable antibodies in CVS 
might be the first at risk for HPV infections. However, a recent study showed that in mice also 
low vaccine-derived antibody concentrations can neutralize the virus and inhibit the binding 
of the virus to the basal cells of the cervical epithelium at another stage of infection [21, 22]. 
Although we showed that after HPV16/18 vaccination cross-reactive antibodies against HPV52 
and 58 were detectable in both serum and CVS, the biological relevance of these antibodies 
is probably limited, as vaccine monitoring studies did not observe any cross-protection [5, 6].
Moreover, at present the lowest level at which HPV16 and 18 antibodies exert their protective 
effect against an HPV infection is unknown.
Although in most mucosal tissues IgA-producing cells are predominant, the endocervical 
mucosa contains a higher proportion of plasma-derived or locally produced IgG antibodies, 
which are detectable in cervico-vaginal secretions [17, 23-25]. The higher IgG proportions in 
cervico-vaginal secretions might also depend on the location of sampling and different sampling 
techniques [24]. However, after natural infection it is shown that HPV-specific IgA antibodies are 
detectable at the cervix, mainly in persistent HPV infections [26-29]. Data about IgA antibody 
responses after vaccination are limited. Although IgA levels were much lower as compared to 
IgG levels, we detected HPV16 and 18 specific IgA responses with high correlations between 
serum and CVS. Whether these vaccine-derived HPV16 and 18 IgA antibody levels in the 
systemic circulation play a role in HPV neutralization is unknown. However, Bontkes et al. 
already observed that after HPV infections systemic IgA responses in women with abnormal 
cytology were actually more associated with HPV clearance than locally produced IgA at the 
cervical mucosa. The systemic IgA responses might be an indication of a successful cellular 
immune response induced at the local lymph nodes, mediated by cytokines [30]. 
The correlations of HPV16 and 18 IgG and IgA antibody levels between serum and CVS 
might denote that vaccine derived antibodies transudate from the systemic circulation to the 
cervical mucosa [18, 31]. As antibody levels in CVS remained constant for at least 2 years 
post-vaccination, these levels might contribute to a protective environment at the cervix. 
This hypothesis is supported by the high correlations between antibody levels specific for 
diphtheria and tetanus toxoid in serum and CVS because these vaccine-induced antibodies 
104
are not produced at the cervical matrix. In CVS, increasing HPV antibody concentrations were 
found when more erythrocytes were detected. This indicates that exudated blood probably 
originating from small lesions in the cervix also can contribute to the presence of HPV-specific 
antibodies at the cervix. Protection at the cervix is not necessarily only based on antibodies 
that transudate or exudate from the systemic circulation to the mucosa. It can also be facilitated 
by other immune mechanisms e.g., local production of antibodies in which IgG and IgA are 
produced primarily in mucosal associated lymphoid tissues and are actively transported into 
mucosal secretions [32].
7.6 Conclusion
In conclusion, after vaccination with the bivalent HPV vaccine HPV16 and 18 IgG and IgA 
antibodies were detectable in CVS and these antibody concentrations correlate well with serum 
antibody levels. Antibody levels in CVS were lower as compared to serum and levels remained 
constant up to two years post-vaccination. The correlation between Tt and Dt IgG antibodies 
in serum and CVS suggests that vaccine induced antibodies in the systemic circulation might 
transudate and/or exudate to the cervical mucosa although other immune mechanisms can not 
be excluded. These important immune mechanisms probably contribute to sufficient antibody 
levels at sites where HPV infections actually take place and therefore can provide protection 
against HPV infection and/or re-infections.  
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8.1 Abstract
We compared the immunogenicity and safety of the bivalent HPV16/18 vaccine between 
female patients with JIA and healthy female adolescents. 68 patients and 55 healthy females 
aged 12-18 years were included in a prospective controlled observational cohort and were 
vaccinated at 0, 1, and 6 months. Primary outcomes were immunogenicity expressed as 
seropositivity rate after three vaccine doses at 7 and 12 months and HPV-specific geometric 
mean antibody concentrations. Secondary outcomes were HPV16/18-specific memory B-cell 
responses in a subset of participants and safety, defined as adverse events and the effect of 
vaccination on JIA disease activity. All participants were seropositive for HPV16 and HPV18 
at 7 months. One patient turned seronegative at 12 months for HPV16/18. No significant 
differences were found between patients and controls in HPV-specific antibody concentrations, 
however, antibody concentrations were consistently lower in patients. No effect of methotrexate 
on HPV16-antibodies (p=0.79) or HPV18-antibodies (p=0.37) was detected. All patients on 
anti-TNFα treatment were seropositive after vaccination. The kinetics of HPV16/18 memory 
B-cell responses was comparable between patients and controls, but the magnitude of B-cell 
responses at 7 and 12 months appeared lower in patients. No relevant differences in adverse 
events were found. HPV vaccination did not aggravate JIA disease. The bivalent HPV16/18 
vaccine is immunogenic and well tolerated in JIA patients. However, HPV-specific antibodies 
and B-cell responses tended to be lower in patients compared with healthy controls. Clinical 
trial listing: NCT00815282.
8.2 Introduction
Effective and safe vaccination is essential in individuals whose function of the immune 
system is affected by chronic disorders because these individuals are at increased risk of 
infections due to the immunosuppressive effect of the disease or its treatment [1]. Current 
mass immunisation strategies via national immunisation programmes have greatly reduced 
the burden of childhood infections, but do not take into account the efficacy of vaccinations in 
these high-risk patients [2]. 
The most common chronic rheumatic disease in childhood associated with increased 
susceptibility to infections is juvenile idiopathic arthritis (JIA) [3]. The treatment of JIA involves 
immunosuppressive drugs and biologicals, increasing the susceptibility to infections [4]. In 
order to prevent infections, effective and safe vaccination is vital for these patients. One of 
the vaccines included in national immunisation programmes of various countries worldwide is 
the human papillomavirus (HPV) vaccine to prevent cervical cancer. In healthy young women 
the bivalent HPV vaccine is safe and immunogenic, and induces a high degree of protection 
against HPV16/18 infection and their associated pre-malignant lesions [5-7]. However, the 
efficacy, immunogenicity and safety of HPV vaccination in patients with JIA are yet unknown 
[8]. We conducted a prospective controlled observational cohort study in order to assess the 
immunogenicity and safety of HPV vaccination in female JIA patients compared to healthy 
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female adolescents. Vaccine-induced serologic and cellular immune responses were analysed 
during 12 months. The safety of the HPV vaccine was assessed by comparing adverse events 
between patients and controls and by analysing the effect of vaccination on JIA disease activity.
8.3 Materials and methods
8.3.1 Study design and participants
In the Netherlands, the bivalent HPV vaccine was included in the national immunisation 
programme in 2010 for girls aged 12 years. A nationwide catch-up vaccination campaign was 
performed in 2009 for girls aged 13-16 years. From the start of this vaccination campaign 
in March 2009 until May 2011, a prospective controlled observational cohort study was 
performed, in which female JIA patients and healthy controls aged 12-18 years were enrolled. 
Patients were recruited from the paediatric rheumatology unit of the University Medical Centre 
Utrecht. All patients met the International League of Associations for Rheumatology criteria for 
JIA [9]. No restrictions regarding medication use were applied. Controls were recruited from 
two secondary schools in the Netherlands. All patients and controls who voluntarily opted 
for HPV vaccination were eligible for participation. Written informed consent was obtained 
from participants and their parents/guardians. The study was approved by the medical ethics 
review committee of the Central Committee on Research involving Human Subjects (CCMO, 
The Hague, the Netherlands) and was conducted in accordance with good clinical practice 
guidelines.
8.3.2 Vaccination and follow-up
Participants received 3 doses of the bivalent Cervarix vaccine (GlaxoSmithKline Biologicals, 
Rixensart, Belgium) in a 0, 1, 6 months schedule. Study visits occurred before the first 
vaccination, and at 3, 7, and 12 months. 
8.3.3 Immunogenicity measures
Immunogenicity was analysed by measuring the level and avidity of HPV-specific IgG 
antibodies and memory B-cell responses. The level of IgG antibodies against HPV L1 virus-
like-particle (VLP)16 and VLP18 was measured in all participants at each time point using 
a VLP-based multiplex immunoassay (MIA) [10]. Sera were incubated with VLP-conjugated 
beads. HPV-specific antibodies were detected using R-phycoerythrin conjugated goat anti-
human IgG (Jackson ImmunoResearch laboratories Inc, West Grove, Pennsylvania, USA) and 
analysed using the Bioplex system 200 with Bioplex software (Bio-Rad Laboratories, Hercules, 
California, USA). Sera were considered HPV-antibody seropositive at a cut-off of 9 Luminex 
Units/mL (LU/mL) for HPV16, and 13 LU/mL for HPV18. 
In serum samples from 18 JIA patients and 18 controls, avidity of HPV16/18-specific IgG 
antibodies at 12 months was assessed by using a modification of the abovementioned multiplex 
immunoassay. HPV16/18-specific antibody concentrations were adapted to 6000 Median 
Fluorescent Intensity. Ammonium thiocyanate (NH4SCN; Sigma-Aldrich St. Louis, Missouri, 
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USA) was used to dissociate low-avidity antigen-to-antibody binding [11]. After incubation of 
VLP-conjugated beads with serum, 2.5M NH4SCN in PBS or PBS only was added for 10 
minutes at room temperature. Residual bound IgG antibodies were detected and analysed 
as described above. The percentage of antibodies that remain bound to the VLP-conjugated 
beads after treatment with NH4SCN defines the avidity index.
At each time point, HPV16/18-specific memory B-cells were measured in a random subset 
of 5-10 participants. Heparinised blood samples were obtained for isolation of peripheral 
blood mononuclear cells (PBMCs) using Ficoll density-gradient centrifugation (Amersham 
Pharmacia, Uppsala, Sweden). B-cells were purified and polyclonally stimulated as described 
previously [12]. HPV16/18-specific ELIspot assays were performed by coating multiscreen-IP 
plates (MISPS4510, Millipore) with PBS containing either 10 µg/ml anti-human total IgG-Fc 
(MP Biomedicals, Ohio, USA), 30 µg/mL VLP16 or 20 µg/mL VLP18. For the detection of 
plaques appearing as blue spots, alkaline-phosphatase conjugated goat anti-human IgG was 
added. Spots were analysed using an ELIspot reader [12]. Geometric mean (GM) numbers 
of HPV16/18-specific memory B-cells were expressed per 105 B-cells. When no HPV16/18-
specific spots were measurable, these samples were set at a value of 0.1.
8.3.4 Safety measures
Safety outcome measures were analysed using a standardised diary for 14 days after each 
vaccine dose. Serious adverse events were systematically registered in all participants. 
The effect of HPV vaccination on JIA disease activity was assessed. Disease activity was 
measured by the Juvenile Arthritis Disease Activity Score including 27 joints (JADAS-27) [13], 
a composite score based on four of the six American College of Rheumatology core criteria 
for JIA [14]. The JADAS-27 is calculated as the sum of the scores of its four components and 
ranges from 0 (low disease activity) to 57 (high disease activity).
8.3.5 Statistical analysis
A sample size calculation based on the primary outcome immunogenicity revealed that with 
55 healthy controls and 55 patients there was 81% power with a two-sided α of 0.05 to detect 
a 15% lower seropositivity rate in JIA patients compared to healthy controls, with an expected 
seropositivity rate of 99% in healthy controls [9]. 
Comparison of seropositivity rate after three vaccine doses at 7 and 12 months was performed 
by Pearson’s Chi-square test. HPV-specific antibody concentrations were reported as geometric 
mean concentrations (GMCs) with 95% confidence intervals (CI). Differences between patients 
and healthy controls in HPV-specific GMCs over the total study period were analysed using a 
linear mixed model. This model takes into account all available samples and allows repeated 
measurements on the same individual with unequal time periods between measurements. The 
model, with fixed effects for disease and time, was adjusted for the number of vaccinations and 
time elapsed since vaccination. It included a random effect of time for each individual to account 
for clustering of observations within individuals. A likelihood-ratio test was performed to test 
the effect of JIA disease on the levels and course of HPV-specific antibody concentrations. A 
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preplanned subgroup analysis was performed to assess the effect of methotrexate or biologicals 
by comparing GMCs between patients with and without medication using the Students’ t-tests. 
GM numbers of memory B-cells were compared between the time points by the Mann-Whitney 
U test. 
Adverse events were reported as absolute frequencies or as median values with interquartile 
range (IQR). Differences in adverse events between patients and controls were tested by the 
two-sided Mann-Whitney U tests for quantitative parameters, and by the Pearson’s Chi-square 
test for categorical parameters. JIA disease activity, presented as median values with IQR, 
was compared before and after vaccination by the Wilcoxon matched-pairs signed-ranks test. 
Effect modification was assessed in patients with high baseline disease activity (JADAS-27 ≥ 
6.0) and in patients using methotrexate. Statistical analysis was carried out with SPSS version 
20.0.0 (SPSS Inc, Chicago, Illinois, USA). All reported p-values were based on two-sided tests 
for significance, and p<0.05 was considered statistically significant. 
8.4 Results
8.4.1 Baseline characteristics
Of 55 healthy female adolescents and 68 female patients with JIA enroled in the trial, 49 (89%) 
healthy controls and 63 (93%) JIA patients could be analysed in the primary immunogenicity 
analysis (Fig. 1). In all, 8 (7%) participants dropped out from the study (Table 1). The full three-
dose vaccination schedule was administered to 50 (91%) healthy controls and 66 (97%) JIA 
patients, whereas HPV vaccination was postponed in seven patients because of the use of 
biologicals (n = 5) or for personal logistic reasons (n = 2). These patients were excluded from 
the on-protocol immunogenicity analysis. In JIA patients, median disease activity at time of 
inclusion was low (JADAS-27 of 3.1 points). 
8.4.2 Immunogenicity
The primary analysis for immunogenicity in the total vaccinated cohort showed that all patients 
and healthy controls were seropositive 7 months after the first vaccination. All controls were 
seropositive for HPV16 and HPV18 at 12 months, whereas one patient had turned seronegative 
for HPV16 and HPV18 after demonstrating HPV-specific antibody concentrations comparable 
with the total JIA population at 3 and 7 months. This oligoarticular JIA patient was vaccinated 
according to protocol. Four JIA patients had received only one vaccination after 3 months; two 
of these patients were still seronegative for HPV16 and three were still seronegative for HPV18 
at that time point. These patients turned seropositive after the third dose. Thus, the full three-
dose HPV vaccination schedule induced high seropositivity rates in JIA patients, comparable 
with healthy controls.
No statistical significant differences were detected in HPV-specific GMCs over time between 
JIA patients and healthy controls (Fig. 2). The likelihood-ratio test (4 degrees of freedom) for 
the effect of disease was 5.64 for HPV16 (p=0.23) and 2.27 for HPV18 (p=0.69). Although non-
significant, HPV-specific GMCs were consistently lower in JIA patients compared with controls. 
112
Fig. 1. Enrolment of healthy controls and patients with JIA.
a) includes all female adolescents that received at least one HPV vaccine dose.
b) includes all female adolescents with at least one serum sample after the first HPV vaccine dose.
c) disease activity was measured using the Juvenile Arthritis Disease Activity Score involving 27 joints, 
this could be assessed in 68 patients in whom a disease activity score could be calculated before and 
at least once after HPV vaccination.
d) includes only the serum samples drawn according-to-protocol from 48 healthy controls and 56 JIA 
patients who were vaccinated according to the schedule 0, 1, and 6 months. Compared with the primary 
analyses, one healthy control was lost to follow-up after 3 months, and seven JIA patients were excluded 
because the second or third HPV vaccination was postponed.
e) includes only the disease activity scores calculated in patients that were vaccinated and clinically 
assessed according to protocol. Compared to the primary analyses, HPV vaccination was postponed in 
seven patients, and four clinical assessments of three patients were not in accordance with the protocol. 
Abbreviations: HPV, human papillomavirus vaccination; JIA, Juvenile Idiopathic Arthritis; vs., versus
113
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Baseline characteristics JIA (n=68) HC (n=55)
Age, mean (±SD)a, y 14.1 (±1.6) 14.3 (±1.2)
Compliance with vaccinationb
Received only one dose 0 (0%) 0 (0%)
Received only two doses 1 (1%) 1 (2%)
Received three doses 66 (97%) 50 (91%)
3rd vaccine uncertain due to dropout 1 (1%) 4 (7%)
Study visit completion
Attended 3 months visit 64 (94%) 46 (84%)
Attended 7 months visit 63 (93%) 47 (85%)
Attended 12 months visit 63 (93%) 46 (84%)
Dropouts in total vaccinated cohort 2 (3%) 6 (11%)
(Serious) adverse events 0 (0%) 0 (0%)
Lost to follow-up 0 (0%) 2 (4%)
Withdrawn for personal reason 2 (3%) 3 (5%)
Venous punctures too demanding 0 (0%) 1 (2%)
Seropositivity at baseline
HPV-16 2 (3%) 0 (0%)
HPV-18 1 (1%) 1 (2%)
JIA subtype
Oligoarticular JIA, Persistentc 23 (34%)
Oligoarticular JIA, Extendedc 13 (19%)
Polyarticular JIA, RF positive 7 (10%)
Polyarticular JIA, RF negative 12 (18%) ND
Systemic onset JIA 6 (9%)
Enthesitis related JIA 1 (2%)
Psoriatic arthritis 3 (4%)
JIA not specified 3 (4%)
Disease characteristics
ANA positive‡ 39/65
RF positive 12/58
HLA-B27 positive 4/25 ND
Age at onset, median (IQR), y 9.4 (3.6-12.1)
Duration of JIA, median (IQR), y 4.6 (1.7-10.4)
Disease activity, median (IQR)
JADAS-27 3.1 (1.2-6.8)
Joints with active arthritis 0 (0-1)
Patient well-being assessment, 10cm VASd 1.9 (0.3-4.6) ND
PGA of disease activity, 10cm VASd 0.9 (0-1.5)
ESR, mm/hr 8 (5-12)
Medication use
MTX 24 (36%)
Table 1. Baseline characteristics and serious adverse events during follow-up.
114
Dose, mean (±SD), mg/m2/week 10.2 (±3.1)
NSAIDS 37 (54%)
Other DMARDSe 6 (9%) ND
Anti-TNFα treatment 9 (13%)
Dose, median (IQR), mg/week 45 (25-50)
Anti-IL1 treatment 1 (1%)
Oral steroids 0 (0%)
Serious adverse events 
Participants reporting SAE 11 (16%) 1 (2%)
Number of SAEs reported 14 1
Surgery  2 preplanned surgeries 1 preplanned surgery
Appendicitis
Perforated eardrum
Correction of cerebral AVM
Hospital admission 3x diagnostic endoscopyf None
Analysis of gait 
abnormalitiesg
Transient lower back pain
Preplanned lasertherapy 
for uveitis
Allergic reaction to anti-
TNFα
Epileptic insult: cerebral 
AVM
Severe pharyngitis
Note: Unless otherwise indicated, frequencies (percentage) are depicted. a) p=0.36 (Student’s t-test); b) The 
second HPV vaccination was postponed in three patients and the third HPV vaccination in four JIA patients; c) 52% 
(12/23) of the patients with persistent oligoarticular JIA and 85% (11/13) of the patients with extended oligoarticular 
JIA were ANA positive; d) Well-being and disease activity were both measured on a 10 cm visual-analogue scale, in 
which 0 represented “very well” overall well-being or no disease activity, and 10 represented “very poor” overall well-
being or maximum disease activity; e) Five patients used leflunomide (10-20mg) and one oligoarticular JIA patient 
used mycophenolate mofetil for the treatment of severe uveitis ; f) 3 patients underwent an endoscopy at which 
inflammatory bowel disease was diagnosed. In all 3 patients, abdominal pain, diarrhoea with the passage of mucus, 
periods of constipation and intermittent rectal bleeding were already present prior to the first HPV vaccine dose; 
g) Gait abnormaliteis in one patient had a psychosomatic cause; ANA, antinuclear antibody; AVM, arteriovenous 
malformation; DMARDS, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HC, healthy 
control; HLA, human leucocyte antigen; HPV, human papillomavirus; IL, interleukin; MTX, methotrexate; ND, not 
determined; NSAIDS, nonsteroidal anti-inflammatory drugs; PGA, Physician Global Assessment of disease activity; 
RF, rheumatoid factor; SAE, serious adverse event; TNF, tumour necrosis factor; VAS, visual-analogue scale.
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Similar results were found in the according-to-protocol analyses (data not shown). HPV16/18-
specific GMCs in 52 serum samples of 32 patients using methotrexate were compared with 
GMCs in 71 samples of 31 patients without methotrexate. Methotrexate did not affect HPV16-
antibodies (2578 LU/mL (95% CI 1338 to 4967) versus 2844 LU/mL (95% CI 2034 to 3976); 
p=0.79) or HPV18-antibodies (860 LU/mL (95% CI 963 to 3595) versus 1335 LU/mL (95% CI 
951 to 1873); p=0.37).
All patients on methotrexate were seropositive at 12 months after the first vaccination, except 
for one patient. Although antibody concentrations were non-significantly lower in patients on 
anti-TNFα treatment, all patients were seropositive after three vaccine doses. The number of 
patients on anti-TNFα was too small to draw definite conclusions. 
Avidity of HPV16/18-specific antibodies was comparable in a random sample of 18 JIA patients 
and 18 healthy controls (Fig. 3). The avidity index of HPV16-specific antibodies was 86% (95% 
CI 84% to 88%) in patients and 83% (95% CI 77% to 89%) in controls. Similar indices were 
found for HPV18 in patients (86% (95% CI 83% to 90%)) and controls (86% (95% CI 82% to 
89%)).
Overall, the number of total IgG-producing B-cells was similar in JIA patients (GM 7.9 (95% 
CI 6.8 to 9.2)) and healthy controls (GM 6.7 (95% CI 5.6 to 8.1)). In JIA patients, HPV16/18-
specific memory B-cell responses increased at 3 months (HPV16 p=0.004; HPV18 p=0.002) 
and 7 months (HPV16 p=0.15; HPV18 p=0.03) after vaccination, and subsequently declined 
(Fig. 4). The kinetics of the HPV16/18 memory B-cell response was comparable in patients 
and controls, but the magnitude of B-cell responses appeared lower in JIA patients at 7 and 
12 months. 
Fig. 2. HPV16- and HPV18-specific geometric mean IgG antibody concentrations. Geometric mean 
HPV16/18-specific IgG antibody concentrations (with 95% CI) against HPV16 (A) and HPV18 (B) are 
indicated at baseline and during follow-up for healthy controls (open dots) and JIA patients (black dots) at 
baseline (0 month), 1 month after the second vaccination (3 months), 1 month after the third vaccination 
(7 months), or 1 year after the first vaccination (12 months). 
HC, healthy controls; HPV, human papillomavirus; JIA, juvenile idiopathic arthritis patients.
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Memory B-cells against HPV16 could not be detected in five patients and two controls and 
against HPV18 in three patients and one control, although they all had detectable antibody 
concentrations. It remains unclear why these participants failed to mount a HPV16/18-specific 
memory B-cell response. The treatment of the five patients was not severely immunosuppressive: 
only one used methotrexate with anti-TNFα, whereas two used methotrexate and two did not 
use any immunosuppressive drug. 
8.4.3 Safety
Regarding vaccine safety, redness and bruising at the injection site were reported more 
frequently by healthy girls (Table 2), while the duration of these local symptoms was similar. 
The frequency of general symptoms was comparable in patients and controls. In the context of 
chronic arthritis characterising JIA disease, new onset or worsening of pre-existing arthralgia 
is of special interest. The occurrence of arthralgia was similar in both groups, yet the mean 
duration was significantly longer in JIA patients (p<0.001). Serious adverse events occurred 
more often in JIA patients (Table 1). The majority of these serious events were preplanned 
interventions, diagnostic hospital admissions for pre-existing complaints or adverse events 
associated with the treatment of JIA disease and were therefore judged to be unrelated to HPV 
vaccination. 
Disease activity measured by the JADAS-27 did not worsen after HPV vaccination (Fig. 5A). 
In fact, compared to baseline the JADAS-27 was significantly lower at 7 months (2.8 (IQR 
0.2-6.0) vs 3.1 (IQR 1.2-6.8); p=0.007) and at 12 months after inclusion (1.8 (IQR 0.1-4.6); 
p=0.006). Similar results were found in the according-to-protocol analysis (data not shown); in 
the subgroup of 18 patients with high baseline disease activity (Fig. 5B); in 24 patients using 
methotrexate (Fig. 5C); and in 9 patients using anti-TNFα treatment (data not shown). Overall, 
these data indicate that HPV vaccination does not negatively affect JIA disease activity.
Fig. 3. Avidity index of HPV16- and HPV18-specific IgG antibodies. Mean avidity indices (with 95%CI) 
for 18 healthy controls (open dots) and 18 JIA patients (black dots) at 12 months follow-up are indicated. 
HC, healthy controls; HPV, human papillomavirus; JIA, juvenile idiopathic arthritis patients.
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Fig. 4. Geometric mean numbers of HPV16 and HPV18 memory B-cells. Geometric mean numbers of 
HPV16 (A and B) and HPV18 (C and D) memory B-cells are indicated per 105 B-cells for JIA patients 
(black dots, A and C) and healthy controls (open dots, B and D). Each dot indicates one participant at 
baseline (0 month), 1 month after the second vaccination (3 months), 1 month after the third vaccination 
(7 months), or 1 year after the first vaccination (12 months). * p<0.05, ** p<0.01
HC, healthy controls; HPV, human papillomavirus; JIA, Juvenile Idiopathic Arthritis patients
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Table 2. Safety outcomes.
JIA HC p
Solicited adverse events within 14 days after vaccination*
Participants assessed 54 44
Diaries assessed 138 120
Local adverse events
Pain 52 (96%) 44 (100%) 0.500
Mean duration (days) 1.4 (1.2 to 1.6) 1.3 (1.1 to 1.4) 0.253
Redness 20 (37%) 43 (98%) <0.001
Mean duration (days) 1.2 (0.8 to 1.7) 1.0 (0.7 to 1.3) 0.350
Bruising 14 (26%) 39 (89%) <0.001
Mean duration (days) 1.7 (0.9 to 2.5) 1.3 (0.8 to 1.7) 0.332
Swelling 25 (46%) 18 (41%) 0.593
Mean duration (days) 1.7 (1.2 to 2.1) 1.4 (0.9 to 2.0) 0.550
Induration 26 (48%) 21 (48%) 0.967
Mean duration (days) 1.7 (1.4 to 2.1) 1.4 (0.8 to 1.9) 0.194
General adverse events
Syncope after vaccination 1 (2%) 0 (0%) nd
Rash† 11 (20%) 6 (14%) 0.404
Arthralgia† 11 (20%) 6 (14%) 0.381
Mean duration (days) 2.0 (0.8 to 3.2) 0.6 (0.3 to 0.8) 0.024
Myalgia† 29 (54%) 19 (43%) 0.300
Mean duration (days) 1.0 (0.7 to 1.3) 0.8 (0.5 to 1.1) 0.368
Fatigue 30 (56%) 22 (50%) 0.584
Mean duration (days) 2.5 (1.8 to 3.2) 1.3 (0.9 to 1.7) 0.005
Headache 22 (41%) 22 (50%) 0.359
Mean duration (days) 2.4 (1.4 to 3.4) 1.6 (1.1 to 2.2) 0.164
Fever‡ 6 (11%) 3 (7%) 0.727
Mean duration (days) 1.2 (0.7-1.6) 4.7 (0.2 to 3.1) 0.500
Serious adverse events 
Participants assessed 68 50 nd
Participants reporting SAE 11 (16%) 1 (2%) nd
Number of SAEs reported 14 1 nd
Surgery
Preplanned mandibular 
surgery
Preplanned ear correction
Preplanned eye surgery 
for glaucoma
Appendicitis
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Correction of perforated 
eardrum
Correction of cerebral AVM
Hospital admission 3x diagnostic endoscopy§ None
Analysis of gait 
abnormalities¶
Transient severe lower 
back pain 
Preplanned lasertherapy 
for uveitis
Allergic reaction to anti-
TNFα
Epileptic insult due to 
cerebral AVM
Severe pharyngitis
Note: * The number (%) of participants experiencing adverse events after at least one vaccine dose is depicted with the 
associated mean (95%CI) duration of the adverse event. 
† Newly onset symptoms or worsening of pre-existing symptoms 
‡ Fever was defined as a temperature above >38•5ºC  
§ 3 patients had an endoscopy, after which the diagnosis inflammatory bowel disease was made. In all 3 patients, 
abdominal pain, diarrhoea with the passage of mucus, periods of constipation and intermittent rectal bleeding were 
already present prior to the first HPV vaccine dose. 
¶ Psychosomatic cause 
AVM, arteriovenous malformation; HC, healthy control; JIA, juvenile idiopathic arthritis; nd, not determined; SAE, serious 
adverse event.
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8.5 Discussion
This prospective controlled study shows that the bivalent HPV16/18 vaccine induces high 
seropositivity rates and strong HPV16/18-specific antibody responses in female adolescents 
with JIA, comparable to healthy female adolescents. The quality of the HPV16/18-specific 
antibodies measured by their avidity and the kinetics of HPV16/18-specific memory B-cell 
responses were similar in patients and healthy controls, although the magnitude of B-cell 
responses at 7 and 12 months tended to be lower in patients. Regarding safety, local injection 
site symptoms were more common in healthy controls whereas general symptoms tended to 
last longer in patients. HPV vaccination did not negatively affect JIA disease activity. 
Vaccine-derived HPV-specific antibodies are considered largely responsible for the protection 
against persistent HPV infections and precancerous lesions [5, 15, 16]. 
With regard to the avidity of HPV-specific antibodies, it is unknown whether high avidity 
antibodies play a critical role in protection against HPV infection [17]. HPV-specific memory 
Fig. 5. Disease activity in JIA patients during 12 months follow-up. Median (IQR) JIA disease activity, 
expressed as the JADAS-27, in the year following the first HPV vaccination is depicted in the total JIA 
population (A), in 18 patients with high baseline disease activity, defined as a JADAS-27 of at least 6.0 
points (B), and in 24 patients using methotrexate at baseline (C). No increase in JADAS-27 was detected 
after HPV vaccination. * p<0.05, ** p<0.01. HPV, human papillomavirus; JADAS-27, Juvenile Arthritis 
Disease Activity Score including 27 joints; JIA, juvenile idiopathic arthritis patients; MTX, methotrexate.
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B-cells are important determinants of long-term protection since they provide this rapid burst 
of antibody upon rechallenge and play a role in maintaining serological memory over time 
[18-22]. The comparable strong HPV16/18-specific antibody response, avidity of HPV16/18-
specific antibodies and kinetics of HPV16/18-specific memory B-cell responses indicate that at 
least these surrogate endpoints for HPV vaccine efficacy are similar in JIA patients and healthy 
controls. 
Despite the good short-term immunogenicity of the bivalent HPV vaccine in JIA patients, 
there is reason for cautiousness. Numerous studies have analysed vaccine responses in 
patients with rheumatic diseases up to two years after vaccination. Responses were generally 
comparable to healthy controls, although various studies found non-significantly lower antibody 
concentrations [8]. Also in our study HPV-specific antibody concentrations were consistently 
lower in JIA patients, albeit non-significant. These lower responses may be due to underlying 
defects in the immune system of JIA patients. Premature aging of the immune system resulting 
in low antibody responses to vaccinations has been described [23]. Furthermore, a minority 
of patients with autoimmune diseases have associated primary immunodeficiencies [24]. 
Besides the lower short-term responses, the long-term persistence of several vaccine-specific 
antibodies has been shown to be significantly lower in JIA patients compared with healthy 
controls [25]. In addition, the magnitude of HPV-specific B-cell responses tended to be lower in 
JIA patients at 7 and 12 months after vaccination. The lower serological and cellular responses 
might indicate that over time, protection against HPV infection is not guaranteed. 
Since vaccinations may theoretically aggravate the course of autoimmune diseases via 
bystander activation or molecular mimicry [26], a JIA-specific measure for HPV vaccine safety 
is the effect of vaccination on JIA disease activity. Our study design, in which patients served as 
their own controls, enabled detection of worsening disease activity after vaccination if indeed 
HPV vaccination would have deteriorating effects. With data of 53 patients at 3 and 54 patients 
at 7 months, a minimum difference in JADAS-27 of 1.6 out of 57 points could be detected. No 
detrimental effect of HPV vaccination on JIA disease activity was detected, not even in patients 
with high baseline disease activity, or patients using methotrexate or anti-TNFα. 
Adverse events were systematically documented in both patients and controls. Non-serious 
adverse events were generally similar in patients and controls, transient and of short duration. 
Serious adverse events occurred more frequent in JIA patients than in healthy controls, but 
none were deemed related to HPV vaccination. The majority of these serious events were 
associated with the treatment or diagnosis of (complicated) JIA disease. In all three patients 
diagnosed with inflammatory bowel disease during the study, the onset of complaints was prior 
to the first vaccination.  
In case of at least 15% difference in seropositivity rate the null hypothesis (i.e. seropositivity 
rate in patients and controls is similar) would be rejected. In order to detect a 15% difference 
in seropositivity rate between patients and controls, we needed to include 55 patients and 
healthy controls. Although the number of healthy controls was too small (49 instead of 55), the 
difference in seropositivity rate between patients and controls was only 2%. As inclusion of the 
intended 55 healthy controls would not have led to a 15% difference in seropositivity rate, we 
122
believe that our conclusion that seropositivity rate after HPV vaccination is similar in patients 
and controls is justified. The low participation rate was partly due to the low HPV vaccination 
coverage (49.9% for the first vaccine dose) in the Netherlands [27]. 
8.6 Conclusion
Safe and effective vaccination of individuals whose function of the immune system is affected 
by chronic diseases is a challenge in current immunisation strategies as these strategies may 
fail to target high-risk individuals [2]. Since children with rheumatic diseases have high risks of 
infections [28], it is essential to know whether these patients benefit from HPV vaccination. The 
bivalent HPV vaccine does not aggravate JIA disease, is well tolerated and is immunogenic in 
the 12 months after the first HPV vaccination. Since our results do not exclude the possibility 
that long-term protection against HPV infection is inadequate in JIA patients, we recommend 
a proactive approach in the immunesurveillance of JIA patients, even though it is yet unknown 
what antibody concentrations are needed for protection against HPV infection [5, 7]. If antibody 
concentrations wane below antibody levels associated with natural infection, revaccination 
should be considered. Moreover, continued secondary prevention via cervical smears seems 
prudent in these patients.
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9.1 Abstract
Effective vaccination against human papillomavirus (HPV) is essential in patients with 
rheumatic diseases, particularly systemic lupus erythematosus (SLE), given their increased 
risk of persistent HPV infections and (pre)malignant cervical lesions. The immunogenicity of the 
bivalent HPV16/18 vaccine was compared between female patients with rheumatic diseases 
and healthy adolescents. A prospective controlled observational pilot study was performed 
including patients with various rheumatic diseases (SLE, n = 6), juvenile dermatomyositis 
(JDM, n = 6), overlap syndromes (n = 4)) and 49 healthy adolescents. Participants received 
three vaccine doses (0, 1, 6 months), and study-visits occurred at 0, 3, 7, and 12 months. HPV-
specific IgG antibodies were measured by VLP-based multiplex immunoassays. (ClinicalTrials.
gov: NCT00815282). All patients and controls were seropositive for HPV16/18 after three 
vaccine doses, except for one JDM patient who was seronegative for HPV18 at 7 months. 
However, HPV16/18-specific antibody concentrations were markedly lower in all patients, 
albeit non-significant. The majority of patients used immunosuppressive drugs, yet patients 
without medications also showed lower humoral responses compared to healthy controls. The 
bivalent HPV16/18 vaccine appeared less immunogenic in patients with SLE, JDM and overlap 
syndromes compared to healthy adolescents. A large prospective trial is warranted to unravel 
the mechanisms behind these poor humoral responses.
 
9.2 Introduction
Persistent genital infections with human papillomavirus (HPV) serotype 16 and 18 can 
result in cervical intraepithelial neoplasia (CIN) and cervical cancer. To protect against HPV 
infections, two HPV vaccines have been developed. In healthy young women these vaccines 
are safe, immunogenic, and effective in inducing protection against HPV16/18 infections and 
their associated pre-malignant lesions [1, 2]. The HPV vaccination is most effective when 
administrated to girls before they become sexually active. The bivalent HPV vaccine is 
considered more immunogenic against HPV16/18 than the quadrivalent vaccine [1, 2]. 
Effective vaccination against HPV is crucial in individuals with rheumatic diseases, who are at 
increased risk of infections due to the immunosuppressive effect of the disease or its treatment 
[3]. This accounts for patients with systemic lupus erythematosus (SLE) in particular, as these 
patients have a higher risk of multiple and persistent HPV infections leading to a higher 
prevalence of CIN compared to healthy individuals [4, 5]. Interestingly, the immunogenicity of 
the quadrivalent HPV vaccine in patients with SLE is lower than in healthy controls for HPV16 
and HPV18 [6]. However, the immunogenicity of the more immunogenic bivalent HPV16/18 
vaccine in the target population, namely HPV-naive adolescent patients, is yet unknown.
The current pilot study describes the immunogenicity of the bivalent HPV16/18 vaccine in 
patients with juvenile SLE, juvenile dermatomyositis (JDM), and overlap syndromes compared 
with healthy female adolescents. These data are obtained from a larger prospective controlled 
clinical trial including female patients with various rheumatic diseases. 
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9.3 Materials and methods
9.3.1 Study design and participants
The bivalent HPV16/18 vaccine was included in the Dutch national immunisation programme 
in 2010 for girls aged 12 years, preceded by a catch-up campaign in 2009 for girls aged 
13–16 years. From March 2009 until May 2011, female patients with rheumatic diseases and 
healthy controls aged 12–18 years who voluntarily opted for HPV vaccination were enrolled in 
a prospective controlled observational cohort study. Patients were recruited from the paediatric 
rheumatology unit of the University Medical Centre Utrecht. All SLE patients fulfilled ≥4 
American College of Rheumatology criteria for SLE [7] and JDM patients met the Bohan and 
Peter classification for definite or probable JDM [8]. Controls were recruited from two secondary 
schools in the Netherlands. Suspected or proven cervical cancer was an exclusion criterion. 
Written informed consent was obtained from participants and their parents or guardians. The 
medical ethics committee of the Central Committee on Research involving Human Subjects 
approved the study (ClinicalTrials.gov, number NCT00815282).
9.3.2 HPV vaccination
Participants received 3 doses of the bivalent Cervarix vaccine (GlaxoSmithKline (GSK) 
Biologicals, Rixensart, Belgium) in a 0, 1, 6 months schedule. Study visits occurred before 
vaccination, and at 3, 7 and 12 months. 
9.3.3 HPV16/18-specific IgG antibody concentrations
Immunogenicity was analysed by measuring the level of HPV-specific IgG antibodies against 
HPV L1 virus-like-particle (VLP)16 and VLP18 using a VLP-based multiplex immunoassay. 
Sera were incubated with VLP-conjugated beads. HPV-specific antibodies were detected using 
R-phycoerythrin conjugated goat anti-human IgG (Jackson ImmunoResearch laboratories Inc, 
West Grove, Pennsylvania, USA) and analysed using the Bioplex system 200 with Bioplex 
software (Bio-Rad Laboratories, Hercules, California, USA). Sera were considered HPV-
antibody seropositive at a cut-off of 9 Luminex Units/mL (LU/mL) for HPV16, and at 13 LU/mL 
for HPV18. HPV-specific antibody concentrations were expressed as geometric mean antibody 
concentrations (GMCs).
9.3.4 Statistical analysis
Demographic characteristics of patients and controls were compared by the independent 
sample Student’s t-test. Seropositivity rate after three vaccine doses at 7 and 12 months was 
compared between patients (juvenile SLE, JDM or overlap syndromes) and healthy controls by 
Pearson's Chi-square test. Differences in HPV-specific GMCs between patients and controls 
were analysed using the Student’s t-test. 
Considering the rarity of these juvenile rheumatic diseases, the sample size was expected to 
be too small to reach sufficient statistical power for definite conclusions concerning differences 
between patients and controls in seroprotection rate and HPV-specific antibody concentrations. 
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Therefore, the current pilot study is primarily meant to describe the immunogenicity of the 
bivalent HPV16/18 vaccine in these three patient groups.
Statistical analysis was carried out with SPSS version 20.0.0 (SPSS inc, Chicago, Illinois, 
USA). Limit values for significance were set at 0.05. Confidence intervals (CI) were expressed 
as 95%CI.
9.4 Results
9.4.1 Demographic characteristics
Six patients with SLE aged 15.0 (±1.5) years with mean disease duration of 3.5 (±2.2) years 
were included. Disease activity was low (median SLEDAI 3.0 (range 0 to 8)) at baseline and 
remained low (range 0 to 12) during follow-up for all SLE patients. Twelve serum samples 
were available from patients with SLE after vaccination. Six JDM patients aged 15.3 (±2.3) 
years with mean disease duration of 7.0 (±3.7) years participated. All JDM patients had normal 
CMAS scores (51 points) at baseline and during follow-up, reflecting persistent remission. 
From these patients, thirteen serum samples were available post vaccination. Four patients 
with overlap syndromes aged 14.4 (±2.0) years and disease duration of 6.0 (±3.8) years were 
also included, with 8 available serum samples after vaccination. Healthy controls were aged 
14.3 (±1.2) years at time of inclusion. The age at time of inclusion did not differ between 
patients and healthy controls (ANOVA, p=0.319). In contrast to patients, one healthy control 
was seropositive for HPV18 at baseline. After vaccination, 128 serum samples were available 
from 49 healthy controls.
9.4.2 HPV16/18 seropositivity
All patients were seropositive after three vaccine doses at 7 months, except for one JDM 
patient (patient 10, table 1) who was seronegative for HPV18 after initial low HPV18-specific 
antibody concentrations (20.5 LU/mL) at 3 months. HPV16-specific antibody concentrations in 
this patient were also low (15.7 LU/mL) at 3 months and were just above seropositivity levels 
(9.1 LU/mL) after three vaccine doses. This patient did not use any immunosuppressive drug. 
All controls were seropositive for HPV16 and HPV18 at 7 and 12 months.
9.4.3 HPV16/18-specific antibody concentrations
HPV16/18-specific antibody concentrations were markedly lower in patients compared to 
healthy controls (Fig. 1A-D). Despite the low sample size, the differences with controls reached 
statistical significance in JDM patients (Fig. 1C-D) at 7 months for HPV16-specific GMCs 
(p=0.003) and HPV18-specific GMCs (p=0.043), and in patients with overlap syndromes at 7 
months (p=0.041) and 12 months (p=0.027) for HPV16-specific GMCs (Fig. 1C). The kinetics 
of the antibody response in patients also differed from healthy controls. In contrast to healthy 
controls, no serologic response was detected at 3 months after the first two vaccine doses in 
SLE patients, and the third vaccine dose was essential to induce HPV16/18-specific antibodies. 
In patients with JDM and overlap syndromes on the other hand, the serologic respons
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Table 1. Clinical characteristics of patients at baseline and medication use during 12 months after the 
first HPV vaccination.
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induced by the first two vaccine doses was comparable to the response seen in healthy controls, 
whereas the humoral response on the third dose was markedly different from healthy controls.
9.4.4 HPV16/18-specific antibody concentrations versus immunosuppressive drugs
To describe the effect of immunosuppressive drugs on HPV-specific antibody concentrations, 
patient groups were pooled and medication groups were formed based on the use of each specific 
drug in at least two visits during follow-up (Table 2). Noteworthy, patients without medications 
or nonsteroidal anti-inflammatory drugs (NSAIDs) monotherapy (one patient with SLE, four 
with JDM, and two with overlap syndrome) also showed lower antibody responses compared 
to healthy controls. Generally, patients on glucocorticosteroids and hydroxychloroquine were 
able to mount a relatively high antibody response, which was roughly comparable to healthy 
controls at 7 months but lower at 12 months after vaccination. As expected, the patient in 
whom rituximab and mycophenolate mofetil (MMF) were started, showed markedly lower 
HPV-specific antibody concentrations at 7 and 12 months.
Fig. 1. HPV16 and HPV18 specific geometric mean antibody concentrations. Geometric mean antibody 
concentrations against HPV16 (A, C) and HPV18 (B, D) are indicated at baseline and during follow-
up for healthy patients (open dots) and SLE patients (black dots), JDM patients (black squares), and 
patients with overlap syndromes (black triangles) at baseline (0 months), one month after the second 
vaccination (3 months), one month after the third vaccination (7 months), or one year after the first 
vaccination (12 months). 
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Table 2. HPV-specific antibody concentrations versus immunosuppressive drugs.
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9.5 Discussion
This prospective controlled pilot study shows that the bivalent HPV16/18 vaccine induces 
seropositivity in a high proportion of female adolescents with SLE, JDM and overlap 
syndromes, comparable with healthy female adolescents. However, the magnitude of the 
humoral response, measured by HPV16/18-specific antibody concentrations is markedly 
lower. Although it is unknown what antibody concentrations are needed for protection against 
HPV infection, vaccine-derived HPV-specific antibodies are considered largely responsible 
for the protection against persistent HPV infections and precancerous lesions [9]. Therefore, 
protection against HPV infection in juvenile patients with rheumatic diseases might not be 
guaranteed in due course. 
Numerous studies have evaluated the immunogenicity of various vaccines in patients with 
autoimmune rheumatic diseases, including SLE [10-12]. The Haemophilis influenza type B, 
hepatitis B, tetanus toxoid, influenza, pneumococcal, and varicella zoster vaccines all induced 
a significant humoral response in the majority of SLE patients [10-12]. However, the induced 
humoral responses were generally lower than in healthy controls and a significant minority 
of patients remained unprotected despite vaccination. Compared with healthy controls, the 
immunogenicity of the influenza vaccine was found to be similar in juvenile patients with SLE 
(n = 23), JDM (n = 9) and mixed connective tissue disease (n = 4), whereas lower antibody 
responses were noted after varicella zoster vaccination in patients with JDM (n = 4) and after 
tetanus toxoid vaccination in patients with SLE (n = 40) [10-12]. The lower HPV16/18-specific 
antibody concentrations found in our study are in accordance with these latter results.
Lower HPV16/18-specific antibody concentrations were also found in vaccinated adult 
patients with SLE [6]. The HPV16/18-specific antibodies were generally lower in users of 
immunosuppressive medications, primarily prednisone and MMF [6]. In our study, the one 
patient using MMF monotherapy also showed lower antibody concentrations. Patients with 
glucocorticosteroids were able to mount a humoral response, albeit lower than in healthy 
controls at 12 months after vaccination. The small and heterogeneous patient population makes 
it difficult to distinguish whether the immunosuppression is caused by medication use or by the 
underlying disease itself. Nevertheless, HPV16/18-specific antibody concentrations were also 
lower in patients not using immunosuppressive drugs, indicative of aberrant immune responses 
caused by the underlying disease itself. Several alterations in the immune system may lead to 
poor humoral responses against vaccine antigens. For example, in juvenile SLE patients low 
CD4+ and CD8+ T-cell and natural killer cell numbers, abnormal B-cell receptor signalling, high 
immune activation, high apoptosis levels and altered expression of costimulatory molecules 
have been described in relation to vaccination [13]. 
Non-live composite vaccines such as the HPV vaccine are generally considered safe in patients 
with rheumatic diseases [11, 14]. HPV vaccination in 50 adult patients with SLE found no 
effect of this vaccine on disease activity, with a similar flare rate (0.22/patient/year) after HPV 
vaccination compared to a historical cohort (0.20/patient/year, p=0.81) [6]. Also in our study, 
SLE disease activity remained low and normal CMAS scores were consistently measured 
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in JDM patients during follow-up. Beside the effect of HPV vaccination on disease activity, 
it is currently recommended to remain vigilant for the occurrence of venous thromboembolic 
events after HPV vaccination in SLE patients [14], as such events have been reported in 
healthy subjects [15]. No thromboembolic events occurred in the adult patients or in the current 
study [6]. However, larger patient numbers are needed to undoubtedly assess the safety of 
HPV vaccination in patients with SLE, JDM or overlap syndromes.
The current study is limited by the small and heterogeneous sample size, making direct 
extrapolation of our results to all juvenile patients with SLE, JDM or overlap syndromes 
impossible. Gathering larger prospective cohorts is therefore of paramount importance to enable 
a more powerful conclusion. Nevertheless, this is the only existing study on HPV vaccination 
in adolescent females with these rheumatic diseases, showing strikingly lower antibody 
concentrations compared to healthy controls. These data suggest that immunosurveillance of 
HPV-specific antibody concentrations and continued secondary prevention via cervical smears 
may be prudent in these patients, and call for further immunological analyses to unravel the 
mechanisms behind these reduced immune responses. 
9.6 Conclusion
The bivalent HPV16/18 vaccine seems to induce markedly lower HPV16/18-specific antibody 
concentrations in female adolescents with SLE, JDM and overlap syndromes compared to 
healthy controls. A larger prospective trial is currently initiated to establish the safety and 
efficacy of the HPV vaccine in relation to immunosuppressive drugs and to identify the factors 
contributing to the poor humoral response against HPV.
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10.1 The role of humoral immunity
Cervical cancer is one of the most common cancers worldwide [1]. In 99.7% of the cases, 
cervical cancer is caused by persistent infections with the human papillomavirus (HPV) [2-10]. 
In addition, HPV is associated with other ano-genital cancers in both men and women. Two 
vaccines against the most common high-risk HPV types (HPV16/18) have been developed. 
The prophylactic bivalent HPV vaccine (Cervarix) has been implemented in 2010 in the 
Dutch national immunization program for 12-year-old girls. In addition, a catch-up vaccination 
campaign among girls 13-16 years of age (vaccination coverage 52%) in 2009 preceded the 
national implementation [11]. In the Netherlands, vaccination coverage was initially low (around 
50%) due to negative media attention and amounted to 56% in 2012 [12]. 
With the introduction of the HPV vaccines, HPV serology and immunology is now of major 
importance for monitoring the impact of HPV vaccination among the general population. 
Vaccine clinical trials have shown that the HPV vaccines are effective in the prevention of 
HPV16 and 18 infections in healthy women [13, 14]. To provide protection, HPV vaccines need 
to induce sufficient antibody levels at sites were HPV infections take place.
The biological significance of naturally derived HPV antibodies is still not clear. It is known that 
persistent HPV infections are strongly associated with the presence of HPV-specific antibodies 
[15-20]. However, do these antibodies protect against subsequent HPV infection? What is the 
difference between naturally derived and vaccine-derived HPV-specific immune responses? 
The principal aims of this study were to investigate the quality, quantity and characteristics of 
HPV humoral immune responses after HPV infection and vaccination. HPV immune responses 
were assessed in a population-based study, in vaccination target groups and in immune 
compromised girls. In this chapter, the main conclusions of the thesis are summarized and 
discussed. Recommendations concerning HPV epidemiology and immunization against HPV 
and perspectives for future research are proposed and discussed. 
10.2 Antibody detection methods
Serologic assays available for the evaluation of HPV humoral responses are Enzyme Linked 
Immunosorbent  Assays (ELISA) [21], multiplex immunoassays (MIA) [22-25] and a pseudovirion 
based neutralization assay (PBNA) [26]. The most meaningful evaluation of the functional 
immune response after HPV immunization or HPV infection is provided by the PBNA, which 
is recognized as the ‘gold standard’ for assessing HPV-specific neutralizing antibodies [26]. 
However, its use in large sero-epidemiological studies or clinical trials is challenging since this 
assay is laborious and the production of pseudovirions is a complicated procedure. 
The fluorescent bead-based multiplex immunoassays, i.e. MIA, are a good alternative for the 
more conventional methods for instance the ELISA. The MIA can rapidly detect, with reduced 
amounts of serum compared to ELISA, multiple analytes in a single well with high reproducibility 
and sensitivity [27-30].
In our studies, we used the VLP-MIA that correlated well with the VLP-ELISA developed by 
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GSK in ‘in house’ bridging experiments with serum panels (unpublished data). Moreover, the 
VLP-ELISA, showed a good correlation with the PBNA [31]. We found the VLP-MIA to be highly 
reproducible and type-specific. The VLP-MIA showed also a high percentage of concordance 
with the competitive luminex immunoassay (cLIA) (chapter 4). 
The use of VLPs for research purposes is limited as the production is time consuming and 
difficult and therefore only a small number of VLP types are currently available. To monitor the 
stability of the VLPs, used in our VLP-MIA, we tested the binding of HPV-specific monoclonal 
antibodies directed against conformational and linear epitopes to the VLPs. VLPs coupled to 
the fluorescent microspheres could be stored for at least nine months. During this storage time 
the monoclonal antibodies were frequently tested and we did not observe any differences in the 
stability of the VLPs. The VLP-MIA measures a broad range of HPV-specific antibodies induced 
after infection or HPV vaccination. The VLP-MIA does not distinguish between neutralizing and 
non-neutralizing HPV-specific antibodies because the VLPs contain both neutralizing and non-
neutralizing epitopes.
In contrast, the PBNA and the cLIA can distinguish between non-neutralizing and neutralizing 
antibodies. Comparisons between commonly used HPV serological assays (PBNA, cLIA, GST-
L1-MIA, VLP-MIA, and VLP-ELISA) are hampered due to the use of different cut-off estimates 
and the lack of a good international reference standard [22, 23, 31, 32] (chapter 2). Cut-off 
values, needed in order to distinguish between seropositive and seronegative samples are 
preferably age-specific, gender-specific and risk-group-specific thereby facilitating the use in 
different settings of clinical studies. For our VLP-MIA a cut-off was determined based upon a 
serum panel from children 1-10 years of age. As it is unlikely that these children are sexually 
active, it can be assumed that their serum samples are negative. Although these children were 
(very) young, in some serum samples HPV-specific antibodies were detected. We tested a 
small subset of these seropositive samples in the PBNA and found that HPV-specific antibodies 
in children did not have neutralizing capacity (chapter 3). 
The establishment of an international reference serum for antibodies to at least HPV16 and 
18 with an arbitrarily assigned unitage in international units (IU) would facilitate comparison of 
results between assays assessing the antibody response in vaccinees or in epidemiological 
studies [33]. Currently, only an international reference serum for HPV16 is available [34], which 
contains a low antibody concentration and is therefore not suitable for vaccine monitoring 
studies and hardly for sero-epidemiological populations of the pre-vaccination era. For vaccine-
induced protection and post-infection seroconversion the establishment of an international 
reference serum with a high level of HPV-specific antibodies is required.
Keeping these limitations in mind, we found the VLP-MIA to be a suitable tool in quantifying 
antibody responses to several HPV types for use in sero-epidemiological and in vaccination 
monitoring studies. 
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10.3 HPV-specific antibodies derived after HPV infection
10.3.1 HPV-specific antibody characteristics 
Neutralizing antibodies are believed to be the main effectors of protection against HPV infection 
by preventing the initial entry of the virus and internalization into basal epithelial cells [35]. 
Naturally derived HPV-specific antibodies might substantially contribute to the protection against 
HPV reinfections [36-39]. However, it is not clear whether the protective capacity of naturally 
derived HPV-specific antibodies is age-dependent [40], whether the level of antibodies might 
influence protection against subsequent HPV infection, and finally whether this protection can 
be attributed to neutralizing antibodies or other immune protective mechanisms [38]. 
In chapter 3, we investigated the antibody characteristics after HPV infection. We found that 
naturally induced HPV-specific antibodies were highly type-specific and tended to be neutralizing 
but mainly in individuals positive for one HPV type. In individuals positive for multiple HPV 
types, the antibodies were found to be less specific and cross-reactive, and tended to be non-
neutralizing. We did not found a correlation between antibody levels and neutralizing capacity 
of naturally derived HPV-specific antibodies in the small sample sizes tested. However, to 
confirm our findings, it is necessary to test larger serum panels in the PBNA to corroborate the 
differences in neutralizing capacity between HPV type-specific antibodies and cross-reactive 
antibodies.
We hypothesized that in single-HPV type positive sera the HPV type-specific antibodies might 
be induced after transient HPV infections, whereas for multi-HPV type positive sera the HPV 
type-specific antibodies might be derived after persistent HPV infections. A high viral load 
could induce an acute and strong immune response [41, 42] in which it is more likely that 
naturally derived antibodies are also directed against HPV type-specific neutralizing epitopes. 
Cross-reactive HPV antibodies in multi-HPV type positive sera might be induced for instance 
by persistent HPV infections that generate and maintain a less developed humoral immune 
response by a slow gradual boosting effect. Moreover, continued exposure to more than one 
HPV type may favour the induction of HPV type-specific antibodies that are directed against 
the common non-neutralizing epitopes shared by different HPV types. This might mean that 
naturally induced HPV-type specific antibodies in multi-HPV type positive women could not or 
only partially protect against subsequent HPV infection as individuals seropositive for multiple 
HPV types are still at risk for subsequent infections with related HPV types (chapter 3). 
Characterizing the different epitopes, that are recognized by naturally derived HPV-specific 
antibodies and by cross-reactive antibodies, will provide more insight in the neutralizing and 
non-neutralizing epitope repertoire on HPV and/or VLPs. Is there a relation between the HPV-
specific antibody levels induced by the prophylactic vaccines or derived after natural infection 
and the neutralizing capacity of these antibodies? Although we could not demonstrate a 
correlation between antibody concentration and neutralizing capacity albeit in a small serum 
panel, larger serum panels are needed to provide a better insight whether the HPV-specific 
antibody level can be considered as a true correlate of protection. 
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10.3.2 HPV-specific antibody seroprevalence
In naturally occurring HPV infections there is no or minimal viraemia and access of antigen 
to lymph nodes is limited. Moreover, HPV is able to evade immune recognition, in part, 
through its modulating effect on Langerhans cells and dendritic cells [43, 44]. Consequently, 
the production of HPV-specific antibodies is hampered. Only 50-60% of infected individuals 
develop HPV-specific antibodies after HPV infection. These naturally derived antibodies are 
strongly associated with persistent HPV infections [15-19, 21, 41, 42]. Persistent HPV infections 
can result in the development of cervical intraepithelial neoplasia (CIN) and eventually result 
in cervical cancer. Data on HPV-specific antibodies after HPV infections are scarce as it is not 
common to determine the HPV-specific antibody levels in large serosurveillance studies and 
assays for the detection of HPV-specific antibodies are not readily and commercially available 
(see paragraph 10.2). However, these studies are useful for monitoring infection dynamics and 
determining changes in HPV seroprevalence over time in the HPV type repertoire. Moreover, 
HPV antibody seroprevalence is essential to estimate lifetime cumulative HPV exposure and 
past HPV infections, and to monitor HPV vaccination programs. 
We have shown in population-based serosurveillance studies that the situation on HPV 
seroprevalence has changed over time in the Netherlands (chapter 5). HPV seroprevalence 
for especially HPV16 but also for HPV18, 31 and 45, seropositivity for multiple HPV types 
and for HPV16/18 combinations have increased over an 11-year period between 1995-96 
and 2006-07. This increase in HPV antibody seroprevalence is probably due to changes in 
sexual behaviour, for instance a younger age of sexual debut between these two time periods. 
A further decrease in age of first sexual intercourse in combination with the low vaccination 
coverage, may lead to an increase in CIN lesions in young women.
10.3.2.1 Children
In infants and young children the HPV-specific antibody levels were found to be close to the 
assay cut-off values (chapter 4). In most population-based serosurveillance studies, low 
HPV16 seroprevalences were observed in children up to 9 years of age, which is in line with 
our findings. HPV-specific antibodies in infants are probably maternal IgG antibodies that wane 
within a few months after birth [45, 46]. However, infants can also be exposed to HPV via 
maternal genital HPV infection during birth [46, 47]. Seroprevalence of HPV antibodies in 
young children can be explained by other routes of HPV transmission than sexual activities, as 
HPV can also be present in the oral mucosa, tonsils and fingers [46, 48, 49]. In young children, 
cutaneous HPV types are highly present and therefore we cannot exclude that cutaneous HPV 
infection might induce cross-reactive antibodies against some high-risk HPV types. It might be 
relevant to study HPV-DNA prevalence in children as HPV infections can also cause a variety 
of mucosal and cutaneous infections in children.  
10.3.2.2 Older aged individuals
Sexually transmitted infections (STIs) are generally considered to predominantly affect 
young people. However, nowadays the population in industrialized countries is ageing and 
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although sexual activity declines with age [50], an increase in STIs is observed in middle aged 
individuals [51]. In line with Jena et al. [51], we observed an increase in HPV seroprevalence 
in older aged individuals between 1995-96 and 2006-07 (chapter 5). The development of new 
therapeutic interventions, for instance Viagra, increased the possibility to be sexual active at 
older ages [51]. Also, sexually active older aged women are more vulnerable to STIs, due 
to post-menopausal changes. Post-menopausal changes can cause atrophy or thinning of 
mucosa with decreased lubrication. This could increase the risk of the development of small 
lesions of the cervix which facilitate the entry of pathogens [52]. Older women could become 
more susceptible for new HPV infections, however, the risk of developing cervical cancer in 
these older aged individuals due to new HPV infections might be less relevant for treatment as 
the development of cervical cancer will take more than 16 years [53-55]. The increase in HPV 
seroprevalence in older aged individuals could also be due to the reactivation of latent HPV 
infections, which occurred earlier in life [56]. Other STI (i.e. Chlamydia, gonorrhoea, genital 
herpes, genital warts and infectious syphilis) might be a risk for the health of the older aged 
people too. Therefore, older people could benefit from targeted sexual health promotion and 
STI prevention messages which are now mostly focussed on young adults [57].
10.4 HPV-specific antibodies derived after HPV vaccination
10.4.1 Vaccine-derived humoral immune responses in the systemic circulation
Prophylactic bivalent HPV vaccination has been implemented in the national immunization 
program in 2010 with a catch-up campaign for 13-16 years old girls one year earlier. As it will 
take a long period before the effect of the HPV vaccination becomes apparent in the national 
cervical screening programme among 30-60 years old women, it is necessary to monitor the 
effectiveness of the HPV vaccination in another manner. The current assumption is that the 
prophylactic HPV VLP vaccines protect via antibodies, but evidence that antibodies are the 
immunological tool for protection is based, at present, only on preclinical studies in animals 
and on CIN2 endpoint in humane vaccine studies [35, 58]. Vaccine-derived HPV-specific 
antibodies are 10-100 times higher than naturally induced antibodies in serum (chapter 7) 
[14, 59, 60]. This is most likely due to the route of immunization, antigen concentration and 
the adjuvant used [35]. HPV VLP vaccines are delivered intra-muscularly with high antigen 
dose, and there is rapid and direct access to lymph nodes and spleen where adaptive immune 
responses and the production of HPV-specific antibodies are initiated. Rotelli-Martins et al. 
already showed that vaccine-derived antibody levels of HPV16 and 18 remained constant for 
over 8 years in vaccinated women [14]. 
We investigated the kinetics of humoral immune responses after vaccination by measuring 
vaccine-derived HPV-specific memory B-cells at different time points. In healthy individuals, 
the kinetics of the HPV16/18-specific memory B-cell responses followed the kinetics of the 
vaccine-derived HPV16/18 antibody levels (chapter 8). These humoral immune responses 
were similar with other studies [61, 62].
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10.4.1.1 Vaccine-derived cross-reactive antibodies
We studied the vaccine-derived HPV-specific antibody levels up to two years after vaccination 
in serum and also in cervical secretion samples (CVS) (chapter 7). After vaccination, we 
observed that serum antibodies induced by HPV16/18 vaccine also cross-reacted with 
HPV types 31, 33, 52 and 58, and 45 which are phylogenetically related to HPV16 and 18, 
respectively. Antibodies with neutralizing capacity against non-vaccine HPV types were most 
frequently found for HPV31 and 45 and scarcely for HPV33 [63]. Although also antibody levels 
were found for HPV52 and 58 after vaccination, the biological relevance of these antibody 
levels is limited. In vaccine monitoring studies no cross-protection by these HPV52 and HPV58 
antibodies was observed possibly because they recognize common non-neutralizing epitopes 
that are shared by the different HPV types [64, 65]. We observed that vaccine-derived cross-
reactive HPV-specific antibodies were mainly vaccine type species-specific and closely related 
to HPV16 or HPV18 (chapter 3). In contrast to cross-reactive antibodies derived after HPV 
infection, vaccine-derived cross-reactive antibodies can partially protect against subsequent 
HPV infections. 
10.4.1.2 Immunosuppressed individuals
Effective and safe vaccination is also essential in individuals whose function of the immune 
system is affected by the effect of its disease or the use of immunosuppressive drugs [66, 67]. 
The immunosuppressive effect of the disease or its treatment can lead to an increased risk 
of several infections including HPV [68]. We found that the bivalent prophylactic HPV vaccine 
induces also strong HPV16/18-specific humoral immune responses in immune compromised 
girls (arthritis patients), although the magnitudes of the vaccine-derived HPV16/18-specific 
antibody responses and memory B-cells were consistently lower (chapter 8 and 9). Our 
results underline the need for prolonged surveillance of HPV-specific antibody concentrations 
and continued secondary prevention by cytology and HPV testing on cervical smears in these 
patients. We cannot exclude the possibility that long-term protection against HPV infection by 
prophylactic vaccination is inadequate in immune compromised girls. 
10.4.1.3 Correlate of protection
At present, the minimum level of antibody needed for protection has yet to be established. 
Vaccine clinical trials used CIN2 as surrogate endpoint for vaccine efficacy. However, vaccine 
efficacy against CIN3, the immediate precursor for invasive cervical cancer provides the most 
stringent evidence of potential cancer prevention [13]. A limitation of CIN3 as endpoint is that 
cohorts with larger sample sizes and a longer follow-up period are needed to draw conclusions 
regarding vaccine efficacy because of the lower incidence of CIN3 [13]. Therefore, we searched 
for other possible correlates of protection. The use of antibody levels as correlate of protection 
is complicated. After HPV vaccination, almost no disease cases occurred within vaccine 
clinical trials and reactivation of prevalent HPV infections could not be clearly distinguished 
from breakthrough infections due to vaccine failure [69].
Another potential surrogate of protection might be antibody avidity. Antibodies with high avidity 
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implicate a successful activated immune system and are therefore a surrogate of successful 
priming [70]. It is known that avidity maturation occurs following subsequent (HPV) vaccinations 
but the relation between HPV-specific antibody avidity to protection has not been explored yet 
[71]. 
We observed that the avidity of vaccine induced antibodies was 3 times higher than the avidity 
of antibodies derived after HPV infections (chapter 3). We found also that naturally derived 
neutralizing HPV-specific antibodies tended to be associated with higher antibody avidity 
than non-neutralizing antibodies, albeit tested in a small sample set. This is in line with the 
findings of Namujju et al., who found that naturally induced HPV16 antibodies of low avidity 
were associated with possible susceptibility to infection with other HPV types [72]. The level 
of antibody avidity could provide insight into the distinction between HPV-specific antibodies 
derived after HPV infection and vaccination. Moreover, antibody avidity might shed light on the 
quality of a vaccine-derived or naturally induced HPV-specific immune response. However, 
larger studies on antibody avidity and the neutralizing capacity of antibodies after HPV infection 
are needed to explore whether antibody avidity is indeed a potential surrogate of protection.
10.4.2 Vaccine-derived humoral immune responses at the cervix
Prophylactic HPV vaccination should induce a first line of defense by eliciting sufficient amounts 
of antibodies to prevent HPV from entering the keratinocytes in the cervix [73]. After HPV 
vaccination, detectable antibody levels in cervico-vaginal secretions (CVS) among vaccinated 
girls were found, but these antibody levels were approximately 60 fold lower than the antibody 
levels in the systemic circulation (chapter 7). Despite high serum antibody levels not all 
vaccinated girls had detectable HPV16 and 18 antibodies in their CVS. These results were 
confirmed by other studies [59, 74-76]. The antibody level at which HPV16 and 18 antibodies 
exert their protective effect against HPV infection is still unknown. However, studies in mice 
showed that already very low antibody concentrations can protect against HPV infections 
[69, 77]. Vaccine-derived antibodies in the systemic circulation might transudate through the 
cervical mucosa [73, 78]. 
This hypothesis is supported by our results described in chapter 7, in which we found a 
good correlation between HPV16 and 18 antibody levels in serum and CVS. Moreover, a 
high correlation was also found between antibody levels specific for tetanus toxoid in serum 
and CVS. Antibodies against tetanus toxoid are certainly not locally produced at the cervical 
mucosa. Another immunological mechanism that could account for the correlation between 
vaccine-derived antibody levels in serum and CVS is the exudation of antibodies. Small lesions 
in the cervix could contribute to the exudation of antibodies and in line with this, we found higher 
HPV-specific antibody levels with increasing blood traces in the cervical secretion. Protection 
at the cervix is not necessarily only based on antibodies that transudate or exudate from the 
systemic circulation to the mucosa. It can also be facilitated by other immune mechanisms 
for instance local production of antibodies in which IgG and IgA are produced primarily in 
mucosal associated lymphoid tissues and subsequently are actively transported into mucosal 
secretions [79].
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10.4.2.1 IgA antibody responses
IgA responses are not as long-lasting as IgG responses and maintenance of a serum IgA 
response is believed to require repeated antigenic stimulation [80]. Therefore, IgA antibodies 
are considered to be a marker for active infection, frequent reactivation of a latent viral infection, 
and repeated viral infection. However, it is not yet known whether IgA antibody responses also 
play a role in virus neutralization. Bontkes et al. observed that after HPV infections systemic 
IgA responses in women with abnormal cytology were more associated with HPV clearance 
than locally produced IgA at the cervical mucosa. The systemic IgA responses might be 
an indication of a successful cellular immune response induced at the local lymph nodes, 
mediated by cytokines [81]. After HPV vaccination, HPV16 and 18-specific IgA antibodies were 
detectable by us in CVS, probably derived from transudation and/or exudation mechanisms 
although local production cannot be excluded. 
10.4.2.2 Menstrual cycle
HPV-specific antibody levels at the cervix could be influenced by the menstrual cycle [82]. 
Nardelli-Haefiger et al. observed that around ovulation antibody levels might decrease 
because of a protective mechanism that reduces the level of anti-sperm antibodies in the 
female genital tract at time of ovulation [83]. It would be interesting to further explore the effect 
of the menstrual cycle on the antibody levels derived after HPV infection and vaccination. The 
fluctuation of antibody levels during the menstrual cycle could influence the local protection 
against HPV at the cervix. Consequently, women might be more at risk for new HPV infections 
due to the lower antibody levels during time of ovulation. Studying the antibody levels at the 
cervix in young women is now easier due to the self-sampling method of cervical secretion with 
a tampon. The girls found this collection method easy to use and comfortable and therefore 
self-sampling with a tampon could contribute to better participation rates in large-scale studies 
(chapter 7). 
10.5 Future perspectives
10.5.1 Monitoring HPV-specific seroprevalence among the Dutch population
To monitor possible further changes in sexual behaviour and HPV seroprevalence in young 
adolescents and in elderly over the years it would be advisable to perform a subsequent 
serosurveillance study following the serosurveillance study performed in 2006-07, for instance 
10 years thereafter. Studying the HPV-specific seroprevalence among the Dutch population 
could generate information on groups at risk for HPV infections, herd immunity after HPV 
vaccination, and possible type-replacement (HPV types not included in the HPV vaccine). 
Questionnaires for young adolescents and older aged individuals could be extended with 
more questions about sexual behaviour, for instance lifetime number of sexual partners. More 
insight in sexual behaviour among these specific age groups could better explain the rise in 
HPV seroprevalence observed between 1995-96 and 2006-07. In addition, harmonisation of 
questionnaires used in different serosurveillance studies would make comparisons between 
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them easier. 
10.5.2. HPV DNA swabs
Next to the collection of sera in these serosurveillance studies, the collection of cervical DNA by 
cervix brush or lavage devices among HPV vaccinated or non-vaccinated young adolescents 
is of interest to investigate the influence of the HPV vaccine on the HPV type repertoire and 
possible HPV type replacement. The collection of cervical DNA is currently performed in a large 
HPV vaccination monitoring study (HAVANA, HPV Amongst Vaccinated And Non-vaccinated 
Adolescents). In addition, the collection of cervical DNA would also be interesting for the 
population older than 50 years of age. The increase in HPV seroprevalence in older aged 
individuals might be due to new HPV infections or to the reactivation of latent HPV infections 
acquired earlier in life [56]. 
10.5.3 Vaccinating boys
There is an intense debate going on whether boys should be included in the HPV routine 
vaccination program which is currently targeted only at young girls. It has now been recognized 
that HPV can cause besides squamous cell carcinoma (SCC) of the cervix, also SCC of 
the anus, penis, mouth and oro-pharynx [84-87]. Therefore, men might also benefit directly 
from the HPV vaccination. Because precursor lesions of these carcinomas (oro-pharyngeal 
carcinomas) are not well recognized or poorly defined and the time necessary for development 
into cancer probably takes decades, vaccination of boys has not been included in the vaccination 
programme. Important for this debate is the magnitude of herd immunity that will be conferred 
to men from HPV vaccinated women. If vaccinating girls reduces the burden of HPV-related 
diseases in men also through herd immunity, vaccinating boys will provide only limited additional 
reductions in the morbidity and mortality and therefore will not be cost-effective [88]. Brisson 
et al. showed that vaccinating 12-year-old girls will result in significant herd effects and thus 
indirect protection of boys against HPV infection and disease [88]. These herd effects increase 
with higher vaccine coverage. Currently, in many countries, including the Netherlands, HPV 
vaccine coverage is only just over 50% among young girls and in case the vaccine coverage 
will not increase over time, boys might not benefit from HPV vaccination as well. Another 
argument for vaccinating boys is that although precursor lesions of oro-pharyngeal carcinomas 
are poorly defined, the prevalence of HPV associated oro-pharyngeal carcinomas is rising 
and exceeds the absolute numbers of cervical carcinomas. In addition, risk groups that are 
probably not affected by herd immunity, for instance homosexual men, might also benefit from 
HPV vaccination. Also among homosexual men the prevalence of anal carcinoma is rising. 
Therefore, we have to consider whether boys need to be included in the HPV vaccination 
program. An advantage is that vaccinating boys might have a stimulating effect on the HPV 
vaccination attendance rates among girls, since vaccination of only girls is used by opponents 
of vaccination as discrimination of women. Participation of boys in vaccination programs could 
remove arguments as “only women are responsible for HPV transmission” and “only women 
have to solve the problem of cervical cancer”.
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10.5.4 Cellular immunity
The HPV vaccine induces high HPV-specific antibody levels and memory B-cell responses 
[59, 61]. T-cells play a central role in cell-mediated immunity [89]. T-helper cells can activate 
by the production of specific cytokines other immune cells, such as B-cells to further develop 
or secrete antibodies. Cytotoxic T-cells can kill cells that are infected with viruses and cancer 
cells and the natural killer T-cells may play a role in the first line of defense against HPV 
infection [90]. However, vaccine induced T-cell responses are hardly investigated after HPV 
vaccination. Therefore, it would be worthwhile to investigate if the prophylactic HPV vaccine 
also induces a persistent HPV-specific T-cell response in both the systemic circulation and at 
sites were HPV infections take place.
10.6 Conclusion
In conclusion, our research shows that HPV serology is of major importance for investigating 
the immune responses after HPV infection and for monitoring the effects of HPV vaccination. 
The measurement of HPV-specific naturally induced antibodies is useful to provide information 
about trends in HPV seroprevalence over time and can be used to assess past HPV infections. 
In this thesis, we showed that HPV antibody seroprevalence on a population level changed 
over an 11-year period. Moreover, the increase in HPV16 antibody seroprevalence observed 
among young adolescents has shifted to younger ages over that same time period, justifying 
the implementation of the HPV vaccination at the age of 12 years. We also showed that 
individuals seropositive for multiple HPV types are at risk for subsequent HPV infections as 
multi-positive sera tended to be non-neutralizing. Fortunately, immunocompromised girls, 
affected by idiopathic arthritis disease, do benefit from the HPV vaccination as their immune 
responses are comparable to healthy age controls albeit in a lower magnitude. These findings 
warrant a continuation of seroprevalence studies. 
Investigating the humoral immune response among vaccination target groups has shed light on 
the immunological mechanisms that contribute to detectable and protective HPV-type specific 
antibody levels at the sites were HPV infections actually take place, the cervix, originally 
induced in the systemic circulation. In addition, assessing the humoral immune response will 
provide insight in the immunological effects of HPV vaccination individually and for the whole 
population by for instance herd immunity.
Finally we have shown that analysing the HPV type specific antibodies is an important 
immunological tool for studying the quality, quantity and characteristics of the HPV immune 
response after HPV infection and vaccination.
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Human papillomavirus (HPV) is one of the most common sexually transmitted pathogens 
worldwide. From the general population 80% will be infected at some time during life. Most 
people are infected with HPV soon after their first sexual intercourse.
More than 120 HPV types have been identified of which 15 are classified as high-risk (hr) or 
oncogenic HPV types. They belong to the α7 and α9 species. Hr HPV has now been recognised 
as the causative agent of cervical cancer and its precursor cervical intraepithelial neoplasia 
(CIN). Moreover, HPV infections are also associated with a significant number of squamous 
cell carcinoma of the anus, vulva, vagina, penis, mouth and oro-pharynx. HPV16 and 18 are 
the most common hr HPV types and responsible for 70% of all cervical cancer cases. 
The mucosal surface of the genital tract provides the first line of defence against genital HPV 
infection. Naturally derived HPV-specific antibodies at sites where HPV infections take place 
may have neutralizing capacity and can inhibit the binding of HPV to cell surface receptors 
necessary for entering the host cells. Neutralizing antibodies may also enable viral uptake by 
antigen presenting cells that will lead to the destruction of the virus. 
In the Netherlands the bivalent HPV vaccine (Cervarix®, containing HPV16/18 L1 virus-like 
particles (VLP), GlaxoSmithKline Biologicals) was implemented into the national immunization 
program in 2010 in a 2+1 schedule for girls 12 years of age. In addition, a catch-up vaccination 
campaign was initiated among girls aged 13-16 years. The bivalent HPV vaccine provides 
sustained protection against HPV16/18 infections over at least eight years after the first 
vaccination. The HPV16/18 antibody levels derived after HPV vaccination were found to be 
10-100 times higher as compared to naturally derived HPV-specific antibody levels. 
In this dissertation, we studied the quality, quantity and characteristics of the humoral immune 
response after HPV infection and after HPV vaccination. 
Antibody characteristics
To assess humoral immune responses after HPV vaccination and infection, several serological 
assays have been developed. The most meaningful evaluation of the functional immune 
response after HPV vaccination or infection is provided by the pseudovirion-based neutralization 
assay (PBNA), which is the ‘gold standard’ for the measurement of HPV-specific neutralizing 
antibodies. However, its use in large sero-epidemiological studies or clinical trials is challenging 
since this assay is laborious and the production of pseudovirions is a complicated procedure. 
Most serological analyses of antibody responses after HPV infection have relied on assays, 
e.g. competitive Luminex immunoassay (cLIA), VLP-ELISA and gluthathione-S-transferase 
L1 based multiplex immunoassay (GST-L1-MIA) that are alternatives of the PBNA. A good 
correlation was observed between the PBNA and the VLP-ELISA for HPV16 and 18. 
In chapter 2 we compared 3 assays for the measurement of HPV-specific serum antibody 
levels: the VLP-MIA, the cLIA, and the GST-L1-MIA. These assays showed good correlations 
for both naturally induced and vaccine-derived HPV-specific antibody levels. Although these 
serological assays have different assay characteristics, they can all be used for the detection 
of naturally derived and vaccine-derived HPV-specific antibodies. In our studies, we have 
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used the VLP-MIA. This assay can measure HPV-specific antibodies against 7 hr HPV types 
simultaneously (HPV16, 18, 31, 33, 45, 52 and 58). The VLP-MIA correlates well with the 
VLP-ELISA. We showed that the VLP-MIA is reproducible and that the binding of monoclonal 
antibodies recognizing conformational epitopes on HPV16 and 18 was type-specific.
In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects, such as 
avidity, neutralizing capacity and cross-reactivity, of the humoral antibody response after HPV 
infection and vaccination, as described in chapter 3. Vaccine-derived antibodies were mainly 
serotype-specific and cross-reacted only partially with other HPV types within the species. 
Naturally derived HPV-specific antibodies from single-positive sera were, as expected, highly 
type-specific and tended to be neutralizing. In contrast, antibodies of multi HPV type-positive 
sera were less specific, cross-reactive, and tended to be non-neutralizing. 
Immune parameters other than antibody levels that might correlate with protection have not 
been defined and data on antibody characteristics such as avidity are scarce. Antibody avidity 
generally increases over time following encounter with an antigen and memory responses are 
characterized by the production of high-avidity antibodies. We determined the avidity of HPV-
specific antibodies and  found that the avidity of vaccine-derived antibodies was approximately 
3 times higher than after HPV infection. These results imply that the avidity of HPV antibodies 
might be used as a potential surrogate of protection. However, further research is needed to 
corroborate this hypothesis.
HPV seroprevalence
A  detectable antibody response to the L1 capsid protein develops in 50-70% of infected 
individuals. These naturally derived HPV-specific antibody levels are relatively stable over 
time. Therefore, the HPV antibody response is a measure of past HPV exposure which can be 
investigated in serosurveillance studies. 
 Chapter 4 concerns a population-based serosurveillance study performed in 2006-07, in which 
we studied the age-specific seroprevalence of seven hr HPV serotypes (HPV16, 18, 31, 33, 
45, 52 and 58) among the Dutch general population in a pre-vaccination era. HPV is a sexually 
transmitted virus and people are infected soon after first sexual intercourse. Therefore, HPV 
vaccination is targeted at pre-adolescents. This age is also justified by the results we found. 
A step-up in HPV seroprevalence of women and men is observed at ages of sexual debut 
around 15-19 years. This increase in HPV seroprevalence was most pronounced in women. 
Relatively constant HPV seroprevalences were found in the middle aged cohorts and the HPV 
seroprevalence slightly decreased in the elderly. 
HPV seroprevalences in the pre-vaccine era (12-16 years) can be used as baseline to evaluate 
long-term population effects of HPV16/18 vaccination. We can monitor for instance the effect 
of vaccination on virus circulation in both women and men, possible type replacement and herd 
immunity after HPV vaccination. Changes in HPV seroprevalence among the Dutch general 
population of the seven hr HPV types, identified by our VLP-MIA between 1995-96 and 2006-
07 are described in chapter 5. HPV antibody seroprevalences in the general population have 
increased in the Netherlands with 3.1% over that 11-year period due to a significant higher 
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seroprevalence for HPV16, 18, 31 and 45. HPV16 seroprevalence among young women shifted 
to younger ages (from 20-24 to 15-19 years), probably due to changes in sexual behaviour 
over that period, in particular the age of sexual debut. 
Interestingly, an increase in HPV seropositivity in older aged individuals (>40 years) was also 
observed between these two time periods and might be due to an increase in sexual activity 
among older aged individuals because of the development of new therapeutic interventions 
that can be used when having sexual problems, especially in men. Sexually active older women 
might be more vulnerable to sexually transmitted infections because of post-menopausal 
changes. These post-menopausal changes can cause atrophy or thinning of mucosa with 
decreased lubrication that can result in small lesions of the cervix and facilitate the entry of 
pathogens when these women are sexually active. These age groups are thus more at risk for 
sexually transmitted infections.  
Vaccine-derived immune responses
Together with the vaccine implementation, the HAVANA (HPV Amongst Vaccinated And Non-
vaccinated Adolescents) study was designed to assess the early effects of the vaccination 
program. In this study, young girls (14-16 years of age) were enrolled expected to become 
sexually active in the next years post-vaccination. By taking yearly cervical swabs, blood and 
cervical secretion samples (CVS) from these girls we were able to monitor HPV-DNA status 
in cervical swabs and to relate these results with the presence of HPV-specific antibodies 
in serum and CVS. By the combination of these parameters we are able to monitor in these 
young adolescents the expected age-related HPV-DNA increase associated with increased 
sexual activity. Monitoring the type specific HPV-DNA prevalence in cervico-vaginal secretions 
and vaccine-induced HPV-specific antibody responses in serum and CVS before and shortly 
after introduction of routine HPV16/18 L1 vaccination offers the opportunity to evaluate early 
effects of the vaccination program.
As expected, the HPV-DNA prevalence among young girls prior to vaccination was low 
(chapter 6). Of the hr HPV-DNA positive girls approximately one third were HPV antibody 
seropositive for at least one of the seven HPV types tested, and almost 80% of these girls had 
HPV-specific antibodies of the corresponding HPV type. In the near future, within this study 
population acquisition of new HPV infections will be evaluated in relation to their vaccination 
status, serostatus and risk factors for HPV (sero)positivity will be studied longitudinally. 
The bivalent HPV16/18 vaccine induces high antibody concentrations in serum while data 
about antibody responses in CVS are limited. In chapter 7 we describe the pre- and post-
vaccination IgG and IgA antibody responses against seven hr HPV types in CVS and serum. 
After vaccination, HPV16 and 18 specific IgG and IgA antibodies were detectable in CVS and 
these antibody concentrations correlate well with serum antibody levels, although IgA levels 
were much lower as compared to IgG levels. The correlations of HPV16 and HPV18 IgG and 
IgA antibody levels between serum and CVS might denote that vaccine derived antibodies 
transudate and/or exudate from the systemic circulation to the cervical mucosa although other 
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immune mechanisms cannot be excluded. HPV-specific antibody levels in CVS were lower 
as compared to serum, however, these antibody levels remained constant up to two years 
post-vaccination and might therefore contribute to a protective environment at the cervix. 
This hypothesis is supported by the high correlation between the antibody levels of tetanus 
toxoid and diphtheria toxoid in serum and CVS because these vaccine-induced antibodies are 
not produced at the cervical matrix. Transudation and exudation of HPV-specific antibodies 
probably contribute to sufficient antibody levels at sites where HPV infections actually take 
place and therefore may provide protection against HPV infection and/or re-infections.  
Effective and safe vaccination is essential in individuals with impaired immunity caused by chronic 
disorders, such as juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE), 
because these individuals are at increased risk of infections due to the immunosuppressive 
effect of the disease or the immunosuppressive treatment.  Arthritis patients with SLE have 
an increased risk of multiple and persistent HPV infections leading to a higher prevalence of 
CIN compared to healthy individuals. In chapter 8 and 9 we describe the immunogenicity 
and safety of the bivalent HPV vaccine in girls with JIA, SLE, juvenile dermatomyositis, or 
overlap syndromes and compared these with healthy female adolescents aged 12-18 years. 
The HPV vaccine is safe and immunogenic in the 12 months after the first HPV vaccination, 
but the magnitude of antibody responses and memory B-cell responses appeared to be lower 
in patients compared with healthy controls. Since long-term protection against HPV infection 
might be inadequate in JIA patients, we recommend surveillance of HPV-specific antibody 
concentrations and next to HPV vaccination also frequent secondary prevention via cervical 
smears. Also in patients with arthritis-like disease based on SLE, juvenile dermatomyositis, or 
overlap syndromes the HPV vaccine appeared less immunogenic in comparison to healthy 
girls. These results warrant a larger prospective study to unravel the mechanisms behind these 
poor humoral immune responses.
Importance of HPV serology
In chapter 10 the findings of this thesis and the importance of serology in future HPV research 
are discussed. HPV-specific seroprevalence studies are necessary to monitor the vaccine-
derived protection against HPV and to generate information on groups at risk for HPV infections, 
herd immunity after HPV vaccination and possible type-replacement in vaccinated individuals. 
Therefore, it would be advisable to perform a subsequent serosurveillance study in which the 
effect of HPV vaccination can be monitored, for instance 10 years after the serosurveillance 
study performed in 2006-07. Next to the collection of sera in these serosurveillance studies, 
the collection of cervical DNA among HPV vaccinated or non-vaccinated adolescents is of 
interest to investigate the impact of the HPV vaccine on HPV repertoire, possible HPV type 
replacement and vaccine efficacy.
Currently, the HPV vaccination is targeted only at young girls. However, boys might also benefit 
directly from HPV routine vaccination as it is now recognized that HPV can cause squamous 
cell carcinoma that affect men (anus, penis, mouth, oro-pharynx). Important for this debate is 
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the magnitude of herd immunity that will be conferred to men from HPV vaccinated women. 
Herd effects increase with higher vaccine coverage. However, in the Netherlands HPV vaccine 
coverage amounts only just over 50% among young girls and in case the vaccine coverage 
will not increase over time, boys might benefit only from direct HPV vaccination. In addition, 
vaccinating boys may have a stimulating effect on the HPV vaccine coverage among girls, as 
opponents of (HPV) vaccination indicate the vaccination of only girls as gender discrimination.
In this thesis we showed that HPV serology is of great added value for investigating the 
immune responses after HPV infection and for monitoring the effects of HPV vaccination. 
The measurement of HPV-specific naturally induced antibodies is important to provide 
information about trends in HPV seroprevalence over time and to monitor past HPV infections. 
Investigating the humoral immune responses among vaccination target groups has shed light 
on the immunological mechanisms that contribute to detectable and protective HPV-type 
specific antibody levels at the cervix, originally induced in the systemic circulation. In addition, 
assessment of the humoral immune response will provide insight in the immunological effects 
of HPV vaccination individually (protection against HPV) and for the whole population (possible 
induction of herd immunity) which will provide valuable information for the prevention of cervical 
cancer.
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Samenvatting
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Het humaan papillomavirus (HPV) is één van de meest voorkomende seksueel overdraagbare 
ziekteverwekkers wereldwijd. Ongeveer 80% van de bevolking zal eens in zijn leven een HPV 
infectie oplopen en de meeste mensen raken vlak na hun eerste seksuele activiteit met HPV 
geïnfecteerd.
Momenteel zijn er meer dan 120 HPV typen geïdentificeerd, waarvan er 15 bekend staan als 
de hoog-risico (hr) oftewel zeer waarschijnlijk kankerverwekkende HPV typen. 
Infecties met hr HPV kunnen resulteren in de ontwikkeling van baarmoederhalskanker en 
haar voorstadia cervicale intraepitheliale neoplasie (CIN). HPV veroorzaakt niet alleen 
baarmoederhalskanker, maar kan ook bijdragen aan de ontwikkeling van kanker aan de anus, 
vulva, vagina, penis, mond en keel. HPV16 en HPV18 zijn de meest voorkomende hr HPV 
typen en samen verantwoordelijk voor 70% van alle baarmoederhalskanker gevallen. 
HPV infecteert voornamelijk de genitale regio. Daarom is het slijmvlies van de genitale 
regio de eerste verdedigingszone tegen HPV infecties. Na een infectie met HPV kunnen er 
HPV-specifieke antilichamen ontwikkeld worden. Antilichamen tegen HPV kunnen het virus 
neutraliseren op plaatsen waar HPV het lichaam binnendringt, zoals de baarmoederhals, 
en daardoor de nodige bescherming bieden. Deze antilichamen kunnen bijvoorbeeld de 
binding van HPV aan receptoren op de cellen die HPV infecteert (keratinocyten) blokkeren. 
Tevens bevorderen neutraliserende antilichamen de opname van het virus door antigeen 
presenterende cellen, die het virus afbreken. Helaas ontwikkeld niet iedereen antilichamen 
na een HPV infectie en de antilichamen zijn niet altijd in staat om het virus te neutraliseren 
waardoor herinfecties mogelijk zijn.
In Nederland is in 2010 het bivalente HPV vaccin (Cervarix®, GlaxoSmithKline 
Biologicals), bestaande uit HPV16 en 18 virusachtige deeltjes (VLP), opgenomen in het 
Rijksvaccinatieprogramma in een 2+1 schema voor 12 jarige meisjes om op een alternatieve 
wijze antilichamen tegen het virus op te wekken. Daarnaast is er een inhaalcampagne 
georganiseerd waarbij 13-16 jarige meisjes zich eenmalig konden laten vaccineren. Het 
bivalente HPV vaccin beschermt tegen HPV16/18 infecties voor ten minste 8 jaar na de 
eerste HPV vaccinatie wanneer meisjes het volledige vaccinatie schema hebben doorlopen. 
Na vaccinatie zijn de HPV16/18 specifieke antilichaam concentraties 10-100 keer hoger dan 
antilichaam concentraties die na een HPV infectie gegenereerd worden. 
In dit proefschrift hebben we de kwaliteit, kwantiteit en de karakteristieken van de humorale 
immuunrespons na een HPV infectie en na vaccinatie onderzocht.
Antilichaam karakteristieken
Om de antilichaam respons na HPV vaccinatie of infectie te bestuderen zijn er verschillende 
technieken ontwikkeld. Van deze technieken kan de pseudovirion neutralisatie assay (PBNA) 
als beste de functionele immuunrespons na HPV vaccinatie of na HPV infectie monitoren en 
wordt daarom ook wel als de gouden standaard gezien voor het detecteren van HPV-specifieke 
neutraliserende antilichamen.  Een nadeel van deze assay is dat hij erg arbeidsintensief is en 
dat de productie van pseudovirions een erg gecompliceerde procedure is. In hoofdstuk 2 
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hebben we 3 andere technieken voor het bepalen van HPV-specifieke antilichamen in het 
bloed met elkaar vergeleken: de VLP multiplex immunoassay (MIA), de competitieve luminex 
immunoassay en de gluthathione-S-transferase L1 MIA. Deze technieken laten onderling 
goede correlaties zien van zowel de HPV-specifieke antilichaam concentraties geïnduceerd 
door een HPV infectie als door vaccinatie. Ondanks dat deze technieken van elkaar verschillen, 
kunnen ze alle drie gebruikt worden voor het detecteren van HPV-specifieke antilichamen. 
In de studies beschreven in dit proefschrift hebben we gebruik gemaakt van de VLP-MIA. 
Deze techniek kan antilichamen tegen zeven hr HPV typen (HPV16, 18, 31, 33, 45, 52 en 
58) tegelijkertijd bepalen. Daarnaast, komen de resultaten verkregen met deze techniek goed 
overeen met die van de VLP-ELISA  die op zijn beurt weer goed overeenkomt met die van 
de PBNA. Tevens hebben wij laten zien dat de VLP-MIA reproduceerbaar is en dat door de 
binding met monoklonale antilichamen type specifieke conformationele epitopen van HPV16 
en 18 kunnen worden aangetoond.
Om de HPV-specifieke IgG antilichaam karakteristieken te onderzoeken, hebben we 
verschillende parameters, zoals aviditeit, neutraliserende capaciteit en kruisreactiviteit van de 
humorale antilichaam respons onderzocht van hr HPV typen (hoofdstuk 3). Wij vonden dat 
HPV-specifieke antilichamen na vaccinatie over het algemeen genotype specifiek zijn en een 
klein gedeelte van deze antilichamen zijn kruisreagerend met andere HPV typen uit dezelfde 
clade. Bloedmonsters met HPV-specifieke antilichamen tegen één HPV type geïnduceerd 
na een HPV infectie waren, zoals we ook verwacht hadden, type-specifiek en waren ook 
neutraliserend voor het kleine panel wat getest is. Daarentegen waren de HPV antilichamen in 
multiple positieve bloedmonsters minder specifiek, waren deze antilichamen kruisreagerend 
en leken ze niet neutraliserend te zijn. 
Naast de specifieke HPV antilichaam concentraties zijn andere parameters, die ook iets 
kunnen vertellen over de mate van bescherming, nog niet bekend en data over antilichaam 
karakteristieken zoals aviditeit zijn nauwelijks beschikbaar. De aviditeit van de antistoffen 
neemt over het algemeen genomen toe na het regelmatig in contact komen met een antigeen. 
Hierdoor worden ‘memory’ responsen ontwikkeld welke gepaard gaan met de productie van 
hoog-avide antilichamen. Wij hebben de aviditeit van HPV-specifieke antilichamen bepaald 
en vonden dat de aviditeit van vaccin geïnduceerde HPV-specifieke antilichamen ongeveer 3 
keer hoger was dan de aviditeit van antilichamen ontwikkeld na een HPV infectie. Daarom zou 
de aviditeit van HPV antilichamen misschien gebruikt kunnen worden als een surrogaat van 
bescherming hoewel meer onderzoek nodig is om deze hypothese te bevestigen. 
HPV seroprevalentie
Een detecteerbare antilichaam respons tegen het L1 capside eiwit van HPV (de eiwitmantel van 
het virus) wordt ontwikkeld in 50-70% van de geïnfecteerde mensen. Deze natuurlijk verworven 
HPV-specifieke antilichamen zijn voor lange tijd op relatief constant niveau aanwezig in het 
bloed. Daarom is de serologische HPV respons (de detectie van HPV antilichamen) een maat 
voor HPV infecties die in het verleden hebben plaats gevonden.
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In hoofdstuk 4 hebben we gebruik gemaakt van een grote serosurveillance studie 
(dwarsdoorsnede van de Nederlandse bevolking) uitgevoerd in 2006-07. In deze studie 
hebben we de leeftijdsspecifieke seroprevalentie van HPV antilichamen van zeven hr HPV 
serotypen (HPV16, 18, 31, 33, 45, 52 en 58) bepaald onder de Nederlandse bevolking (0-79 
jaar oud) vóór de invoering van de HPV vaccinatie. Omdat HPV een seksueel overdraagbaar 
virus is en mensen snel na hun seksueel debuut geïnfecteerd raken, wordt de HPV vaccinatie 
aangeboden aan jonge meisjes. De resultaten van onze studie bevestigen dat dit een goede 
leeftijd is aangezien een toename in HPV seroprevalentie onder zowel vrouwen als mannen 
werd waargenomen rondom de leeftijd van seksueel debuut (15-19 jaar). Deze toename in 
seroprevalentie was het duidelijkst voor vrouwen. Redelijk constante HPV seroprevalenties 
werden waargenomen rond middelbare leeftijd waarna de seroprevalentie in oudere mensen 
iets daalde. 
Seroprevalentie data van de 12-16 jarigen van voor de invoering van HPV vaccinatie kunnen 
gebruikt worden als basis voor het verder evalueren van de lange termijn effecten van de 
HPV16/18 vaccinatie op de Nederlandse bevolking. Met behulp van deze seroprevalentie 
studies kunnen we het effect van vaccinatie op het aantal infecties en als afgeleide daarvan 
ook op virus circulatie in zowel mannen als vrouwen onderzoeken, de mogelijke veranderingen 
in het voorkomen van de verschillende HPV types monitoren, en kunnen we meer inzicht 
krijgen in groepsimmuniteit na HPV vaccinatie. Veranderingen in HPV seroprevalentie onder 
de Nederlandse bevolking van zeven hr HPV typen tussen de periode 1995-96 en 2006-07 is 
beschreven in hoofdstuk 5. Uit ons onderzoek blijkt dat de HPV antilichaam seroprevalentie 
in de Nederlandse bevolking is toegenomen met 3.1% in een periode van 11 jaar door een 
significante stijging in de seroprevalentie voor HPV16, 18, 31 en 45. HPV16 seroprevalentie 
onder jonge vrouwen is verschoven naar jongere leeftijden binnen die periode van 11 jaar (van 
20-24 naar 15-19 jaar). Waarschijnlijk wordt deze verschuiving in seroprevalentie veroorzaakt 
door veranderingen in seksueel gedrag in die jaren, in het bijzonder een jongere leeftijd 
van seksueel debuut. Het is interessant dat ook bij ouderen (>40 jaar) een toename in HPV 
seropositiviteit wordt waargenomen in deze periode van 11 jaar. Dit kan verklaard worden door 
het feit dat nu een hoger percentage ouderen nog steeds seksueel actief is dan voorheen, 
misschien wel door de ontwikkelingen op het gebied van therapeutische medicatie die gebruikt 
kunnen worden wanneer problemen op seksueel gebied een rol zouden kunnen spelen. Ook 
kunnen seksueel actieve oudere vrouwen kwetsbaarder zijn voor seksueel overdraagbare 
infecties door de post-menopausale veranderingen die in hun lichaam optreden. Deze post-
menopausale veranderingen kunnen atrofie of verdunningen in de mucosa veroorzaken 
waarbij minder cervicale secretie wordt geproduceerd. Dit kan resulteren in kleine wondjes 
op de cervix. Juist deze kleine wondjes zijn de ingangen waar ziekteverwekkers zoals HPV 
het lichaam kunnen binnendringen wanneer deze vrouwen seksueel actief zijn. Daarom lopen 
deze leeftijdsgroepen dus meer risico op een seksueel overdraagbare aandoening.
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Immuunrespons na HPV vaccinatie
Tegelijkertijd met het invoeren van de HPV vaccinatie, werd de HAVANA (HPV Amongst 
Vaccinated And Non-vaccinated Adolescents) studie gestart om de eerste effecten van het 
vaccinatie programma te monitoren. In deze studie zijn jonge meisjes (14-16 jaar) geïncludeerd 
waarvan het normaliter verwacht kan worden dat ze seksueel actief worden in de jaren vlak 
na vaccinatie. Jaarlijks worden bij deze meisjes cervicale swabs, bloed en cervicale secretie 
monsters (CVS) afgenomen. Deze studie stelt ons in staat om de aanwezigheid van HPV-
DNA in cervicale swabs te monitoren en deze data te koppelen aan de resultaten van HPV-
specifieke antilichamen in bloed en in cervicale secretie. Hierdoor is het mogelijk om inzicht te 
krijgen in de vroege effecten van het HPV vaccinatie programma voor en kort na de introductie 
van het HPV vaccin. Zoals verwacht was de HPV-DNA prevalentie onder jonge meisjes vóór 
de HPV vaccinatie laag (hoofdstuk 6). Van de hr HPV-DNA positieve meisjes is ongeveer 
een derde ook positief voor HPV antilichamen voor in ieder geval één van de zeven geteste 
HPV typen. Meisjes die hr HPV-DNA positief en seropositief zijn hebben in bijna 80% HPV-
specifieke antilichamen tegen het corresponderende HPV type. In de nabije toekomst zal in 
deze studiepopulatie nieuw verkregen HPV infecties in relatie tot de vaccinatie status van de 
meisjes, serostatus en risico factoren voor HPV (sero)positiviteit op de wat langere termijn 
kunnen worden bestudeerd. 
Het bivalente HPV16/18 vaccin induceert hoge antilichaam concentraties in het bloed, maar 
data over de HPV antilichaam concentraties bij de baarmoeder in de cervicale secretie zijn 
beperkt, terwijl juist bij de baarmoeder het HPV vaccin bescherming moet bieden. In hoofdstuk 
7 beschrijven we de IgG en IgA antilichaam responsen voor en na vaccinatie tegen zeven hr 
HPV typen in CVS en in het bloed. IgG antilichamen zijn voornamelijk in het bloed terug te 
vinden en IgA antilichamen worden voornamelijk geproduceerd bij de mucosa (bijvoorbeeld 
de genitale regio). Na HPV vaccinatie waren IgG en IgA antilichamen specifiek voor HPV16 
en 18 detecteerbaar in CVS. De correlatie tussen IgG en IgA antilichamen detecteerbaar in 
CVS en in het bloed was goed, hoewel IgA antilichaam concentraties wel veel lager waren 
dan de IgG concentraties. Tevens waren de antilichaam concentraties in CVS weer een stuk 
lager dan in het bloed maar bleven wel op een constant niveau tot in ieder geval twee jaar na 
vaccinatie aantoonbaar. Hieruit kunnen we voorzichtig concluderen dat vaccin geïnduceerde 
antilichamen vanuit het bloed naar de baarmoeder lekken (transudatie) of dat antilichamen 
door middel van kleine hoeveelheden bloed, ontstaan bij wondjes, in de cervicale secretie 
terecht komen (exudatie). Toch kunnen immunologische mechanismen zoals locale productie 
van HPV-specifieke antilichamen niet worden uitgesloten.
De hypothese dat HPV-specifieke antilichamen door transudatie en exudatie bij de cervicale 
mucosa terecht komen wordt ondersteund door de hoge correlaties tussen de IgG antilichaam 
concentraties specifiek voor tetanus toxoid en difterie toxoid in het bloed en in CVS. Deze vaccin 
geïnduceerde antilichamen worden namelijk niet geproduceerd bij de cervix. Op plaatsen waar 
HPV infecties voornamelijk plaats vinden dragen transudatie en exudatie van HPV-specifieke 
antilichamen hoogstwaarschijnlijk bij aan mogelijk voldoende bescherming tegen HPV infectie 
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Effectief en veilig vaccineren zijn belangrijk voor mensen die een slecht werkend 
immuunsysteem hebben wat veroorzaakt kan worden door chronische aandoeningen zoals 
juveniele idiopathische artritis (JIA, ook wel bekend als jeugdreuma) en systemische lupus 
erythematosus (SLE, auto-immuunziekte met symptomen in voornamelijk de organen). 
Personen met JIA of SLE lopen een verhoogd risico op infecties veroorzaakt door de immuun 
onderdrukkende effecten van hun ziekte of door de medicatie die deze mensen moeten 
gebruiken. Patiënten met SLE hebben een verhoogd risico op multiple en persistente HPV 
infecties die kunnen leiden tot een verhoogd risico op de voorstadia van baarmoederhalskanker 
vergeleken met gezonde mensen.
In hoofdstuk 8 en 9 onderzoeken we de immunogeniciteit en de veiligheid van het bivalente 
HPV vaccin bij meisjes met JIA, SLE, juveniele dermatomyositis (JDM, auto-immuunziekte 
welke ontstekingen aan huid en aderen veroorzaakt), of overlappende syndromen en vergelijken 
die bij gezonde meisjes tussen de 12-18 jaar. Het HPV vaccin is veilig en immunogeen in 
de eerste 12 maanden na de eerste HPV vaccinatie, maar de JIA patiënten ontwikkelen 
wel lagere HPV-specifieke antilichaam concentraties en minder HPV-specifieke ‘memory’ 
B-lymphocyten dan de gezonde controle groep. Door deze verminderde immuunresponsen in 
de patiënten met JIA is bescherming tegen HPV infecties door het HPV vaccin op lange termijn 
niet verzekerd. Daarom raden we aan om de HPV-specifieke antilichaam concentraties in de 
loop van de tijd te monitoren en daarnaast preventieve maatregelen te nemen door frequent 
cervicale uitstrijkjes te laten plaatsvinden bij deze patiënten. Ook in patiënten met SLE, JDM 
en overlappende syndromen lijkt het HPV vaccin minder immunogeen te zijn dan bij gezonde 
meisjes. Een grotere studie is nodig om het mechanisme achter deze verminderde humorale 
immuunresponsen te achterhalen.
Het belang van HPV serologie
HPV specifieke seroprevalentie studies zijn nodig voor het monitoren van de vaccin verworven 
bescherming tegen HPV en om informatie te verkrijgen over groepen die (extra) risico lopen 
op HPV infecties, groepsimmuniteit na HPV vaccinatie en veranderingen in het voorkomen 
van verschillende HPV types in gevaccineerde mensen. Het is interessant om een volgende 
serosurveillance studie uit te voeren waarin de effecten van de HPV vaccinatie kunnen 
worden bestudeerd, bijvoorbeeld 10 jaar na de laatste serosurveillance studie die werd 
uitgevoerd in 2006-07. Naast het verzamelen van bloedmonsters in serosurveillance studies 
is het verzamelen van genitaal DNA onder HPV gevaccineerde en niet gevaccineerde jong 
volwassenen interessant om de impact van het HPV vaccin op het HPV repertoire en de 
mogelijke veranderingen hierin te onderzoeken en voor het bepalen van de vaccin effectiviteit. 
Momenteel is de HPV vaccinatie alleen routinematig beschikbaar voor jonge meisjes. Toch 
kunnen jongens ook baat hebben bij HPV vaccinatie. HPV kan namelijk ook kanker aan 
de anus, penis, mond en keel in mannen veroorzaken. Het aandeel van groepsimmuniteit 
door het vaccineren van meisjes, waar jongens een voordeel van kunnen hebben, is een 
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belangrijk punt in dit debat. Het effect van groepsimmuniteit neemt toe bij een hogere 
vaccinatiegraad. In Nederland is de HPV vaccinatiegraad onder meisjes iets hoger dan 50% 
en in het geval dat de vaccinatiegraad niet verder zal toenemen, hebben de jongens geen 
profijt van groepsimmuniteit en kunnen ze beter ook gevaccineerd worden. Daarnaast zou het 
vaccineren van jongens een stimulerend effect kunnen hebben op de deelname van meisjes 
aan het HPV vaccinatieprogramma omdat vaccineren van alleen meisjes bij tegenstanders als 
geslachtsdiscriminatie wordt gezien. 
In dit proefschrift hebben we laten zien dat HPV serologie van groot belang is voor onderzoek 
naar de immuunrespons na een HPV infectie en inzicht kan geven in de vaccin geïnduceerde 
immuunrespons. Het analyseren van HPV-specifieke antilichamen is een belangrijke 
immunologische tool voor het bestuderen van de kwaliteit, kwantiteit en karakteristieken van 
een HPV immuunrespons na zowel een HPV infectie als na HPV vaccinatie. Daarnaast is 
de humorale immuunrespons een belangrijke parameter om de immunologische effecten van 
vaccinatie op individueel en populatie niveau (bijv. groepsimmuniteit) te monitoren. 
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Mijn proefschrift is na ruim 4 jaar dan nu echt klaar! Wat heb ik genoten van dit traject en wat 
heb ik een hoop geleerd. Een proefschrift schrijven doe je zeker niet alleen en daarom wil ik 
graag de volgende mensen bedanken.
Dr. F. R. M. van der Klis, copromotor, lieve Fiona, bedankt dat je mij deze kans hebt gegeven. 
Eindelijk ligt daar dan dat HPV boekje! Ik heb zoveel van je mogen leren. Bedankt dat ik altijd 
even binnen kon lopen voor van alles, of voor als het even lastig was en ik even moest horen 
dat alles nog goed ging. Wat hebben we een pret gehad op de HPV congressen en onze 
schunnige HPV grapjes, waar vaak alleen wij om konden lachen en anderen ons een beetje 
geschokt zaten aan te kijken. Je was er altijd bij, de poster presentaties en bij mijn praatjes. 
Dank je wel Fiona!
Dr. G. A. M Berbers, copromotor, beste Guy, soms zul je wel eens gedacht hebben wat moet 
dat worden met Mirte! Maar Guy, hier ligt dan toch dat boekje met 8 artikelen! Een super 
eindresultaat. Bedankt Guy, voor het vele vele nakijken van alle artikelen, je adviezen, je 
precisie in alles en vooral je geduld. Ook van jou heb ik veel geleerd waar ik in de toekomst 
nog zeker veel profijt van zal hebben!
Prof. Dr. C. J. L. M. Meijer, promotor, beste Chris, bedankt dat je mij de kans hebt gegeven om 
het HPV serologie avontuur aan te gaan. Bedankt voor je interesse, je ideeën en adviezen!
De leden van de leescommissie, Prof. dr. S. H. van der Burg, Prof. dr. R. A. Coutinho, Prof. dr. 
M. P. Koopmans, Dr. M. Pawlita, Prof. dr. P. J. F. Snijders en Prof. dr. C. M. J. E. Vandenbroucke-
Grauls, bedank ik voor het beoordelen van mijn manuscript.
Graag wil ik alle coauteurs en andere samenwerkingen bedanken met in het bijzonder: Madelief, 
Hester, Hein, Marloes en Nico. Lieve Madelief, wat hebben we samen mooie artikelen! Bedankt 
voor al je hulp, vooral bij de Pienter studies. Wat een werk, we werden er allebei soms een 
beetje tureluurs van! Maar het is gelukt. Heel veel succes met de laatste loodjes van jouw 
promotie onderzoek. Dat wordt een prachtig boekje. Hein, wat had je het leuk gevonden om 
dit HPV-serologie boekje in ontvangst te mogen nemen. Bedankt voor alles, voor je interesse 
en je blijdschap voor mijn publicaties. Marloes en Nico, dank voor jullie samenwerking. We 
kunnen trots zijn op hoofdstuk 8 & 9. 
En dan mijn (oud) collega’s van immunosurveillance groep! Rutger, Debbie, Irina, Nelleke, 
Pieter, Gaby, Susanne, Lia, Kemal, Anne-Marie, Rose-Minke, Sjoerd, Lotte, Richarda, Femke 
en Corine bedankt voor jullie gezelligheid de afgelopen jaren. En natuurlijk niet te vergeten...
met z’n allen gezellig tampons inpakken in de koffiekamer voor de HAVANA studie, respect! 
Rutger, lieve Ruti, bedankt voor al jouw hulp op het lab! Zonder jou waren hoofdstuk 2, 3, 4, 5 
en 7 nooit zo snel af geweest! Met jou tot in de late uurtjes cellen opwerken, redbull drinken, 
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magnetronmaaltijden opwarmen en met de hand LP plaatjes afspelen tijdens het cellen tellen. 
We maakten er tot diep in de nacht een feestje of wedstrijdje van! Zandvoort aan de Eem, fietsen 
langs de grachten en de sangria party in Berlijn zal ik niet zo snel vergeten of misschien kan ik 
me sowieso niet alles meer herinneren! Snel weer een keer gaan stappen? Lieve Debbie, wat 
hebben we een lol gehad! Balletten in de gang, spagaatjes, zwaaien naar de werk mannetjes 
en een stripact op het lab. En het leuke was dat alleen jij altijd werd gesnapt door een zeker 
iemand (ene Guy ;) )! Fijn dat ik ‘zo lekker me zelf kon zijn’ bij je. Wat zijn we gegroeid de 
afgelopen jaren, jij gestart met je HBO en ik met mijn promotie onderzoek en nu allebei klaar! 
Lieve Debs, ik hoop dat we elkaar blijven zien! En dan Pieter, wat kon jij mij altijd plagen! Mijn 
bureau mocht niet tegen die van jou aan staan en ik nam met mijn zooi duidelijk te veel ruimte 
in, jij kon je tenminste heerlijk uitleven met grapjes ten koste van mij. Ondanks dat, Pieter, vond 
ik het erg leuk dat je mijn roomy was de laatste paar jaren en heb ik je lekker kunnen irriteren 
met mijn ‘deuntje’, het is nu vast lekker rustig op de kamer. En natuurlijk als Luminex expert 
heb ik veel van je mogen leren! Lieve Gaby, mijn achterbuurvrouw op de kamer, bedankt dat 
ik altijd even mocht spuien, klagen, zeuren en mopperen als ik daar behoefde aan had. Lieve 
Suus, heel erg veel succes met je onderzoek! Rose-Minke, we hebben samen stage gelopen 
op het RIVM en samen zijn we begonnen aan ons promotie onderzoek. Zet hem op Roos, 
de laatste loodjes wegen het zwaarst! Lieve Lia, bedankt voor je hulp bij de B-cell ELIspot 
testen, je adviezen voor Nepal en gewoon onze gezellige kletsjes als ik na al die tijd achter 
de computer even een rondje moest lopen! Sjoerd, mijn onmisbare stagiair! Bedankt voor al 
je werk, wat heb je het goed gedaan! Kijk maar naar hoofdstuk 5. Veel succes met je verdere 
werk. Richarda, jij was bijna klaar met je onderzoek en ik begon pas net! Wat hadden we 
altijd een lol als kamergenootjes; onze gekke dansjes, stressbal meppen en lekker snoeiharde 
rockmuziek luisteren! 
De HPV AIO’s! Suzette, Kirsten, Daan, Nienke, Sofie, Rianne, Annelie en Madelief, wat 
hebben we een lol gehad op alle congressen en in het bijzonder Puerto Rico! Sangria party, 
Jacuzzi party, salsa dansen en zowaar het geslaagde congres feest (met dank aan Annelie 
haar dancemoves)! Bedankt dat jullie altijd naar mijn praatjes kwamen luisteren op de HPV 
congressen, toch een fijn gevoel om jullie daar dan te zien zitten. Helaas was Puerto Rico voor 
de meeste van ons meteen het laatste HPV congres. Laten we snel weer tapas gaan eten en 
afsluiten bij de Griek en een flesje Tsipouro bestellen! Dit keer blijf ik logeren Suus!
Lieve Rianne, mijn congres/vakantie maatje. Eerst op congres en daarna op vakantie! Vanuit 
het congres in Canada naar New York gevlogen om daar nog een aantal dagen te vertoeven 
op Time Square, Rockefeller center en het Liberty Statue te bekijken. Puerto Rico was ook 
nog niet zo slecht! De El Yungue jungle was prachtig. Onze autoritjes over het eiland waren 
hilarisch (ach... maar 1 auto geschampt), kamperen op het strand bij Vieques was fantastisch, 
al hadden we wel een beetje last van muggen en kippen, en ‘s nachts kanoën bij de Biobay 
met overvliegende vissen! Niet te vergeten, ons vliegtuig missen op Londen Heathrow en 
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onze koffers kwijt! Ach ja... we kwamen uiteindelijk altijd weer thuis. Heel veel succes met jouw 
promotie onderzoek, zet hem op!
Mijn paranimfen, Saskia en Lennart. Lieve Sas, je bent al mijn trouwe vriendin sinds de 
brugklas! Je bent erg belangrijk voor mij. Bedankt voor al het luisteren en dat je er altijd bent op 
momenten dat ik je echt nodig heb. We hebben samen al zoveel meegemaakt, zowel leuke als 
ook verdrietige dingen. Dank je wel Sas! En nu ben jij aan de beurt voor je promotieonderzoek 
en dat nog wel bij mijn oud collegaatjes! Pas goed op mijn plantjes! Lieve Lennie, ook jou 
ken ik al een eeuwigheid. Samen lekker wijntjes drinken daar zijn we zeker goed in! Ik ben 
ontzettend blij dat ik jou heb leren kennen en dat jij mijn paranimf wilde zijn!
Lieve andere vrienden uit de vriendengang: Randolph, Thomas, Edwin en Machteld, Hylke en 
Lotte, Jan, Wesley, Beb en Bob/Rob. Lieve Dolph, wat kunnen we toch gek doen. Blij dat jij ook 
altijd zin in eten hebt en zin in bitterballen... Bedankt dat je af en toe zei dat ik het wat rustiger 
aan moest doen. Thomas, gaan we binnenkort weer koken uit het Jamie Oliver kookboek? Ed 
en Hylke, bedankt voor de gezelligheid! Jan, onze eerste doctor in de vriendengroep, bedankt 
voor je interesse in mijn onderzoek. Wes, onze haat/liefde verhouding... er komt, nu mijn 
boekje klaar is vast weer een wat rustigere periode aan voor je, wat waarschijnlijk wel gepaard 
gaat met hopelijk voor jou wat meer liefde en wat minder Duitser grapjes! De strijdbijl kunnen 
we weer even begraven! Lieve Beb en Bob/Rob, bedankt voor alle gezellige en onmisbare 
vrienden weekenden! Lieve vrienden, bedankt voor jullie gezelligheid en gekheid. Voor de 
etentjes, de LV BBQs, kampvuren, biertjes en wijntjes.
Lieve Nanno, jij hebt gewoon dit boekje gelay-out! En het is prachtig geworden. Mijn eeuwige 
dank daarvoor! Lieve Eelkje, mijn allerleukste buur vriendin, wat liggen we toch altijd in een 
deuk bij onze balletlessen! Dank je voor de gezellige prosecco & brie avonden, concerten 
kijken en dat ik met jou heerlijk over alles kan kletsen!
Als laatste, maar zeker niet de minste, mijn familie. Inge en Femke, mijn zussen, ook al zijn 
we alle drie zo ontzettend verschillend en zijn we momenteel alle drie met zulke andere 
dingen in ons leven bezig, bedankt dat jullie er gewoon zijn. Lieve Marnix en Annick, wat is 
er de afgelopen jaren veel gebeurd! Studies afgerond, allemaal aan het werk. Fijn dat we dat 
tegelijkertijd hebben gedaan. Leuk dat jullie altijd zo geïnteresseerd in mijn onderzoek waren 
en Marnix, wat konden we daar lekker vieze grappen over maken. Hiske, zo druk met je studie 
en wat doe je het goed! Lieve Guido en Jose, ontzettend bedankt voor jullie adviezen en jullie 
vermogen om alles wat te relativeren de afgelopen jaren (en afgelopen maanden) als ik weer 
eens te veel hooi op m’n vork nam! 
Lieve mam en pap, ontzettend bedankt dat jullie mij de kans hebben gegeven om te doen 
wat ik leuk vind en mij daarin altijd hebben gesteund! Bedankt dat ik door jullie zorgeloos kon 
studeren. Toen ik vertelde dat ik een promotieonderzoek wilde doen, hadden jullie misschien 
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wat bedenkingen, maar dan na al die jaren verhalen over HPV, antilichamen, tampons, 
congressen en artikelen schrijven ligt daar dan eindelijk dat boekje!! Mijn ‘verslag’ is nu echt 
klaar. Bedankt voor alle etentjes thuis en jullie luisterende oren en lieve knuffels. Ik hou heel 
erg veel van jullie!
Lieve Balt, jij hebt best wel een ‘beetje’ moeten afzien de afgelopen jaren door mijn af en toe 
wisselende stemmingen... maar je was er altijd voor mij! Je hebt me altijd gemotiveerd om door 
te zetten als het wat minder ging. Samen hebben we alles gevierd wat we maar konden vieren 
bij onze stam tapasbar. Bedankt dat je met mij afgelopen februari mijn droomreis wilde maken 
naar Nepal die ik zo ontzettend nodig had en waar we de meest fantastische en bijzondere 
trekking door de Himalaya hebben gemaakt, met als hoogtepunt jouw aanzoek op 4200 meter 
hoogte!! Wat hebben we een fijn leven samen met onze mauwende huisgenootjes Jasou en 
Tamsin. Dank je lief, ik hou van jou!
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